uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q22.301 | Q22 | What is Lexette? | Lexette, also known generically as Halobetasol Propionate, was approved by the FDA in 1990 to treat psoriasis, skin disease, and psoriasis vulgaris. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lexette%" OR LOWER(tradeNames_string) LIKE "%lexette%" OR LOWER(drugSynonyms_string) LIKE "%lexette%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1442', 'tradeNames_string': 'Bryhali, Halobetasol propionate, Lexette, Ultravate', 'drugName': 'Halobetasol Propionate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Skin Disease (EFO_0000701), Atopic Eczema (EFO_0000274), Psoriasis Vulgaris (EFO_1001494)', 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1990, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.420 | Q22 | What is Kapspargo Sprinkle? | Kapspargo Sprinkle, also known generically as Metoprolol Succinate, was approved by the FDA in 1992 to treat congestive heart failure, hypertension, heart failure, and angina pectoris. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%kapspargo sprinkle%" OR LOWER(tradeNames_string) LIKE "%kapspargo sprinkle%" OR LOWER(drugSynonyms_string) LIKE "%kapspargo sprinkle%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2286', 'tradeNames_string': 'Kapspargo sprinkle, Metoprolol succinate, Toprol, Toprol Xl, Toprol-xl', 'drugName': 'Metoprolol Succinate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Beta-1 adrenergic receptor antagonist', 'linkedDiseasesDrug_string': 'Congestive Heart Failure (EFO_0000373), Angina Pectoris (EFO_0003913), Aortic Stenosis (EFO_0000266), Heart Failure (EFO_0003144), Duchenne Muscular Dystrophy (MONDO_0010679), Hypertension (EFO_0000537), Chronic Obstructive Pulmonary Disease (EFO_0000341), Fish-Eye Disease (Orphanet_79292), Hypertrophic Cardiomyopathy (EFO_0000538), Mitral Regurgitation (HP_0001653), Atrial Fibrillation (EFO_0000275)', 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1992, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.153 | Q22 | What is Goprelto? | Goprelto, also known generically as Cocaine Hydrochloride, was approved by the FDA in 2017. It is a small molecule therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%goprelto%" OR LOWER(tradeNames_string) LIKE "%goprelto%" OR LOWER(drugSynonyms_string) LIKE "%goprelto%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3417', 'tradeNames_string': 'Goprelto, Numbrino', 'drugName': 'Cocaine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Sodium channel alpha subunit blocker', 'linkedDiseasesDrug_string': 'Cocaine Dependence (EFO_0002610)', 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.439 | Q22 | What is Morphine Sulfate? | The drug Morphine Sulfate was approved by the FDA in 1984 to treat Chronic pain, cancer, pain, and drug dependence. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%morphine sulfate%" OR LOWER(tradeNames_string) LIKE "%morphine sulfate%" OR LOWER(drugSynonyms_string) LIKE "%morphine sulfate%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3650', 'tradeNames_string': 'Arymo er, Astramorph pf, Avinza, Depodur, Duramorph, Duramorph pf, Duromorph, Filnarine sr, Infumorph, Kadian, Moraxen, Morcap sr, Morphabond, Morphabond er, Morphgesic sr, Morphine sulfate, Morphine sulfate (autoinjector), Ms contin, Mst continus, Oramorph, Oramorph sr, Oramorph udv, Rhotard, Sevredol, Srm-rhotard, Zomorph', 'drugName': 'Morphine Sulfate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Opioid Use Disorder (EFO_0010702), Drug Dependence (EFO_0003890), Neonatal Abstinence Syndrome (EFO_0005799), Chronic Pain (HP_0012532), Pain (EFO_0003843), Osteoarthritis, Knee (EFO_0004616), Myocardial Infarction (EFO_0000612), Pulmonary Arterial Hypertension (EFO_0001361), Sickle Cell Anemia (MONDO_0011382), Hallux Valgus (HP_0001822), Low Back Pain (HP_0003419), Obstructive Sleep Apnea (EFO_0003918), Idiopathic Pulmonary Fibrosis (EFO_0000768), Pruritus (HP_0000989), Opioid Dependence (EFO_0005611)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1984, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.583 | Q22 | What is Fyarro? | Fyarro, also known generically as Sirolimus, was approved by the FDA in 1999 to treat immune system disease and eye disease. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fyarro%" OR LOWER(tradeNames_string) LIKE "%fyarro%" OR LOWER(drugSynonyms_string) LIKE "%fyarro%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2510', 'tradeNames_string': 'Fyarro, Hyftor, Rapamune, Sirolimus', 'drugName': 'Sirolimus', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'FK506-binding protein 1A inhibitor', 'linkedDiseasesDrug_string': 'Familial Adenomatous Polyposis (Orphanet_733), Ovarian Carcinoma (EFO_0001075), Multiple Myeloma (EFO_0001378), Skin Cancer (MONDO_0002898), Wet Macular Degeneration (EFO_0004683), Igg4-Related Retroperitoneal Fibrosis (MONDO_0018848), Iga Glomerulonephritis (EFO_0004194), Graves Ophthalmopathy (EFO_1001466), Pineoblastoma (EFO_1000475), Lymphangioleiomyomatosis (MONDO_0011705), Hypertension (EFO_0000537), Aplastic Anemia (HP_0001915), Immunodeficiency (HP_0002721), Lung Adenocarcinoma (EFO_0000571), Urinary Bladder Carcinoma (MONDO_0004986), Brain Aneurysm (EFO_0003870), Sickle Cell Anemia (MONDO_0011382), Severe Combined Immunodeficiency (MONDO_0015974), Hypercholesterolemia (HP_0003124), Hiv-1 Infection (EFO_0000180), Vascular Malformation (EFO_0006888), Castleman Disease (MONDO_0015564), Liver Cancer (MONDO_0002691), Osteosarcoma (EFO_0000637), Ewing Sarcoma (EFO_0000174), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Kidney Disease (EFO_0003086), Glioblastoma Multiforme (EFO_0000519), Lupus Nephritis (EFO_0005761), Germ Cell Tumor (EFO_0000514), Cancer (MONDO_0004992), Fanconi Anemia (MONDO_0019391), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Squamous Cell Lung Carcinoma (EFO_0000708), Aging (GO_0007568), Myelodysplastic Syndrome (EFO_0000198), Pachyonychia Congenita (MONDO_0016471), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Mantle Cell Lymphoma (EFO_1001469), Acute Lung Injury (EFO_0004610), Beta-Thalassemia (Orphanet_848), Gangliosidosis (MONDO_0017719), Diabetic Retinopathy (EFO_0003770), Acute Lymphoblastic Leukemia (EFO_0000220), Autosomal Dominant Polycystic Kidney Disease (EFO_1001496), Acute Respiratory Distress Syndrome (EFO_1000637), Acute Myeloid Leukemia (EFO_0000222), Multiple System Atrophy (EFO_1001050), Chronic Granulomatous Disease (MONDO_0018305), Diffuse Large B-Cell Lymphoma (EFO_0000403), Metastasis (EFO_0009708), Vitiligo (EFO_0004208), Small Cell Lung Carcinoma (EFO_0000702), Sarcopenia (EFO_1000653), Severe Aplastic Anemia (EFO_0006927), Thyroid Cancer (MONDO_0002108), Malignant Peripheral Nerve Sheath Tumor (EFO_0000760), Anemia (MONDO_0002280), Cutaneous T-Cell Lymphoma (EFO_0002913), Hodgkins Lymphoma (EFO_0000183), Fibroma (EFO_0002424), Rectum Cancer (EFO_1000657), Chronic Kidney Disease (EFO_0003884), Lymphatic Malformation (MONDO_0019313), Frontotemporal Dementia (MONDO_0017276), Diabetic Nephropathy (EFO_0000401), Non-Small Cell Lung Carcinoma (EFO_0003060), Posterior Uveitis (EFO_1001119), Sturge-Weber Syndrome (MONDO_0008501), Neuroblastoma (EFO_0000621), Pulmonary Hypertension (MONDO_0005149), Oral Lichen Planus (EFO_0008517), Eye Disease (EFO_0003966), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Focal Segmental Glomerulosclerosis (EFO_0004236), Bronchitis (EFO_0009661), Breast Cancer (MONDO_0007254), Thalassemia (EFO_1001996), Hemangioendothelioma (MONDO_0021121), Lymphoma (EFO_0000574), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Inclusion Body Myositis (EFO_0007323), Pancreatic Carcinoma (EFO_0002618), Anterior Uveitis (EFO_1000811), Central Nervous System Neoplasm (EFO_1000158), Abnormality Of Blood And Blood-Forming Tissues (HP_0001871), Intermediate Uveitis (EFO_1000986), Neurofibromatosis Type 1 (MONDO_0018975), Glycogen Storage Disease Due To Acid Maltase Deficiency (Orphanet_365), Skin Carcinoma (EFO_0009259), Tuberous Sclerosis (MONDO_0001734), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Age-Related Macular Degeneration (EFO_0001365), Sarcoidosis (MONDO_0019338), Pemphigus (EFO_1000749), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Heart Failure (EFO_0003144), Metastatic Prostate Cancer (EFO_0000196), Polycystic Kidney Disease (EFO_0008620), Sarcoma (EFO_0000691), Type 1 Diabetes Mellitus (MONDO_0005147), Cerebral Arteriovenous Malformation (Orphanet_46724), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Abnormality Of The Cardiovascular System (HP_0001626), Kidney Failure (EFO_1002048), Dry Eye Syndrome (EFO_1000906), Systemic Lupus Erythematosus (MONDO_0007915), Plasma Cell Leukemia (EFO_0006475), Gaucher Disease (MONDO_0018150), Familial Multiple Nevi Flammei (MONDO_0008094), Hyperinsulinism (MONDO_0002177), Chronic Myelogenous Leukemia (EFO_0000339), Gaucher Disease Type 2 (Orphanet_77260), Scleritis (MONDO_0001718), Prostate Cancer (MONDO_0008315), Parkinson Disease (MONDO_0005180), Kidney Angiomyolipoma (EFO_1000312), Acute Graft Vs. Host Disease (EFO_0004599), Immune System Disease (EFO_0000540), Lymphoblastic Lymphoma (MONDO_0000873), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Carcinoma Of Liver And Intrahepatic Biliary Tract (MONDO_0018531), Systemic Scleroderma (EFO_0000717), Amyotrophic Lateral Sclerosis (MONDO_0004976), Neurofibromatosis (EFO_0008514), Birt-Hogg-Dubé Syndrome (Orphanet_122), Desmoid-Type Fibromatosis (EFO_0009907)', 'newLinkedTargets_string': 'FKBP1A (ENSG00000088832)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1999, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.446 | Q22 | What is Naloxone Hydrochloride (Autoinjector)? | Naloxone Hydrochloride (Autoinjector), also known generically as Naloxone Hydrochloride, was approved by the FDA in 1971 to treat unipolar depression, pain, and septic shock. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%naloxone hydrochloride (autoinjector)%" OR LOWER(tradeNames_string) LIKE "%naloxone hydrochloride (autoinjector)%" OR LOWER(drugSynonyms_string) LIKE "%naloxone hydrochloride (autoinjector)%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3927', 'tradeNames_string': 'Evzio, Evzio (autoinjector), Kloxxado, Nalone, Naloxone, Naloxone hydrochloride, Naloxone hydrochloride (autoinjector), Narcan, Narcan neonatal, Narconil, Prenoxad, Zimhi', 'drugName': 'Naloxone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Opioid receptors; mu/kappa/delta antagonist', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Intestinal Obstruction (MONDO_0004565), Septic Shock (EFO_0006834), Pain (EFO_0003843), Constipation (HP_0002019), Opioid Dependence (EFO_0005611), Gambling Behaviour (EFO_0004699)', 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1971, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.270 | Q22 | What is Yutiq? | Yutiq, also known generically as Fluocinolone Acetonide, was approved by the FDA in 1963 to treat atopic eczema, psoriasis, skin disease, freckles, infectious disease, eye inflammation, hemorrhoid, seborrheic dermatitis, uveitis, and macular retinal edema. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%yutiq%" OR LOWER(tradeNames_string) LIKE "%yutiq%" OR LOWER(drugSynonyms_string) LIKE "%yutiq%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4767', 'tradeNames_string': 'Capex, Derma-smoothe/fs, Dermotic, Fluocet, Fluocinolone acetonide, Fluonid, Fluotrex, Fs shampoo, Iluvien, Retisert, Synalar, Synalar fte, Synalar-c, Synalar-hp, Synalar-n, Synandone, Yutiq', 'drugName': 'Fluocinolone Acetonide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': 'Uveitis (EFO_1001231), Psoriasis (EFO_0000676), Macular Degeneration (EFO_0009606), Hemorrhoid (EFO_0009552), Infectious Disease (EFO_0005741), Atopic Eczema (EFO_0000274), Eye Inflammation (EFO_0005752), Freckles (EFO_0003963), Otitis Externa (EFO_0009560), Seborrheic Dermatitis (EFO_1000764), Skin Disease (EFO_0000701), Posterior Uveitis (EFO_1001119), Glaucoma (MONDO_0005041), Retinopathy (EFO_0003839), Age-Related Macular Degeneration (EFO_0001365), Macular Retinal Edema (MONDO_0003005)', 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1963, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.614 | Q22 | What is Hetlioz? | Hetlioz, also known generically as Tasimelteon, was approved by the FDA in 2014 to treat sleep-wake disorder, Smith-Magenis syndrome, and Chromosomal anomaly. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hetlioz%" OR LOWER(tradeNames_string) LIKE "%hetlioz%" OR LOWER(drugSynonyms_string) LIKE "%hetlioz%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6185', 'tradeNames_string': 'Hetlioz, Hetlioz lq', 'drugName': 'Tasimelteon', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Melatonin receptor agonist', 'linkedDiseasesDrug_string': 'Circadian Rhythm Sleep Disorder (MONDO_0024361), Chromosomal Anomaly (Orphanet_68335), Liver Disease (EFO_0001421), Sleep-Wake Disorder (MONDO_0003406), Kidney Disease (EFO_0003086), Smith-Magenis Syndrome (MONDO_0008434), Major Depressive Disorder (MONDO_0002009), Insomnia (EFO_0004698)', 'newLinkedTargets_string': 'MTNR1A (ENSG00000168412), MTNR1B (ENSG00000134640)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.365 | Q22 | What is Ermeza? | Ermeza, also known generically as Levothyroxine Sodium, was approved by the FDA in 2000 to treat thyroid carcinoma, hypothyroidism, differentiated thyroid carcinoma, thyroid cancer, and congenital hypothyroidism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ermeza%" OR LOWER(tradeNames_string) LIKE "%ermeza%" OR LOWER(drugSynonyms_string) LIKE "%ermeza%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5964', 'tradeNames_string': 'Eltroxin, Ermeza, Euthyrox, Evotrox, L-thyroxine henning, Levo-t, Levolet, Levothroid, Levothyroid, Levothyroxine sodium, Levoxine, Levoxyl, Novothyrox, Soloxine, Synthroid, Thyquidity, Thyro-tabs, Thyrol L, Thyroxine, Tirosint, Tirosint-sol, Unithroid', 'drugName': 'Levothyroxine Sodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Thyroid hormone receptor agonist', 'linkedDiseasesDrug_string': 'Congenital Hypothyroidism (MONDO_0018612), Pain (EFO_0003843), Thyroid Carcinoma (EFO_0002892), Thyroid Cancer (MONDO_0002108), Bipolar Disorder (MONDO_0004985), Hypothyroidism (EFO_0004705), Differentiated Thyroid Carcinoma (EFO_1002017)', 'newLinkedTargets_string': 'THRA (ENSG00000126351), THRB (ENSG00000151090)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2000, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.626 | Q22 | What is Forteo? | Forteo, also known generically as Teriparatide, was approved by the FDA in 2002 to treat osteoporosis. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%forteo%" OR LOWER(tradeNames_string) LIKE "%forteo%" OR LOWER(drugSynonyms_string) LIKE "%forteo%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2407', 'tradeNames_string': 'Bonsity, Forsteo, Forteo', 'drugName': 'Teriparatide', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Parathyroid hormone receptor agonist', 'linkedDiseasesDrug_string': 'Radius Fracture (EFO_0003957), Osteoporosis (EFO_0003882), Osteopenia (HP_0000938), Neurogenic Arthropathy (EFO_1001378), Hip Fracture (EFO_0003964), Postmenopausal Osteoporosis (EFO_0003854), Osteoarthritis (MONDO_0005178), Hypoparathyroidism (EFO_0009451), Hypocalcemia (HP_0002901), Osteoarthritis, Knee (EFO_0004616), Back Pain (HP_0003418), Bone Fracture (EFO_0003931), Osteogenesis Imperfecta (MONDO_0019019)', 'newLinkedTargets_string': 'PTH1R (ENSG00000160801)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2002, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.39 | Q22 | What is Dyanavel Xr? | Dyanavel Xr, also known generically as Amphetamine, was approved by the FDA in 1955 to treat attention deficit hyperactivity disorder. It is a small molecule therapy that acts as a(n) releasing agent. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dyanavel xr%" OR LOWER(tradeNames_string) LIKE "%dyanavel xr%" OR LOWER(drugSynonyms_string) LIKE "%dyanavel xr%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1570', 'tradeNames_string': 'Adzenys er, Adzenys xr-odt, Dyanavel xr', 'drugName': 'Amphetamine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'releasing agent', 'drugMechanismOfAction': 'Norepinephrine transporter releasing agent', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Cocaine Dependence (EFO_0002610)', 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1571', 'tradeNames_string': 'Adzenys er, Adzenys xr-odt, Dyanavel xr', 'drugName': 'Amphetamine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'releasing agent', 'drugMechanismOfAction': 'Dopamine transporter releasing agent', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Cocaine Dependence (EFO_0002610)', 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.130 | Q22 | What is Amondys 45? | Amondys 45, also known generically as Casimersen, was approved by the FDA in 2021 to treat Duchenne muscular dystrophy and muscular dystrophy. It is a oligonucleotide therapy that acts as a(n) positive modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amondys 45%" OR LOWER(tradeNames_string) LIKE "%amondys 45%" OR LOWER(drugSynonyms_string) LIKE "%amondys 45%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4498', 'tradeNames_string': 'Amondys 45', 'drugName': 'Casimersen', 'drugMolecularType': 'Oligonucleotide', 'drugActionType': 'positive modulator', 'drugMechanismOfAction': 'Dystrophin pre-mRNA positive modulator', 'linkedDiseasesDrug_string': 'Muscular Dystrophy (MONDO_0020121), Duchenne Muscular Dystrophy (MONDO_0010679)', 'newLinkedTargets_string': 'DMD (ENSG00000198947)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.429 | Q22 | What is Myrbetriq Granules? | Myrbetriq Granules, also known generically as Mirabegron, was approved by the FDA in 2012 to treat Urinary incontinence, Polyuria, urgency urinary incontinence, and overactive bladder. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%myrbetriq granules%" OR LOWER(tradeNames_string) LIKE "%myrbetriq granules%" OR LOWER(drugSynonyms_string) LIKE "%myrbetriq granules%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1178', 'tradeNames_string': 'Betmiga, Myrbetriq, Myrbetriq granules', 'drugName': 'Mirabegron', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Beta-3 adrenergic receptor agonist', 'linkedDiseasesDrug_string': 'Urgency Urinary Incontinence (EFO_0006865), Polycystic Ovary Syndrome (EFO_0000660), Chronic Interstitial Cystitis (EFO_1000869), Polyuria (HP_0000103), Intracerebral Hemorrhage (EFO_0005669), Overactive Bladder (EFO_1000781), Left Ventricular Hypertrophy (EFO_0003896), Liver Disease (EFO_0001421), Heart Failure (EFO_0003144), Pain (EFO_0003843), Kidney Disease (EFO_0003086), Prediabetes Syndrome (EFO_1001121), Neurogenic Bladder (HP_0000011), Nephrolithiasis (EFO_0004253), Urinary Incontinence (HP_0000020), Achalasia (HP_0002571)', 'newLinkedTargets_string': 'ADRB3 (ENSG00000188778)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.422 | Q22 | What is Nayzilam? | Nayzilam, also known generically as Midazolam, was approved by the FDA in 1985 to treat epilepsy, status epilepticus, and amnesia. It is a small molecule therapy that acts as a(n) positive allosteric modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nayzilam%" OR LOWER(tradeNames_string) LIKE "%nayzilam%" OR LOWER(drugSynonyms_string) LIKE "%nayzilam%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2188', 'tradeNames_string': 'Midazolam in 0.8% sodium chloride, Midazolam in 0.9% sodium chloride, Nayzilam', 'drugName': 'Midazolam', 'drugMolecularType': 'Small molecule', 'drugActionType': 'positive allosteric modulator', 'drugMechanismOfAction': 'GABA-A receptor; anion channel positive allosteric modulator', 'linkedDiseasesDrug_string': "Psoriasis (EFO_0000676), Multiple Myeloma (EFO_0001378), Postmenopausal Osteoporosis (EFO_0003854), Infection (EFO_0000544), Nervous System Disease (EFO_0000618), Ischemic Stroke (HP_0002140), Atopic Eczema (EFO_0000274), Spinal Muscular Atrophy (EFO_0008525), Hypertension (EFO_0000537), Neuropathic Pain (EFO_0005762), Bone Fracture (EFO_0003931), Neck Pain (HP_0030833), Obsessive-Compulsive Disorder (EFO_0004242), Anemia (Phenotype) (EFO_0004272), Borderline Personality Disorder (HP_0012076), Inguinal Hernia (HP_0000023), Sickle Cell Anemia (MONDO_0011382), Aspergillosis (EFO_0007157), Respiratory Failure (EFO_0009686), Atherosclerosis (EFO_0003914), Schizophrenia (MONDO_0005090), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Hemorrhage (MP_0001914), Pain (EFO_0003843), Obesity (EFO_0001073), Pulmonary Tuberculosis (EFO_1000049), Gastrointestinal Stromal Tumor (MONDO_0011719), Amnesia (EFO_1001454), Hypotension (EFO_0005251), Status Epilepticus (EFO_0008526), Cataract (MONDO_0005129), Non-Alcoholic Steatohepatitis (EFO_1001249), Dementia (HP_0000726), Anxiety (EFO_0005230), Acute Myeloid Leukemia (EFO_0000222), Endometriosis (EFO_0001065), Mitochondrial Disease (MONDO_0044970), Fibrodysplasia Ossificans Progressiva (MONDO_0007606), Seizure (HP_0001250), Treatment Resistant Depression (EFO_0009854), Delirium (EFO_0009267), Chronic Hepatitis C Virus Infection (EFO_0004220), Influenza (EFO_0007328), Fluoride Poisoning (EFO_1001328), Urogenital Neoplasm (EFO_0003863), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Low Back Pain (HP_0003419), Multiple Bone Fractures (EFO_0009513), Alzheimer Disease (MONDO_0004975), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Psoriasis Vulgaris (EFO_1001494), Breast Neoplasm (EFO_0003869), Post-Traumatic Stress Disorder (EFO_0001358), Breast Cancer (MONDO_0007254), Chronic Hepatitis B Virus Infection (EFO_0004239), Cardiovascular Disease (EFO_0000319), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Epilepsy (EFO_0000474), Renal Insufficiency (HP_0000083), Aggressive Behavior (EFO_0003015), Drug Dependence (EFO_0003890), Respiratory Syncytial Virus Infection (EFO_1001413), Mesothelioma (EFO_0000588), Infertility (EFO_0000545), Polyp (EFO_0000662), Brain Injury (MONDO_0043510), Depressive Disorder (MONDO_0002050), Neoplasm (EFO_0000616), Heart Failure (EFO_0003144), Chronic Pain (HP_0012532), Tuberculosis (MONDO_0018076), Skin Disease (EFO_0000701), Major Depressive Disorder (MONDO_0002009), Type 2 Diabetes Mellitus (MONDO_0005148), Breech Presentation (HP_0001623), Infectious Disease (EFO_0005741), Cough (HP_0012735), Covid-19 (MONDO_0100096), Metastatic Melanoma (EFO_0002617), Post Operative Nausea And Vomiting (EFO_0004888), Injury (EFO_0000546), Ulcerative Colitis (EFO_0000729), Malaria (EFO_0001068), Hepatitis C Virus Infection (EFO_0003047), Prostate Adenocarcinoma (EFO_0000673), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Nicotine Dependence (EFO_0003768), Septic Shock (EFO_0006834), Schizoaffective Disorder (EFO_0005411), Parkinson Disease (MONDO_0005180), Cocaine Dependence (EFO_0002610), Pruritus (HP_0000989), Suicidal Ideation (EFO_0004320), Sepsis (HP_0100806), Subarachnoid Hemorrhage (EFO_0000713), Bipolar Disorder (MONDO_0004985), Rheumatoid Arthritis (EFO_0000685), Recurrent Tonsillitis (HP_0011110), Amyotrophic Lateral Sclerosis (MONDO_0004976), Fatigue (HP_0012378), Cirrhosis Of Liver (EFO_0001422)", 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1985, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.311 | Q22 | What is Boniva? | Boniva, also known generically as Ibandronate Sodium, was approved by the FDA in 2003 to treat postmenopausal osteoporosis and osteoporosis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%boniva%" OR LOWER(tradeNames_string) LIKE "%boniva%" OR LOWER(drugSynonyms_string) LIKE "%boniva%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1390', 'tradeNames_string': 'Bondronat, Bonviva, Iasibon, Quodixor', 'drugName': 'Ibandronic Acid', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Farnesyl diphosphate synthase inhibitor', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Bone Disease (EFO_0004260), Multiple Myeloma (EFO_0001378), Osteopenia (HP_0000938), Postmenopausal Osteoporosis (EFO_0003854), Breast Cancer (MONDO_0007254), Bone Neoplasm (EFO_0003820), Pain (EFO_0003843), Abdominal Pain (HP_0002027), Osteonecrosis (EFO_0004259), Metastasis (EFO_0009708), Lymphoid Neoplasm (EFO_0001642)', 'newLinkedTargets_string': 'FDPS (ENSG00000160752)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2003, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2230', 'tradeNames_string': 'Boniva, Ibandronate sodium', 'drugName': 'Ibandronate Sodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Farnesyl diphosphate synthase inhibitor', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Osteopenia (HP_0000938), Postmenopausal Osteoporosis (EFO_0003854), Breast Cancer (MONDO_0007254), Pain (EFO_0003843)', 'newLinkedTargets_string': 'FDPS (ENSG00000160752)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2003, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.201 | Q22 | What is Aricept? | Aricept, also known generically as Donepezil Hydrochloride, was approved by the FDA in 1996 to treat Dementia and Alzheimer disease. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%aricept%" OR LOWER(tradeNames_string) LIKE "%aricept%" OR LOWER(drugSynonyms_string) LIKE "%aricept%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_795', 'tradeNames_string': 'Adlarity, Aricept, Aricept evess, Aricept odt, Donepezil hydrochloride', 'drugName': 'Donepezil Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Acetylcholinesterase inhibitor', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Central Nervous System Neoplasm (EFO_1000158), Alzheimer Disease (MONDO_0004975), Cognitive Impairment (HP_0100543), Migraine Disorder (MONDO_0005277), Delirium (EFO_0009267), Down Syndrome (EFO_0001064), Dementia (HP_0000726), Neuropathic Pain (EFO_0005762), Depressive Disorder (MONDO_0002050), Rett Syndrome (MONDO_0010726), Vascular Dementia (EFO_0004718)', 'newLinkedTargets_string': 'ACHE (ENSG00000087085)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4037', 'tradeNames_string': '', 'drugName': 'Donepezil', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Acetylcholinesterase inhibitor', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Cancer (MONDO_0004992), Alzheimer Disease (MONDO_0004975), Multiple Sclerosis (MONDO_0005301), Migraine Disorder (MONDO_0005277), Injury (EFO_0000546), Central Nervous System Disease (EFO_0009386), Vascular Dementia (EFO_0004718), Ischemic Stroke (HP_0002140), Aphasia (HP_0002381), Nicotine Dependence (EFO_0003768), Fragile X Syndrome (MONDO_0010383), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Neuropathic Pain (EFO_0005762), Classical Progressive Supranuclear Palsy (Orphanet_240071), Cocaine Dependence (EFO_0002610), Amblyopia (MONDO_0001020), Autism Spectrum Disorder (EFO_0003756), Central Nervous System Neoplasm (EFO_1000158), Stroke (EFO_0000712), Delirium (EFO_0009267), Depressive Disorder (MONDO_0002050), Rett Syndrome (MONDO_0010726), Cognitive Impairment (HP_0100543), Sensorineural Hearing Loss (EFO_1001176), Down Syndrome (EFO_0001064), Skin Disease (EFO_0000701), Type 2 Diabetes Mellitus (MONDO_0005148), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'ACHE (ENSG00000087085)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.357 | Q22 | What is Inbrija? | Inbrija, also known generically as Levodopa, was approved by the FDA in 1970 to treat Parkinson disease. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%inbrija%" OR LOWER(tradeNames_string) LIKE "%inbrija%" OR LOWER(drugSynonyms_string) LIKE "%inbrija%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4351', 'tradeNames_string': 'Bendopa, Brocadopa, Dopar, Inbrija, Larodopa', 'drugName': 'Levodopa', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Dopamine D3 receptor agonist', 'linkedDiseasesDrug_string': 'Orthostatic Hypotension (EFO_0005252), Albinism (MONDO_0043209), Pain (EFO_0003843), Tourette Syndrome (EFO_0004895), Oculocutaneous Albinism (MONDO_0018910), Spinal Cord Injury (EFO_1001919), Post-Traumatic Stress Disorder (EFO_0001358), Aphasia (HP_0002381), Nicotine Dependence (EFO_0003768), Diabetic Retinopathy (EFO_0003770), Parkinson Disease (MONDO_0005180), Cocaine Dependence (EFO_0002610), Retinitis Pigmentosa (MONDO_0019200), Amblyopia (MONDO_0001020), Autism Spectrum Disorder (EFO_0003756), Restless Legs Syndrome (EFO_0004270), Asthma (MONDO_0004979), Stroke (EFO_0000712), Back Pain (HP_0003418), Brain Injury (MONDO_0043510), Age-Related Macular Degeneration (EFO_0001365), Amyotrophic Lateral Sclerosis (MONDO_0004976), Angelman Syndrome (MONDO_0007113), Chronic Pain (HP_0012532), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'DRD3 (ENSG00000151577)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1970, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.501 | Q22 | What is Aloxi? | Aloxi, also known generically as Palonosetron Hydrochloride, was approved by the FDA in 2003 to treat Vomiting, Nausea and vomiting, Nausea, cancer, post operative nausea and vomiting, and Chemotherapy-induced nausea and vomiting. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%aloxi%" OR LOWER(tradeNames_string) LIKE "%aloxi%" OR LOWER(drugSynonyms_string) LIKE "%aloxi%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1839', 'tradeNames_string': 'Evirex, Evista, Optruma, Ostiral, Raloxifene hydrochloride, Razylan', 'drugName': 'Raloxifene Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'modulator', 'drugMechanismOfAction': 'Estrogen receptor beta modulator', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Breast Cancer (MONDO_0007254), Prostate Adenocarcinoma (EFO_0000673)', 'newLinkedTargets_string': 'ESR2 (ENSG00000140009)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1997, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5777', 'tradeNames_string': '', 'drugName': 'Raloxifene', 'drugMolecularType': 'Small molecule', 'drugActionType': 'modulator', 'drugMechanismOfAction': 'Estrogen receptor beta modulator', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Osteopenia (HP_0000938), Alzheimer Disease (MONDO_0004975), Polycystic Ovary Syndrome (EFO_0000660), Postmenopausal Osteoporosis (EFO_0003854), Breast Cancer (MONDO_0007254), Menopause (EFO_0003922), Schizoaffective Disorder (EFO_0005411), Endometrial Cancer (MONDO_0011962), Schizophrenia (MONDO_0005090), Severe Acute Respiratory Syndrome (EFO_0000694), Prostate Adenocarcinoma (EFO_0000673)', 'newLinkedTargets_string': 'ESR2 (ENSG00000140009)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1997, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3577', 'tradeNames_string': 'Aloxi, Palonosetron hydrochloride', 'drugName': 'Palonosetron Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 3a (5-HT3a) receptor antagonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Nausea (HP_0002018), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Nausea And Vomiting (HP_0002017), Post Operative Nausea And Vomiting (EFO_0004888), Vomiting (HP_0002013)', 'newLinkedTargets_string': 'HTR3A (ENSG00000166736)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2003, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2629', 'tradeNames_string': '', 'drugName': 'Levallorphan', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Mu opioid receptor antagonist', 'linkedDiseasesDrug_string': '', 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1982, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2630', 'tradeNames_string': '', 'drugName': 'Levallorphan', 'drugMolecularType': 'Small molecule', 'drugActionType': 'partial agonist', 'drugMechanismOfAction': 'Kappa opioid receptor partial agonist', 'linkedDiseasesDrug_string': '', 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1982, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5565', 'tradeNames_string': 'Lorfan', 'drugName': 'Levallorphan Tartrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Mu opioid receptor antagonist', 'linkedDiseasesDrug_string': '', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1982, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5566', 'tradeNames_string': 'Lorfan', 'drugName': 'Levallorphan Tartrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'partial agonist', 'drugMechanismOfAction': 'Kappa opioid receptor partial agonist', 'linkedDiseasesDrug_string': '', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038), OPRK1 (ENSG00000082556)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1982, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_229', 'tradeNames_string': 'Palaprin fte', 'drugName': 'Aloxiprin', 'drugMolecularType': 'Unknown', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cyclooxygenase inhibitor', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Pain (EFO_0003843), Fever (HP_0001945)', 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 0, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.149 | Q22 | What is Versacloz? | Versacloz, also known generically as Clozapine, was approved by the FDA in 1989 to treat psychosis, schizoaffective disorder, and schizophrenia. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%versacloz%" OR LOWER(tradeNames_string) LIKE "%versacloz%" OR LOWER(drugSynonyms_string) LIKE "%versacloz%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3784', 'tradeNames_string': 'Clozapine, Clozaril, Fazaclo, Fazaclo odt, Versacloz, Zaponex', 'drugName': 'Clozapine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 2a (5-HT2a) receptor antagonist', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Intellectual Disability (HP_0001249), Dementia (HP_0000726), Schizoaffective Disorder (EFO_0005411), Anxiety (EFO_0005230), Developmental Disability (EFO_0003852), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1989, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3785', 'tradeNames_string': 'Clozapine, Clozaril, Fazaclo, Fazaclo odt, Versacloz, Zaponex', 'drugName': 'Clozapine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Dopamine D2 receptor antagonist', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Intellectual Disability (HP_0001249), Dementia (HP_0000726), Schizoaffective Disorder (EFO_0005411), Anxiety (EFO_0005230), Developmental Disability (EFO_0003852), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1989, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.456 | Q22 | What is Tasigna? | Tasigna, also known generically as Nilotinib Hydrochloride Monohydrate, was approved by the FDA in 2007 to treat chronic myelogenous leukemia. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tasigna%" OR LOWER(tradeNames_string) LIKE "%tasigna%" OR LOWER(drugSynonyms_string) LIKE "%tasigna%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6060', 'tradeNames_string': 'Tasigna', 'drugName': 'Nilotinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase ABL inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Alzheimer Disease (MONDO_0004975), Graft Versus Host Disease (MONDO_0013730), Cerebellar Ataxia (MONDO_0000437), Myeloid Leukemia (MONDO_0004643), Pulmonary Arterial Hypertension (EFO_0001361), Gastrointestinal Stromal Tumor (MONDO_0011719), Metastatic Melanoma (EFO_0002617), Chronic Myelogenous Leukemia (EFO_0000339), Malignant Colon Neoplasm (MONDO_0021063), Breast Cancer (MONDO_0007254), Pigmented Villonodular Synovitis (EFO_1001106), Huntington Disease (MONDO_0007739), Acute Lymphoblastic Leukemia (EFO_0000220), Parkinson Disease (MONDO_0005180), Acute Myeloid Leukemia (EFO_0000222), Soft Tissue Sarcoma (EFO_1001968), Glioma (EFO_0005543), Cutaneous Melanoma (EFO_0000389), Systemic Scleroderma (EFO_0000717), Schwannoma (EFO_0000693), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Chordoma (MONDO_0008978), Giant Cell Tumor (MONDO_0002171), Melanoma (EFO_0000756)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2007, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6061', 'tradeNames_string': 'Tasigna', 'drugName': 'Nilotinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Bcr/Abl fusion protein', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Alzheimer Disease (MONDO_0004975), Graft Versus Host Disease (MONDO_0013730), Cerebellar Ataxia (MONDO_0000437), Myeloid Leukemia (MONDO_0004643), Pulmonary Arterial Hypertension (EFO_0001361), Gastrointestinal Stromal Tumor (MONDO_0011719), Metastatic Melanoma (EFO_0002617), Chronic Myelogenous Leukemia (EFO_0000339), Malignant Colon Neoplasm (MONDO_0021063), Breast Cancer (MONDO_0007254), Pigmented Villonodular Synovitis (EFO_1001106), Huntington Disease (MONDO_0007739), Acute Lymphoblastic Leukemia (EFO_0000220), Parkinson Disease (MONDO_0005180), Acute Myeloid Leukemia (EFO_0000222), Soft Tissue Sarcoma (EFO_1001968), Glioma (EFO_0005543), Cutaneous Melanoma (EFO_0000389), Systemic Scleroderma (EFO_0000717), Schwannoma (EFO_0000693), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Chordoma (MONDO_0008978), Giant Cell Tumor (MONDO_0002171), Melanoma (EFO_0000756)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2007, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_435', 'tradeNames_string': 'Tasigna', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase ABL inhibitor', 'linkedDiseasesDrug_string': 'Systemic Scleroderma (EFO_0000717), Chronic Myelogenous Leukemia (EFO_0000339), Breast Cancer (MONDO_0007254), Parkinson Disease (MONDO_0005180)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2007, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_436', 'tradeNames_string': 'Tasigna', 'drugName': 'Nilotinib Hydrochloride Monohydrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Bcr/Abl fusion protein', 'linkedDiseasesDrug_string': 'Systemic Scleroderma (EFO_0000717), Chronic Myelogenous Leukemia (EFO_0000339), Breast Cancer (MONDO_0007254), Parkinson Disease (MONDO_0005180)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2007, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.654 | Q22 | What is Hycamtin? | Hycamtin, also known generically as Topotecan Hydrochloride, was approved by the FDA in 1996 to treat carcinoma, small cell lung carcinoma, ovarian carcinoma, ovarian neoplasm, small cell carcinoma, ovarian cancer, and malignant epithelial tumor of ovary. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hycamtin%" OR LOWER(tradeNames_string) LIKE "%hycamtin%" OR LOWER(drugSynonyms_string) LIKE "%hycamtin%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5442', 'tradeNames_string': 'Hycamptin, Hycamtin, Topotecan, Topotecan hydrochloride', 'drugName': 'Topotecan Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'DNA topoisomerase I, mitochondrial inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Neuroblastoma (EFO_0000621), Non-Hodgkins Lymphoma (EFO_0005952), Genital Neoplasm, Female (EFO_1001331), Covid-19 (MONDO_0100096), Small Cell Carcinoma (EFO_0008524), Peritoneal Neoplasm (EFO_1001100), Central Nervous System Cancer (EFO_0000326), Metastatic Melanoma (EFO_0002617), Myelodysplastic Syndrome (EFO_0000198), Endometrial Cancer (MONDO_0011962), Clear Cell Sarcoma (EFO_0008498), Desmoplastic Small Round Cell Tumor (EFO_1000895), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Breast Carcinoma (EFO_0000305), Cervical Adenocarcinoma (EFO_0001416), Gliosarcoma (EFO_1001465), Histiocytoma (EFO_0005561), Fallopian Tube Carcinoma (EFO_1000251), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Breast Neoplasm (EFO_0003869), Myxoid Liposarcoma (EFO_0000613), Oligoastrocytoma (EFO_0000630), Prostate Cancer (MONDO_0008315), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Cervical Carcinoma (EFO_0001061), Wilms Tumor (MONDO_0006058), Malignant Glioma (MONDO_0100342), Central Nervous System Neoplasm (EFO_1000158), Retinoblastoma (MONDO_0008380), Rhabdomyosarcoma (EFO_0002918), Anaplastic Oligodendroglioma (EFO_0002501), Small Cell Lung Carcinoma (EFO_0000702), Ganglioneuroblastoma (EFO_0000502), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Glioma (EFO_0005543), Fibrosarcoma (EFO_0002087), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Endometrioid Carcinoma (EFO_0000466), Ovarian Neoplasm (EFO_0003893), Meningeal Neoplasm (EFO_0003851), Cervical Cancer (MONDO_0002974), Chronic Myeloproliferative Disorder (EFO_0002428), Rectum Cancer (EFO_1000657), Mediastinal Cancer (EFO_0007362), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), Mesenchymoma (EFO_1001042), Ewing Sarcoma (EFO_0000174), Non-Small Cell Lung Carcinoma (EFO_0003060), Myoepithelial Tumor (MONDO_0002380), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Sarcoma (EFO_0000691), Fibromyxoid Tumor (MONDO_0037745), Aseptic Meningitis (EFO_1000823), Kidney Wilms Tumor (MONDO_0019004), Glioblastoma Multiforme (EFO_0000519), Peripheral Primitive Neuroectodermal Tumor (MONDO_0018271), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'TOP1MT (ENSG00000184428)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1325', 'tradeNames_string': 'Hycamtin, Potactasol', 'drugName': 'Topotecan', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'DNA topoisomerase I, mitochondrial inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Neuroblastoma (EFO_0000621), Multiple Myeloma (EFO_0001378), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Genital Neoplasm, Female (EFO_1001331), Covid-19 (MONDO_0100096), Small Cell Carcinoma (EFO_0008524), Peritoneal Neoplasm (EFO_1001100), Central Nervous System Cancer (EFO_0000326), Metastatic Melanoma (EFO_0002617), Myelodysplastic Syndrome (EFO_0000198), Endometrial Cancer (MONDO_0011962), Clear Cell Sarcoma (EFO_0008498), Desmoplastic Small Round Cell Tumor (EFO_1000895), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Breast Carcinoma (EFO_0000305), Cervical Adenocarcinoma (EFO_0001416), Gliosarcoma (EFO_1001465), Histiocytoma (EFO_0005561), Fallopian Tube Carcinoma (EFO_1000251), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Breast Neoplasm (EFO_0003869), Myxoid Liposarcoma (EFO_0000613), Oligoastrocytoma (EFO_0000630), Uterine Neoplasm (EFO_0003859), Prostate Cancer (MONDO_0008315), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Cervical Carcinoma (EFO_0001061), Wilms Tumor (MONDO_0006058), Malignant Glioma (MONDO_0100342), Central Nervous System Neoplasm (EFO_1000158), Retinoblastoma (MONDO_0008380), Rhabdomyosarcoma (EFO_0002918), Anaplastic Oligodendroglioma (EFO_0002501), Small Cell Lung Carcinoma (EFO_0000702), Ganglioneuroblastoma (EFO_0000502), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Glioma (EFO_0005543), Fibrosarcoma (EFO_0002087), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Endometrioid Carcinoma (EFO_0000466), Ovarian Neoplasm (EFO_0003893), Cervical Cancer (MONDO_0002974), Meningeal Neoplasm (EFO_0003851), Chronic Myeloproliferative Disorder (EFO_0002428), Rectum Cancer (EFO_1000657), Mediastinal Cancer (EFO_0007362), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), Mesenchymoma (EFO_1001042), Ewing Sarcoma (EFO_0000174), Non-Small Cell Lung Carcinoma (EFO_0003060), Myoepithelial Tumor (MONDO_0002380), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Sarcoma (EFO_0000691), Fibromyxoid Tumor (MONDO_0037745), Aseptic Meningitis (EFO_1000823), Kidney Wilms Tumor (MONDO_0019004), Glioblastoma Multiforme (EFO_0000519), Peripheral Primitive Neuroectodermal Tumor (MONDO_0018271), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'TOP1MT (ENSG00000184428)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.529 | Q22 | What is Iclusig? | Iclusig, also known generically as Ponatinib, was approved by the FDA in 2012 to treat neoplasm. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%iclusig%" OR LOWER(tradeNames_string) LIKE "%iclusig%" OR LOWER(drugSynonyms_string) LIKE "%iclusig%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2277', 'tradeNames_string': 'Iclusig', 'drugName': 'Ponatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Bcr/Abl fusion protein inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Thyroid Neoplasm (EFO_0003841), Lung Adenocarcinoma (EFO_0000571), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Small Cell Lung Carcinoma (EFO_0000702), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Lymphoblastic Leukemia (EFO_0000220), Gastrointestinal Stromal Tumor (MONDO_0011719), Acute Myeloid Leukemia (EFO_0000222), Glioblastoma Multiforme (EFO_0000519), Myelodysplastic Syndrome (EFO_0000198), Chronic Myelogenous Leukemia (EFO_0000339)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6150', 'tradeNames_string': 'Iclusig', 'drugName': 'Ponatinib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Bcr/Abl fusion protein inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Chronic Myelogenous Leukemia (EFO_0000339)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.425 | Q22 | What is Galafold? | Galafold, also known generically as Migalastat Hydrochloride, was approved by the FDA in 2018 to treat Fabry disease. It is a small molecule therapy that acts as a(n) stabiliser. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%galafold%" OR LOWER(tradeNames_string) LIKE "%galafold%" OR LOWER(drugSynonyms_string) LIKE "%galafold%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3147', 'tradeNames_string': 'At-1001, gr-181314a, Galafold', 'drugName': 'Migalastat', 'drugMolecularType': 'Small molecule', 'drugActionType': 'stabiliser', 'drugMechanismOfAction': 'Alpha-galactosidase A stabiliser', 'linkedDiseasesDrug_string': 'Fabry Disease (MONDO_0010526)', 'newLinkedTargets_string': 'GLA (ENSG00000102393)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2018, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_549', 'tradeNames_string': 'Galafold', 'drugName': 'Migalastat Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'stabiliser', 'drugMechanismOfAction': 'Alpha-galactosidase A stabiliser', 'linkedDiseasesDrug_string': 'Fabry Disease (MONDO_0010526)', 'newLinkedTargets_string': 'GLA (ENSG00000102393)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2018, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.448 | Q22 | What is Zimhi? | Zimhi, also known generically as Naloxone Hydrochloride, was approved by the FDA in 1971 to treat unipolar depression, pain, and septic shock. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zimhi%" OR LOWER(tradeNames_string) LIKE "%zimhi%" OR LOWER(drugSynonyms_string) LIKE "%zimhi%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3927', 'tradeNames_string': 'Evzio, Evzio (autoinjector), Kloxxado, Nalone, Naloxone, Naloxone hydrochloride, Naloxone hydrochloride (autoinjector), Narcan, Narcan neonatal, Narconil, Prenoxad, Zimhi', 'drugName': 'Naloxone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Opioid receptors; mu/kappa/delta antagonist', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Intestinal Obstruction (MONDO_0004565), Septic Shock (EFO_0006834), Pain (EFO_0003843), Constipation (HP_0002019), Opioid Dependence (EFO_0005611), Gambling Behaviour (EFO_0004699)', 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1971, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.628 | Q22 | What is Axiron? | Axiron, also known generically as Testosterone, was approved by the FDA in 1972 to treat Hypogonadotropic hypogonadism, Klinefelter's syndrome, orchitis, hypogonadism, and hypogonadotropic hypogonadism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%axiron%" OR LOWER(tradeNames_string) LIKE "%axiron%" OR LOWER(drugSynonyms_string) LIKE "%axiron%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5308', 'tradeNames_string': 'Androderm, Androgel, Androgel 1%, Andropatch, Axiron, Fortesta, Intrinsa, Natesto, Striant, Striant sr, Testim, Testim 1%, Testoderm, Testoderm tts, Testogel, Testopatch, Testopel, Testoral, Testosterone, Tostran, Vogelxo', 'drugName': 'Testosterone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Androgen Receptor agonist', 'linkedDiseasesDrug_string': "Erectile Dysfunction (EFO_0004234), Cancer (MONDO_0004992), Hip Fracture (EFO_0003964), Coronary Artery Disease (EFO_0001645), Multiple Sclerosis (MONDO_0005301), Obesity (EFO_0001073), Aids (EFO_0000765), Hypogonadotropic Hypogonadism (MONDO_0018555), Klinefelter'S Syndrome (EFO_1001006), Aging (GO_0007568), Anorexia Nervosa (MONDO_0005351), Prostate Carcinoma (EFO_0001663), Spinal Cord Injury (EFO_1001919), Orchitis (EFO_1001078), Polycystic Ovary Syndrome (EFO_0000660), Prostate Cancer (MONDO_0008315), Cerebral Arterial Disease (EFO_1000859), Growth Delay (HP_0001510), Muscular Disease (EFO_0002970), Hypogonadotropic Hypogonadism (HP_0000044), Sexual Dysfunction (EFO_0004714), Hypogonadism (MONDO_0002146), Insulin Resistance (EFO_0002614), Abnormality Of Connective Tissue (HP_0003549), Sarcopenia (EFO_1000653), Menopause (EFO_0003922), Infertility (EFO_0000545), Chronic Kidney Disease (EFO_0003884), Kallmann Syndrome (MONDO_0018800), Testicular Carcinoma (EFO_0005088), Heart Failure (EFO_0003144), Metastatic Prostate Cancer (EFO_0000196), Metabolic Syndrome (EFO_0000195), Dyspareunia (HP_0030016), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145), Genetic Disorder Of Sex Development (Orphanet_325690)", 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1972, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.150 | Q22 | What is Tybost? | Tybost, also known generically as Cobicistat, was approved by the FDA in 2012 to treat HIV-1 infection, infection, and HIV infection. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tybost%" OR LOWER(tradeNames_string) LIKE "%tybost%" OR LOWER(drugSynonyms_string) LIKE "%tybost%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4493', 'tradeNames_string': 'Tybost', 'drugName': 'Cobicistat', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cytochrome P450 3A inhibitor', 'linkedDiseasesDrug_string': 'Insulin Resistance (EFO_0002614), Infection (EFO_0000544), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Covid-19 (MONDO_0100096), Acute Lymphoblastic Leukemia (EFO_0000220), Hiv-1 Infection (EFO_0000180), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Aids (EFO_0000765), Pneumocystosis (EFO_0007448), Malaria (EFO_0001068)', 'newLinkedTargets_string': 'CYP3A4 (ENSG00000160868), CYP3A5 (ENSG00000106258), CYP3A43 (ENSG00000021461), CYP3A7 (ENSG00000160870)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.592 | Q22 | What is Sotalol Hydrochloride? | The drug Sotalol Hydrochloride was approved by the FDA in 1992 to treat Ventricular arrhythmia. It is a small molecule therapy that acts as a(n) blocker and antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sotalol hydrochloride%" OR LOWER(tradeNames_string) LIKE "%sotalol hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%sotalol hydrochloride%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4569', 'tradeNames_string': 'Beta-cardone, Betapace, Betapace af, Sorine, Sotacor, Sotalex, Sotalol hydrochloride, Sotylize', 'drugName': 'Sotalol Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Beta-1 adrenergic receptor antagonist', 'linkedDiseasesDrug_string': 'Ventricular Arrhythmia (HP_0004308), Heart Failure (EFO_0003144), Atrial Fibrillation (EFO_0000275)', 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), KCNH2 (ENSG00000055118), ADRB2 (ENSG00000169252)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1992, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4570', 'tradeNames_string': 'Beta-cardone, Betapace, Betapace af, Sorine, Sotacor, Sotalex, Sotalol hydrochloride, Sotylize', 'drugName': 'Sotalol Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'HERG blocker', 'linkedDiseasesDrug_string': 'Ventricular Arrhythmia (HP_0004308), Heart Failure (EFO_0003144), Atrial Fibrillation (EFO_0000275)', 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), KCNH2 (ENSG00000055118), ADRB2 (ENSG00000169252)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1992, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4571', 'tradeNames_string': 'Beta-cardone, Betapace, Betapace af, Sorine, Sotacor, Sotalex, Sotalol hydrochloride, Sotylize', 'drugName': 'Sotalol Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Beta-2 adrenergic receptor antagonist', 'linkedDiseasesDrug_string': 'Ventricular Arrhythmia (HP_0004308), Heart Failure (EFO_0003144), Atrial Fibrillation (EFO_0000275)', 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), KCNH2 (ENSG00000055118), ADRB2 (ENSG00000169252)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1992, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.354 | Q22 | What is Keppra Xr? | Keppra Xr, also known generically as Levetiracetam, was approved by the FDA in 1999 to treat Seizure, Bilateral tonic-clonic seizure, Focal-onset seizure, epilepsy, and epilepsy with generalized tonic-clonic seizures. It is a small molecule therapy that acts as a(n) modulator and blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%keppra xr%" OR LOWER(tradeNames_string) LIKE "%keppra xr%" OR LOWER(drugSynonyms_string) LIKE "%keppra xr%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_283', 'tradeNames_string': 'Desitrend, Elepsia xr, Keppra, Keppra xr, Levetiracetam, Levetiracetam in sodium chloride, Matever, Spritam', 'drugName': 'Levetiracetam', 'drugMolecularType': 'Small molecule', 'drugActionType': 'modulator', 'drugMechanismOfAction': 'Synaptic vesicle glycoprotein 2A modulator', 'linkedDiseasesDrug_string': 'Canavan Disease (MONDO_0010079), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), Movement Disorder (EFO_0004280), Focal-Onset Seizure (HP_0007359), Central Nervous System Cancer (EFO_0000326), Panic Disorder (EFO_0004262), Status Epilepticus (EFO_0008526), Drug-Induced Dyskinesia (EFO_1000904), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Aphasia (HP_0002381), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Partial Epilepsy (EFO_0004263), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Photosensitive Epilepsy (MONDO_0015643), Seizure (HP_0001250), Acute Myeloid Leukemia (EFO_0000222), Alcohol Withdrawal (EFO_0004777), Restless Legs Syndrome (EFO_0004270), Obsessive-Compulsive Disorder (EFO_0004242), Stroke (EFO_0000712), Sickle Cell Anemia (MONDO_0011382), Subarachnoid Hemorrhage (EFO_0000713), Brain Neoplasm (EFO_0003833), Glioma (EFO_0005543), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Bilateral Tonic-Clonic Seizure (HP_0002069), Opioid Dependence (EFO_0005611), Psychosis (EFO_0005407), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Postherpetic Neuralgia (MONDO_0041052), Torticollis (HP_0000473), Polyneuropathy (EFO_0009562), Generalized Non-Motor (Absence) Seizure (HP_0002121), Glioblastoma Multiforme (EFO_0000519), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'CACNA1B (ENSG00000148408), SV2A (ENSG00000159164)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1999, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_284', 'tradeNames_string': 'Desitrend, Elepsia xr, Keppra, Keppra xr, Levetiracetam, Levetiracetam in sodium chloride, Matever, Spritam', 'drugName': 'Levetiracetam', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Voltage-gated N-type calcium channel alpha-1B subunit blocker', 'linkedDiseasesDrug_string': 'Canavan Disease (MONDO_0010079), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), Movement Disorder (EFO_0004280), Focal-Onset Seizure (HP_0007359), Central Nervous System Cancer (EFO_0000326), Panic Disorder (EFO_0004262), Status Epilepticus (EFO_0008526), Drug-Induced Dyskinesia (EFO_1000904), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Aphasia (HP_0002381), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Partial Epilepsy (EFO_0004263), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Photosensitive Epilepsy (MONDO_0015643), Seizure (HP_0001250), Acute Myeloid Leukemia (EFO_0000222), Alcohol Withdrawal (EFO_0004777), Restless Legs Syndrome (EFO_0004270), Obsessive-Compulsive Disorder (EFO_0004242), Stroke (EFO_0000712), Sickle Cell Anemia (MONDO_0011382), Subarachnoid Hemorrhage (EFO_0000713), Brain Neoplasm (EFO_0003833), Glioma (EFO_0005543), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Bilateral Tonic-Clonic Seizure (HP_0002069), Opioid Dependence (EFO_0005611), Psychosis (EFO_0005407), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Postherpetic Neuralgia (MONDO_0041052), Torticollis (HP_0000473), Polyneuropathy (EFO_0009562), Generalized Non-Motor (Absence) Seizure (HP_0002121), Glioblastoma Multiforme (EFO_0000519), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'CACNA1B (ENSG00000148408), SV2A (ENSG00000159164)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1999, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.469 | Q22 | What is Mycapssa? | Mycapssa, also known generically as Octreotide Acetate, was approved by the FDA in 1988 to treat neoplasm, carcinoid tumor, metastasis, and acromegaly. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mycapssa%" OR LOWER(tradeNames_string) LIKE "%mycapssa%" OR LOWER(drugSynonyms_string) LIKE "%mycapssa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_759', 'tradeNames_string': 'Bynfezia pen, Mycapssa, Octreotide acetate, Octreotide acetate (preservative free), Octreotide acetate preservative free, Sandostatin, Sandostatin lar', 'drugName': 'Octreotide Acetate', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Somatostatin receptor agonist', 'linkedDiseasesDrug_string': 'Obesity (EFO_0001073), Kidney Failure (EFO_1002048), Prader-Willi Syndrome (MONDO_0008300), Diarrhea (HP_0002014), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Acromegaly (EFO_1001485), Diabetic Retinopathy (EFO_0003770), Lymphoma (EFO_0000574), Pituitary Tumor (MONDO_0017611), Metastasis (EFO_0009708), Neuroendocrine Neoplasm (EFO_1001901), Intestinal Obstruction (MONDO_0004565), Familial Hyperinsulinism (MONDO_0017182), Constipation (HP_0002019), Carcinoid Tumor (EFO_0004243), Liver Cancer (MONDO_0002691), Thymus Neoplasm (EFO_0002626), Carcinoid Syndrome (EFO_1000852), Neoplasm (EFO_0000616), Enteritis (MONDO_0043579)', 'newLinkedTargets_string': 'SSTR5 (ENSG00000162009), SSTR2 (ENSG00000180616), SSTR4 (ENSG00000132671), SSTR1 (ENSG00000139874), SSTR3 (ENSG00000278195)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1988, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.331 | Q22 | What is Ixempra Kit? | Ixempra Kit, also known generically as Ixabepilone, was approved by the FDA in 2007 to treat breast carcinoma, cancer, neoplasm, breast neoplasm, and breast cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ixempra kit%" OR LOWER(tradeNames_string) LIKE "%ixempra kit%" OR LOWER(drugSynonyms_string) LIKE "%ixempra kit%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2339', 'tradeNames_string': 'Ixempra, Ixempra kit', 'drugName': 'Ixabepilone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tubulin inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Verrucous Carcinoma (EFO_0007535), Anaplastic Large Cell Lymphoma (EFO_0003032), Burkitts Lymphoma (EFO_0000309), Endometrial Cancer (MONDO_0011962), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Breast Neoplasm (EFO_0003869), Prostate Cancer (MONDO_0008315), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Male Breast Carcinoma (EFO_0006861), Lymphoma (EFO_0000574), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Tongue Neoplasm (EFO_0003871), Pancreatic Carcinoma (EFO_0002618), Urinary Bladder Carcinoma (MONDO_0004986), Hypopharyngeal Carcinoma (EFO_0002938), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Oropharyngeal Carcinoma (MONDO_0044926), Head And Neck Malignant Neoplasia (EFO_0006859), Follicular Lymphoma (MONDO_0018906), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Melanoma (EFO_0000756), Stomach Neoplasm (EFO_0003897)', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2007, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.189 | Q22 | What is Valtoco? | Valtoco, also known generically as Diazepam, was approved by the FDA in 1963 to treat Agitation, epilepsy, anxiety, anxiety disorder, Stiff-Person syndrome, and cerebral palsy. It is a small molecule therapy that acts as a(n) positive allosteric modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%valtoco%" OR LOWER(tradeNames_string) LIKE "%valtoco%" OR LOWER(drugSynonyms_string) LIKE "%valtoco%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1439', 'tradeNames_string': 'Alupram 10, Alupram 2, Alupram 5, Apozepam, Atensine, Dialar, Dialar fte, Diastat, Diastat acudial, Diazepam, Diazepam intensol, Dizac, E-Pam, Paxel, Q-pam, Relanium, Scriptopam, Serenack, Solis, Stesolid, Tensium, Tranimul, Valclair, Valium, Valrelease, Valtoco, Vivol', 'drugName': 'Diazepam', 'drugMolecularType': 'Small molecule', 'drugActionType': 'positive allosteric modulator', 'drugMechanismOfAction': 'GABA-A receptor; anion channel positive allosteric modulator', 'linkedDiseasesDrug_string': 'Cerebral Palsy (EFO_1000632), Anxiety Disorder (EFO_0006788), Rotator Cuff Tear (EFO_1001250), Pain (EFO_0003843), Agitation (HP_0000713), Stiff-Person Syndrome (EFO_0007498), Dementia (HP_0000726), Landau-Kleffner Syndrome (EFO_1001010), Anxiety (EFO_0005230), Complex Partial Epilepsy (EFO_1000877), Epilepsy (EFO_0000474), Low Back Pain (HP_0003419), Seizure (HP_0001250), Depressive Disorder (MONDO_0002050), Status Epilepticus (EFO_0008526), Schizophrenia (MONDO_0005090), Injury (EFO_0000546)', 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1963, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.126 | Q22 | What is Kyprolis? | Kyprolis, also known generically as Carfilzomib, was approved by the FDA in 2009 to treat cancer, neoplasm, and multiple myeloma. It is a protein therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%kyprolis%" OR LOWER(tradeNames_string) LIKE "%kyprolis%" OR LOWER(drugSynonyms_string) LIKE "%kyprolis%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2422', 'tradeNames_string': 'Kyprolis', 'drugName': 'Carfilzomib', 'drugMolecularType': 'Protein', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': '26S proteosome inhibitor', 'linkedDiseasesDrug_string': "Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Amyloidosis (EFO_1001875), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Plasmacytoma (EFO_0006738), Plasma Cell Leukemia (EFO_0006475), Neuroendocrine Carcinoma (MONDO_0002120), Prostate Cancer (MONDO_0008315), Mantle Cell Lymphoma (EFO_1001469), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Mycosis Fungoides (EFO_1001051), Diffuse Large B-Cell Lymphoma (EFO_0000403), Small Cell Lung Carcinoma (EFO_0000702), Neoplasm Of Mature B-Cells (EFO_0000096), Waldenstrom Macroglobulinemia (EFO_0009441), Hodgkins Lymphoma (EFO_0000183), Prolymphocytic Leukemia (MONDO_0001023), Follicular Lymphoma (MONDO_0018906), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Kidney Cancer (MONDO_0002367), Primary Systemic Amyloidosis (MONDO_0017816), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211)", 'newLinkedTargets_string': 'PSMD1 (ENSG00000173692), PSMB2 (ENSG00000126067), PSMB1 (ENSG00000008018), PSMB5 (ENSG00000100804), PSMB8 (ENSG00000204264), PSMB9 (ENSG00000240065), PSMB6 (ENSG00000142507), PSMD14 (ENSG00000115233), PSMA1 (ENSG00000129084), PSMA2 (ENSG00000106588), PSMA3 (ENSG00000100567), PSMA4 (ENSG00000041357), PSMA5 (ENSG00000143106), PSMA6 (ENSG00000100902), PSMA7 (ENSG00000101182), PSMA8 (ENSG00000154611), PSMB10 (ENSG00000205220), PSMB11 (ENSG00000222028), PSMB3 (ENSG00000277791), PSMB4 (ENSG00000159377), PSMB7 (ENSG00000136930), ADRM1 (ENSG00000130706), PSMC2 (ENSG00000161057), PSMC1 (ENSG00000100764), PSMC4 (ENSG00000013275), PSMC6 (ENSG00000100519), PSMC3 (ENSG00000165916), PSMC5 (ENSG00000087191), PSMD2 (ENSG00000175166), PSMD3 (ENSG00000108344), PSMD12 (ENSG00000197170), PSMD11 (ENSG00000108671), PSMD6 (ENSG00000163636), PSMD7 (ENSG00000103035), PSMD13 (ENSG00000185627), PSMD4 (ENSG00000159352), PSMD8 (ENSG00000099341), SEM1 (ENSG00000127922)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.609 | Q22 | What is Zioptan? | Zioptan, also known generically as Tafluprost, was approved by the FDA in 2012 to treat glaucoma, open-angle glaucoma, and ocular hypertension. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zioptan%" OR LOWER(tradeNames_string) LIKE "%zioptan%" OR LOWER(drugSynonyms_string) LIKE "%zioptan%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4212', 'tradeNames_string': 'Saflutan, Zioptan', 'drugName': 'Tafluprost', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Prostanoid FP receptor agonist', 'linkedDiseasesDrug_string': 'Open-Angle Glaucoma (EFO_0004190), Ocular Hypertension (EFO_1001069), Glaucoma (MONDO_0005041)', 'newLinkedTargets_string': 'PTGFR (ENSG00000122420)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.99 | Q22 | What is Mirvaso? | Mirvaso, also known generically as Brimonidine Tartrate, was approved by the FDA in 1996 to treat Erythema, glaucoma, hypertension, open-angle glaucoma, rosacea, and ocular hypertension. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mirvaso%" OR LOWER(tradeNames_string) LIKE "%mirvaso%" OR LOWER(drugSynonyms_string) LIKE "%mirvaso%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4923', 'tradeNames_string': 'Alphagan, Alphagan p, Brimonidine tartrate, Brymont, Lumify, Mirvaso, Qoliana', 'drugName': 'Brimonidine Tartrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Adrenergic receptor alpha-2 agonist', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Flushing (HP_0031284), Rosacea (EFO_1000760), Presbyopia (MONDO_0001330), Hand-Foot Syndrome (EFO_1001893), Open-Angle Glaucoma (EFO_0004190), Hypertension (EFO_0000537), Erythema (HP_0010783), Dry Eye Syndrome (EFO_1000906), Hyperemia (EFO_0003822), Ocular Hypertension (EFO_1001069), Glaucoma (MONDO_0005041), Alcohol-Related Disorders (MONDO_0021698), Corneal Edema (EFO_1000879)', 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.146 | Q22 | What is Impoyz? | Impoyz, also known generically as Clobetasol Propionate, was approved by the FDA in 1985 to treat psoriasis, skin disease, and psoriasis vulgaris. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%impoyz%" OR LOWER(tradeNames_string) LIKE "%impoyz%" OR LOWER(drugSynonyms_string) LIKE "%impoyz%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5376', 'tradeNames_string': 'Clarelux, Clobaderm, Clobetasol propionate, Clobetasol propionate (emollient), Clobex, Cormax, Dermovate, Dermovate nn, Embeline, Embeline e, Etrivex, Impeklo, Impoyz, Olux, Olux e, Temovate, Temovate e', 'drugName': 'Clobetasol Propionate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Oral Lichen Planus (EFO_0008517), Graft Versus Host Disease (MONDO_0013730), Scleroderma (EFO_1001993), Psoriasis Vulgaris (EFO_1001494), Herpes Labialis (EFO_1001347), Vulvar Lichen Sclerosus (EFO_1000623), Cataract (MONDO_0005129), Atopic Eczema (EFO_0000274), Bullous Pemphigoid (EFO_0007187), Lichen Planus (EFO_1000726), Alopecia Areata (EFO_0004192), Rheumatoid Arthritis (EFO_0000685), Toxic Epidermal Necrolysis (EFO_0004775), Rectum Cancer (EFO_1000657), Colon Adenocarcinoma (EFO_1001949), Lichen Disease (EFO_1000724), Skin Disease (EFO_0000701), Seborrheic Dermatitis (EFO_1000764), Phlebitis (EFO_1001395)', 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1985, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.243 | Q22 | What is Bydureon? | Bydureon, also known generically as Exenatide, was approved by the FDA in 2005 to treat diabetes mellitus and type 2 diabetes mellitus. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bydureon%" OR LOWER(tradeNames_string) LIKE "%bydureon%" OR LOWER(drugSynonyms_string) LIKE "%bydureon%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3783', 'tradeNames_string': 'Bydureon, Bydureon bcise, Bydureon pen, Byetta', 'drugName': 'Exenatide', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucagon-like peptide 1 receptor agonist', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Coronary Artery Disease (EFO_0001645), Obesity (EFO_0001073), Hyperinsulinemic Hypoglycemia (EFO_0007318), Polycystic Ovary Syndrome (EFO_0000660), Hyperglycemia (HP_0003074), Ischemic Stroke (HP_0002140), Parkinson Disease (MONDO_0005180), Acute Myocardial Infarction (EFO_0008583), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Multiple System Atrophy (EFO_1001050), Cocaine Dependence (EFO_0002610), Renal Insufficiency (HP_0000083), Morbid Obesity (EFO_0001074), Stroke (EFO_0000712), Myocardial Infarction (EFO_0000612), Cerebral Small Vessel Disease (EFO_0008493), Alcohol Dependence (MONDO_0007079), Smoking Cessation (EFO_0004319), Weight Loss (HP_0001824), Prediabetes Syndrome (EFO_1001121), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148)', 'newLinkedTargets_string': 'GLP1R (ENSG00000112164)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.400 | Q22 | What is Megace Es? | Megace Es, also known generically as Megestrol Acetate, was approved by the FDA in 1971 to treat Anorexia, Cachexia, cancer, neoplasm, AIDS, and inborn errors of immunity. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%megace es%" OR LOWER(tradeNames_string) LIKE "%megace es%" OR LOWER(drugSynonyms_string) LIKE "%megace es%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_382', 'tradeNames_string': 'Megace, Megace es, Megestrol acetate, Ovaban', 'drugName': 'Megestrol Acetate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Progesterone receptor agonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Uterine Cancer (MONDO_0002715), Inborn Error Of Immunity (MONDO_0003778), Intraepithelial Neoplasia (MONDO_0024474), Aids (EFO_0000765), Endometrial Cancer (MONDO_0011962), Hot Flashes (HP_0031217), Breast Neoplasm (EFO_0003869), Uterine Neoplasm (EFO_0003859), Breast Cancer (MONDO_0007254), Dementia (HP_0000726), Endometrial Carcinoma (EFO_1001512), Cachexia (HP_0004326), Chronic Obstructive Pulmonary Disease (EFO_0000341), Endometrial Neoplasm (EFO_0004230), Liver Cancer (MONDO_0002691), Head And Neck Malignant Neoplasia (EFO_0006859), Neoplasm (EFO_0000616), Hiv Wasting Syndrome (EFO_0007312), Anorexia (HP_0002039)', 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1971, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.475 | Q22 | What is Pataday Once Daily Relief? | Pataday Once Daily Relief, also known generically as Olopatadine Hydrochloride, was approved by the FDA in 1996 to treat Pruritus, seasonal allergic rhinitis, allergic rhinitis, and allergic conjunctivitis. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pataday once daily relief%" OR LOWER(tradeNames_string) LIKE "%pataday once daily relief%" OR LOWER(drugSynonyms_string) LIKE "%pataday once daily relief%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6184', 'tradeNames_string': 'Olopatadine hydrochloride, Pataday, Pataday once daily relief, Pataday twice daily relief, Patanase, Patanol, Pazeo', 'drugName': 'Olopatadine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Histamine H1 receptor antagonist', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Seasonal Allergic Rhinitis (EFO_0003956), Pruritus (HP_0000989), Allergic Rhinitis (EFO_0005854)', 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.200 | Q22 | What is Adlarity? | Adlarity, also known generically as Donepezil Hydrochloride, was approved by the FDA in 1996 to treat Dementia and Alzheimer disease. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%adlarity%" OR LOWER(tradeNames_string) LIKE "%adlarity%" OR LOWER(drugSynonyms_string) LIKE "%adlarity%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_795', 'tradeNames_string': 'Adlarity, Aricept, Aricept evess, Aricept odt, Donepezil hydrochloride', 'drugName': 'Donepezil Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Acetylcholinesterase inhibitor', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Central Nervous System Neoplasm (EFO_1000158), Alzheimer Disease (MONDO_0004975), Cognitive Impairment (HP_0100543), Migraine Disorder (MONDO_0005277), Delirium (EFO_0009267), Down Syndrome (EFO_0001064), Dementia (HP_0000726), Neuropathic Pain (EFO_0005762), Depressive Disorder (MONDO_0002050), Rett Syndrome (MONDO_0010726), Vascular Dementia (EFO_0004718)', 'newLinkedTargets_string': 'ACHE (ENSG00000087085)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.100 | Q22 | What is Qoliana? | Qoliana, also known generically as Brimonidine Tartrate, was approved by the FDA in 1996 to treat Erythema, glaucoma, hypertension, open-angle glaucoma, rosacea, and ocular hypertension. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%qoliana%" OR LOWER(tradeNames_string) LIKE "%qoliana%" OR LOWER(drugSynonyms_string) LIKE "%qoliana%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4923', 'tradeNames_string': 'Alphagan, Alphagan p, Brimonidine tartrate, Brymont, Lumify, Mirvaso, Qoliana', 'drugName': 'Brimonidine Tartrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Adrenergic receptor alpha-2 agonist', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Flushing (HP_0031284), Rosacea (EFO_1000760), Presbyopia (MONDO_0001330), Hand-Foot Syndrome (EFO_1001893), Open-Angle Glaucoma (EFO_0004190), Hypertension (EFO_0000537), Erythema (HP_0010783), Dry Eye Syndrome (EFO_1000906), Hyperemia (EFO_0003822), Ocular Hypertension (EFO_1001069), Glaucoma (MONDO_0005041), Alcohol-Related Disorders (MONDO_0021698), Corneal Edema (EFO_1000879)', 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.377 | Q22 | What is Saxenda? | Saxenda, also known generically as Liraglutide, was approved by the FDA in 2010 to treat diabetes mellitus, MODY, and type 2 diabetes mellitus. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%saxenda%" OR LOWER(tradeNames_string) LIKE "%saxenda%" OR LOWER(drugSynonyms_string) LIKE "%saxenda%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5245', 'tradeNames_string': 'Saxenda, Victoza', 'drugName': 'Liraglutide', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucagon-like peptide 1 receptor agonist', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Alzheimer Disease (MONDO_0004975), Obesity (EFO_0001073), Eating Disorder (EFO_0005203), Hyperglycemia (HP_0003074), Non-Alcoholic Steatohepatitis (EFO_1001249), Parkinson Disease (MONDO_0005180), Pouchitis (EFO_0003921), Abnormal Glucose Tolerance (EFO_0002546), Bipolar Disorder (MONDO_0004985), Opioid Dependence (EFO_0005611), Short Bowel Syndrome (MONDO_0015183), Smoking Cessation (EFO_0004319), Sleep Apnea (EFO_0003877), Diabetic Nephropathy (EFO_0000401), Mody (Orphanet_552), Heart Failure (EFO_0003144), Weight Loss (HP_0001824), Metabolic Syndrome (EFO_0000195), Prediabetes Syndrome (EFO_1001121), Major Depressive Disorder (MONDO_0002009), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148)', 'newLinkedTargets_string': 'GLP1R (ENSG00000112164)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.330 | Q22 | What is Tibsovo? | Tibsovo, also known generically as Ivosidenib, was approved by the FDA in 2018 to treat acute myeloid leukemia, cancer, and neoplasm. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tibsovo%" OR LOWER(tradeNames_string) LIKE "%tibsovo%" OR LOWER(drugSynonyms_string) LIKE "%tibsovo%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1675', 'tradeNames_string': 'Tibsovo', 'drugName': 'Ivosidenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor', 'linkedDiseasesDrug_string': 'Chondrosarcoma (EFO_0000333), Cancer (MONDO_0004992), Neoplasm (EFO_0000616), Liver Disease (EFO_0001421), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Acute Myeloid Leukemia (EFO_0000222), Glioma (EFO_0005543), Myelodysplastic Syndrome (EFO_0000198), Cholangiocarcinoma (EFO_0005221)', 'newLinkedTargets_string': 'IDH1 (ENSG00000138413)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2018, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.283 | Q22 | What is Infugem? | Infugem, also known generically as Gemcitabine Hydrochloride, was approved by the FDA in 1996 to treat breast carcinoma, ovarian carcinoma, pancreatic carcinoma, non-small cell lung carcinoma, breast cancer, and ovarian cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%infugem%" OR LOWER(tradeNames_string) LIKE "%infugem%" OR LOWER(drugSynonyms_string) LIKE "%infugem%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4', 'tradeNames_string': 'Gemcitabine hydrochloride, Gemzar, Infugem', 'drugName': 'Gemcitabine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'DNA polymerase (alpha/delta/epsilon) inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Ureter Cancer (MONDO_0008627), Plasmacytoma (EFO_0006738), Urothelial Carcinoma (EFO_0008528), Intrahepatic Cholangiocarcinoma (EFO_1001961), Endometrial Cancer (MONDO_0011962), Plasma Cell Leukemia (EFO_0006475), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Hilar Cholangiocarcinoma (EFO_1001959), Breast Carcinoma (EFO_0000305), Cervical Adenocarcinoma (EFO_0001416), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Uterine Neoplasm (EFO_0003859), Breast Cancer (MONDO_0007254), Mantle Cell Lymphoma (EFO_1001469), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Thromboembolism (HP_0001907), Mycosis Fungoides (EFO_1001051), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Urinary Bladder Carcinoma (MONDO_0004986), Gallbladder Cancer (MONDO_0005411), Neoplasm Of Mature B-Cells (EFO_0000096), Mesothelioma (EFO_0000588), Triple-Negative Breast Cancer (EFO_0005537), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Carcinoma (EFO_0000313), Endometrioid Carcinoma (EFO_0000466), Hodgkins Lymphoma (EFO_0000183), Cervical Cancer (MONDO_0002974), Liver Cancer (MONDO_0002691), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Leukemia (EFO_0000565), Nasopharyngeal Neoplasm (EFO_0004252), Uterine Carcinosarcoma (EFO_1000613), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Urinary Bladder Cancer (MONDO_0001187), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145), Lymphoproliferative Syndrome (MONDO_0016537)', 'newLinkedTargets_string': 'POLA1 (ENSG00000101868), POLD4 (ENSG00000175482), POLD3 (ENSG00000077514), POLD1 (ENSG00000062822), POLD2 (ENSG00000106628), POLE (ENSG00000177084), POLA2 (ENSG00000014138), PRIM1 (ENSG00000198056), PRIM2 (ENSG00000146143), POLE2 (ENSG00000100479), POLE3 (ENSG00000148229), RRM1 (ENSG00000167325), RRM2B (ENSG00000048392), RRM2 (ENSG00000171848)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5', 'tradeNames_string': 'Gemcitabine hydrochloride, Gemzar, Infugem', 'drugName': 'Gemcitabine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Ribonucleoside-diphosphate reductase RR1 inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Ureter Cancer (MONDO_0008627), Plasmacytoma (EFO_0006738), Urothelial Carcinoma (EFO_0008528), Intrahepatic Cholangiocarcinoma (EFO_1001961), Endometrial Cancer (MONDO_0011962), Plasma Cell Leukemia (EFO_0006475), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Hilar Cholangiocarcinoma (EFO_1001959), Breast Carcinoma (EFO_0000305), Cervical Adenocarcinoma (EFO_0001416), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Uterine Neoplasm (EFO_0003859), Breast Cancer (MONDO_0007254), Mantle Cell Lymphoma (EFO_1001469), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Thromboembolism (HP_0001907), Mycosis Fungoides (EFO_1001051), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Urinary Bladder Carcinoma (MONDO_0004986), Gallbladder Cancer (MONDO_0005411), Neoplasm Of Mature B-Cells (EFO_0000096), Mesothelioma (EFO_0000588), Triple-Negative Breast Cancer (EFO_0005537), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Carcinoma (EFO_0000313), Endometrioid Carcinoma (EFO_0000466), Hodgkins Lymphoma (EFO_0000183), Cervical Cancer (MONDO_0002974), Liver Cancer (MONDO_0002691), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Leukemia (EFO_0000565), Nasopharyngeal Neoplasm (EFO_0004252), Uterine Carcinosarcoma (EFO_1000613), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Urinary Bladder Cancer (MONDO_0001187), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145), Lymphoproliferative Syndrome (MONDO_0016537)', 'newLinkedTargets_string': 'POLA1 (ENSG00000101868), POLD4 (ENSG00000175482), POLD3 (ENSG00000077514), POLD1 (ENSG00000062822), POLD2 (ENSG00000106628), POLE (ENSG00000177084), POLA2 (ENSG00000014138), PRIM1 (ENSG00000198056), PRIM2 (ENSG00000146143), POLE2 (ENSG00000100479), POLE3 (ENSG00000148229), RRM1 (ENSG00000167325), RRM2B (ENSG00000048392), RRM2 (ENSG00000171848)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.297 | Q22 | What is Sustol? | Sustol, also known generically as Granisetron, was approved by the FDA in 1993 to treat Nausea and vomiting, Nausea, cancer, neoplasm, post operative nausea and vomiting, and Chemotherapy-induced nausea and vomiting. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sustol%" OR LOWER(tradeNames_string) LIKE "%sustol%" OR LOWER(drugSynonyms_string) LIKE "%sustol%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2107', 'tradeNames_string': 'Kytril, Sancuso, Sustol', 'drugName': 'Granisetron', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 3a (5-HT3a) receptor antagonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Sepsis (HP_0100806), Nausea (HP_0002018), Neoplasm (EFO_0000616), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Nausea And Vomiting (HP_0002017), Lymphoma (EFO_0000574), Cervical Carcinoma (EFO_0001061), Post Operative Nausea And Vomiting (EFO_0004888), Mast-Cell Leukemia (EFO_0007359), Vomiting (HP_0002013), Gastroparesis (EFO_1000948), Pruritus (HP_0000989), Malignant Glioma (MONDO_0100342)', 'newLinkedTargets_string': 'HTR3A (ENSG00000166736)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1993, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.406 | Q22 | What is Canasa? | Canasa, also known generically as Mesalamine, was approved by the FDA in 1987 to treat ulcerative colitis and proctitis. It is a small molecule therapy that acts as a(n) agonist and inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%canasa%" OR LOWER(tradeNames_string) LIKE "%canasa%" OR LOWER(drugSynonyms_string) LIKE "%canasa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6047', 'tradeNames_string': 'Apriso, Asacol, Asacol hd, Canasa, Coltec ec, Delzicol, Ipocol, Lialda, Mesalamine, Mesren mr, Mezavant xl, Octasa, Pentasa, Pentasa sr, Rowasa, Salofalk, Sfrowasa', 'drugName': 'Mesalamine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Peroxisome proliferator-activated receptor gamma agonist', 'linkedDiseasesDrug_string': "Lynch Syndrome (MONDO_0005835), Collagenous Colitis (EFO_1001293), Proctitis (EFO_0005628), Crohn'S Disease (EFO_0000384), Berylliosis (EFO_0007168), Hiv Infection (EFO_0000764), Colorectal Adenoma (EFO_0005406), Colitis (EFO_0003872), Irritable Bowel Syndrome (EFO_0000555), Colorectal Carcinoma (EFO_1001951), Eosinophilic Esophagitis (EFO_0004232), Colonic Diverticula (HP_0002253), Diverticulitis (EFO_1001460), Lymphocytic Colitis (EFO_1001294), Malnutrition (EFO_0008572), Ulcerative Colitis (EFO_0000729), Diverticular Disease (EFO_0009959)", 'newLinkedTargets_string': 'PPARG (ENSG00000132170), ALOX5 (ENSG00000012779), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1987, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6048', 'tradeNames_string': 'Apriso, Asacol, Asacol hd, Canasa, Coltec ec, Delzicol, Ipocol, Lialda, Mesalamine, Mesren mr, Mezavant xl, Octasa, Pentasa, Pentasa sr, Rowasa, Salofalk, Sfrowasa', 'drugName': 'Mesalamine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Arachidonate 5-lipoxygenase inhibitor', 'linkedDiseasesDrug_string': "Lynch Syndrome (MONDO_0005835), Collagenous Colitis (EFO_1001293), Proctitis (EFO_0005628), Crohn'S Disease (EFO_0000384), Berylliosis (EFO_0007168), Hiv Infection (EFO_0000764), Colorectal Adenoma (EFO_0005406), Colitis (EFO_0003872), Irritable Bowel Syndrome (EFO_0000555), Colorectal Carcinoma (EFO_1001951), Eosinophilic Esophagitis (EFO_0004232), Colonic Diverticula (HP_0002253), Diverticulitis (EFO_1001460), Lymphocytic Colitis (EFO_1001294), Malnutrition (EFO_0008572), Ulcerative Colitis (EFO_0000729), Diverticular Disease (EFO_0009959)", 'newLinkedTargets_string': 'PPARG (ENSG00000132170), ALOX5 (ENSG00000012779), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1987, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6049', 'tradeNames_string': 'Apriso, Asacol, Asacol hd, Canasa, Coltec ec, Delzicol, Ipocol, Lialda, Mesalamine, Mesren mr, Mezavant xl, Octasa, Pentasa, Pentasa sr, Rowasa, Salofalk, Sfrowasa', 'drugName': 'Mesalamine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cyclooxygenase inhibitor', 'linkedDiseasesDrug_string': "Lynch Syndrome (MONDO_0005835), Collagenous Colitis (EFO_1001293), Proctitis (EFO_0005628), Crohn'S Disease (EFO_0000384), Berylliosis (EFO_0007168), Hiv Infection (EFO_0000764), Colorectal Adenoma (EFO_0005406), Colitis (EFO_0003872), Irritable Bowel Syndrome (EFO_0000555), Colorectal Carcinoma (EFO_1001951), Eosinophilic Esophagitis (EFO_0004232), Colonic Diverticula (HP_0002253), Diverticulitis (EFO_1001460), Lymphocytic Colitis (EFO_1001294), Malnutrition (EFO_0008572), Ulcerative Colitis (EFO_0000729), Diverticular Disease (EFO_0009959)", 'newLinkedTargets_string': 'PPARG (ENSG00000132170), ALOX5 (ENSG00000012779), PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1987, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.125 | Q22 | What is Karbinal Er? | Karbinal Er, also known generically as Carbinoxamine Maleate, was approved by the FDA in 2003 to treat seasonal allergic rhinitis, urticaria, angioedema, allergic conjunctivitis, vasomotor rhinitis, and Rhinitis, Allergic, Perennial. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%karbinal er%" OR LOWER(tradeNames_string) LIKE "%karbinal er%" OR LOWER(drugSynonyms_string) LIKE "%karbinal er%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4593', 'tradeNames_string': 'Carbinoxamine maleate, Clistin, Davenol, Karbinal er', 'drugName': 'Carbinoxamine Maleate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Histamine H1 receptor antagonist', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Angioedema (EFO_0005532), Vasomotor Rhinitis (EFO_0007533), Urticaria (EFO_0005531)', 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2003, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.186 | Q22 | What is Dexilant? | Dexilant, also known generically as Dexlansoprazole, was approved by the FDA in 2009 to treat Peptic ulcer, Esophagitis, gastroesophageal reflux disease, duodenal ulcer, and gastric ulcer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dexilant%" OR LOWER(tradeNames_string) LIKE "%dexilant%" OR LOWER(drugSynonyms_string) LIKE "%dexilant%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_908', 'tradeNames_string': 'Dexilant, Dexilant solutab, Kapidex', 'drugName': 'Dexlansoprazole', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Potassium-transporting ATPase inhibitor', 'linkedDiseasesDrug_string': "Esophagitis (HP_0100633), Gastric Ulcer (EFO_0009454), Duodenal Ulcer (EFO_0004607), Peptic Esophagitis (EFO_1001095), Peptic Ulcer (HP_0004398), Barrett'S Esophagus (EFO_0000280), Gastroesophageal Reflux Disease (EFO_0003948)", 'newLinkedTargets_string': 'ATP4A (ENSG00000105675), ATP4B (ENSG00000186009)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.205 | Q22 | What is Syndros? | Syndros, also known generically as Dronabinol, was approved by the FDA in 1985 to treat Nausea and vomiting, Nausea, Anorexia, cancer, and Chemotherapy-induced nausea and vomiting. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%syndros%" OR LOWER(tradeNames_string) LIKE "%syndros%" OR LOWER(drugSynonyms_string) LIKE "%syndros%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3038', 'tradeNames_string': 'Dronabinol, Marinol, Syndros', 'drugName': 'Dronabinol', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Cannabinoid CB1 receptor agonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Nausea (HP_0002018), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Multiple Sclerosis (MONDO_0005301), Migraine Without Aura (MONDO_0100431), Pain (EFO_0003843), Tourette Syndrome (EFO_0004895), Irritable Bowel Syndrome (EFO_0000555), Cannabis Dependence (EFO_0007191), Anorexia Nervosa (MONDO_0005351), Post-Traumatic Stress Disorder (EFO_0001358), Migraine With Aura (MONDO_0005475), Psoriatic Arthritis (EFO_0003778), Osteoarthritis, Knee (EFO_0004616), Dementia (HP_0000726), Neuropathic Pain (EFO_0005762), Arthropathy (HP_0003040), Alcohol Drinking (EFO_0004329), Drug Dependence (EFO_0003890), Sickle Cell Anemia (MONDO_0011382), Hair-Pulling (HP_0012167), Bipolar Disorder (MONDO_0004985), Schizophrenia (MONDO_0005090), Obstructive Sleep Apnea (EFO_0003918), Alcohol Dependence (MONDO_0007079), Opioid Dependence (EFO_0005611), Hiv Infection (EFO_0000764), Cognitive Impairment (HP_0100543), Amyotrophic Lateral Sclerosis (MONDO_0004976), Osteoarthritis (MONDO_0005178), Nausea And Vomiting (HP_0002017), Essential Tremor (EFO_0003108), Chronic Pain (HP_0012532), Torticollis (HP_0000473), Type 2 Diabetes Mellitus (MONDO_0005148), Anorexia (HP_0002039)', 'newLinkedTargets_string': 'CNR1 (ENSG00000118432)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1985, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.444 | Q22 | What is Evzio (Autoinjector)? | Evzio (Autoinjector), also known generically as Naloxone Hydrochloride, was approved by the FDA in 1971 to treat unipolar depression, pain, and septic shock. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%evzio (autoinjector)%" OR LOWER(tradeNames_string) LIKE "%evzio (autoinjector)%" OR LOWER(drugSynonyms_string) LIKE "%evzio (autoinjector)%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3927', 'tradeNames_string': 'Evzio, Evzio (autoinjector), Kloxxado, Nalone, Naloxone, Naloxone hydrochloride, Naloxone hydrochloride (autoinjector), Narcan, Narcan neonatal, Narconil, Prenoxad, Zimhi', 'drugName': 'Naloxone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Opioid receptors; mu/kappa/delta antagonist', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Intestinal Obstruction (MONDO_0004565), Septic Shock (EFO_0006834), Pain (EFO_0003843), Constipation (HP_0002019), Opioid Dependence (EFO_0005611), Gambling Behaviour (EFO_0004699)', 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1971, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.250 | Q22 | What is Fintepla? | Fintepla, also known generically as Fenfluramine Hydrochloride, was approved by the FDA in 2020 to treat Seizure and Dravet syndrome. It is a small molecule therapy that acts as a(n) agonist and antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fintepla%" OR LOWER(tradeNames_string) LIKE "%fintepla%" OR LOWER(drugSynonyms_string) LIKE "%fintepla%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3886', 'tradeNames_string': 'Fintepla, Ponderax, Ponderax pacaps, Pondimin', 'drugName': 'Fenfluramine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Serotonin 1d (5-HT1d) receptor agonist', 'linkedDiseasesDrug_string': 'Photosensitive Epilepsy (MONDO_0015643), Dravet Syndrome (Orphanet_33069), Seizure (HP_0001250)', 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), HTR1D (ENSG00000179546), SIGMAR1 (ENSG00000147955)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3887', 'tradeNames_string': 'Fintepla, Ponderax, Ponderax pacaps, Pondimin', 'drugName': 'Fenfluramine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Serotonin 2c (5-HT2c) receptor agonist', 'linkedDiseasesDrug_string': 'Photosensitive Epilepsy (MONDO_0015643), Dravet Syndrome (Orphanet_33069), Seizure (HP_0001250)', 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), HTR1D (ENSG00000179546), SIGMAR1 (ENSG00000147955)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3888', 'tradeNames_string': 'Fintepla, Ponderax, Ponderax pacaps, Pondimin', 'drugName': 'Fenfluramine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Sigma opioid receptor antagonist', 'linkedDiseasesDrug_string': 'Photosensitive Epilepsy (MONDO_0015643), Dravet Syndrome (Orphanet_33069), Seizure (HP_0001250)', 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), HTR1D (ENSG00000179546), SIGMAR1 (ENSG00000147955)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.421 | Q22 | What is Midazolam In 0.9% Sodium Chloride? | Midazolam In 0.9% Sodium Chloride, also known generically as Midazolam, was approved by the FDA in 1985 to treat epilepsy, status epilepticus, and amnesia. It is a small molecule therapy that acts as a(n) positive allosteric modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%midazolam in 0.9% sodium chloride%" OR LOWER(tradeNames_string) LIKE "%midazolam in 0.9% sodium chloride%" OR LOWER(drugSynonyms_string) LIKE "%midazolam in 0.9% sodium chloride%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2188', 'tradeNames_string': 'Midazolam in 0.8% sodium chloride, Midazolam in 0.9% sodium chloride, Nayzilam', 'drugName': 'Midazolam', 'drugMolecularType': 'Small molecule', 'drugActionType': 'positive allosteric modulator', 'drugMechanismOfAction': 'GABA-A receptor; anion channel positive allosteric modulator', 'linkedDiseasesDrug_string': "Psoriasis (EFO_0000676), Multiple Myeloma (EFO_0001378), Postmenopausal Osteoporosis (EFO_0003854), Infection (EFO_0000544), Nervous System Disease (EFO_0000618), Ischemic Stroke (HP_0002140), Atopic Eczema (EFO_0000274), Spinal Muscular Atrophy (EFO_0008525), Hypertension (EFO_0000537), Neuropathic Pain (EFO_0005762), Bone Fracture (EFO_0003931), Neck Pain (HP_0030833), Obsessive-Compulsive Disorder (EFO_0004242), Anemia (Phenotype) (EFO_0004272), Borderline Personality Disorder (HP_0012076), Inguinal Hernia (HP_0000023), Sickle Cell Anemia (MONDO_0011382), Aspergillosis (EFO_0007157), Respiratory Failure (EFO_0009686), Atherosclerosis (EFO_0003914), Schizophrenia (MONDO_0005090), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Hemorrhage (MP_0001914), Pain (EFO_0003843), Obesity (EFO_0001073), Pulmonary Tuberculosis (EFO_1000049), Gastrointestinal Stromal Tumor (MONDO_0011719), Amnesia (EFO_1001454), Hypotension (EFO_0005251), Status Epilepticus (EFO_0008526), Cataract (MONDO_0005129), Non-Alcoholic Steatohepatitis (EFO_1001249), Dementia (HP_0000726), Anxiety (EFO_0005230), Acute Myeloid Leukemia (EFO_0000222), Endometriosis (EFO_0001065), Mitochondrial Disease (MONDO_0044970), Fibrodysplasia Ossificans Progressiva (MONDO_0007606), Seizure (HP_0001250), Treatment Resistant Depression (EFO_0009854), Delirium (EFO_0009267), Chronic Hepatitis C Virus Infection (EFO_0004220), Influenza (EFO_0007328), Fluoride Poisoning (EFO_1001328), Urogenital Neoplasm (EFO_0003863), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Low Back Pain (HP_0003419), Multiple Bone Fractures (EFO_0009513), Alzheimer Disease (MONDO_0004975), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Psoriasis Vulgaris (EFO_1001494), Breast Neoplasm (EFO_0003869), Post-Traumatic Stress Disorder (EFO_0001358), Breast Cancer (MONDO_0007254), Chronic Hepatitis B Virus Infection (EFO_0004239), Cardiovascular Disease (EFO_0000319), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Epilepsy (EFO_0000474), Renal Insufficiency (HP_0000083), Aggressive Behavior (EFO_0003015), Drug Dependence (EFO_0003890), Respiratory Syncytial Virus Infection (EFO_1001413), Mesothelioma (EFO_0000588), Infertility (EFO_0000545), Polyp (EFO_0000662), Brain Injury (MONDO_0043510), Depressive Disorder (MONDO_0002050), Neoplasm (EFO_0000616), Heart Failure (EFO_0003144), Chronic Pain (HP_0012532), Tuberculosis (MONDO_0018076), Skin Disease (EFO_0000701), Major Depressive Disorder (MONDO_0002009), Type 2 Diabetes Mellitus (MONDO_0005148), Breech Presentation (HP_0001623), Infectious Disease (EFO_0005741), Cough (HP_0012735), Covid-19 (MONDO_0100096), Metastatic Melanoma (EFO_0002617), Post Operative Nausea And Vomiting (EFO_0004888), Injury (EFO_0000546), Ulcerative Colitis (EFO_0000729), Malaria (EFO_0001068), Hepatitis C Virus Infection (EFO_0003047), Prostate Adenocarcinoma (EFO_0000673), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Nicotine Dependence (EFO_0003768), Septic Shock (EFO_0006834), Schizoaffective Disorder (EFO_0005411), Parkinson Disease (MONDO_0005180), Cocaine Dependence (EFO_0002610), Pruritus (HP_0000989), Suicidal Ideation (EFO_0004320), Sepsis (HP_0100806), Subarachnoid Hemorrhage (EFO_0000713), Bipolar Disorder (MONDO_0004985), Rheumatoid Arthritis (EFO_0000685), Recurrent Tonsillitis (HP_0011110), Amyotrophic Lateral Sclerosis (MONDO_0004976), Fatigue (HP_0012378), Cirrhosis Of Liver (EFO_0001422)", 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1985, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.625 | Q22 | What is Aubagio? | Aubagio, also known generically as Teriflunomide, was approved by the FDA in 2012 to treat immune system disease and multiple sclerosis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%aubagio%" OR LOWER(tradeNames_string) LIKE "%aubagio%" OR LOWER(drugSynonyms_string) LIKE "%aubagio%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5674', 'tradeNames_string': 'Aubagio', 'drugName': 'Teriflunomide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dihydroorotate dehydrogenase inhibitor', 'linkedDiseasesDrug_string': 'Multiple Sclerosis (MONDO_0005301), Tropical Spastic Paraparesis (EFO_0007527), Kidney Disease (EFO_0003086), Celiac Disease (EFO_0001060), Immune System Disease (EFO_0000540)', 'newLinkedTargets_string': 'DHODH (ENSG00000102967)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.132 | Q22 | What is Zykadia? | Zykadia, also known generically as Ceritinib, was approved by the FDA in 2014 to treat cancer, neoplasm, and non-small cell lung carcinoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zykadia%" OR LOWER(tradeNames_string) LIKE "%zykadia%" OR LOWER(drugSynonyms_string) LIKE "%zykadia%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2434', 'tradeNames_string': 'Zykadia', 'drugName': 'Ceritinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'EML4-ALK', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neuroblastoma (EFO_0000621), Neoplasm (EFO_0000616), Inflammatory Myofibroblastic Tumor (MONDO_0015798), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Soft Tissue Sarcoma (EFO_1001968), Melanoma (EFO_0000756), Anaplastic Large Cell Lymphoma (EFO_0003032), Thyroid Cancer (MONDO_0002108), Glioblastoma Multiforme (EFO_0000519), Cutaneous Melanoma (EFO_0000389), Cholangiocarcinoma (EFO_0005221)', 'newLinkedTargets_string': 'ALK (ENSG00000171094), EML4 (ENSG00000143924), NPM1 (ENSG00000181163)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2435', 'tradeNames_string': 'Zykadia', 'drugName': 'Ceritinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'ALK tyrosine kinase receptor inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neuroblastoma (EFO_0000621), Neoplasm (EFO_0000616), Inflammatory Myofibroblastic Tumor (MONDO_0015798), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Soft Tissue Sarcoma (EFO_1001968), Melanoma (EFO_0000756), Anaplastic Large Cell Lymphoma (EFO_0003032), Thyroid Cancer (MONDO_0002108), Glioblastoma Multiforme (EFO_0000519), Cutaneous Melanoma (EFO_0000389), Cholangiocarcinoma (EFO_0005221)', 'newLinkedTargets_string': 'ALK (ENSG00000171094), EML4 (ENSG00000143924), NPM1 (ENSG00000181163)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2436', 'tradeNames_string': 'Zykadia', 'drugName': 'Ceritinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor)', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neuroblastoma (EFO_0000621), Neoplasm (EFO_0000616), Inflammatory Myofibroblastic Tumor (MONDO_0015798), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Soft Tissue Sarcoma (EFO_1001968), Melanoma (EFO_0000756), Anaplastic Large Cell Lymphoma (EFO_0003032), Thyroid Cancer (MONDO_0002108), Glioblastoma Multiforme (EFO_0000519), Cutaneous Melanoma (EFO_0000389), Cholangiocarcinoma (EFO_0005221)', 'newLinkedTargets_string': 'ALK (ENSG00000171094), EML4 (ENSG00000143924), NPM1 (ENSG00000181163)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.408 | Q22 | What is Glumetza? | Glumetza, also known generically as Metformin Hydrochloride, was approved by the FDA in 1995 to treat diabetes mellitus and type 2 diabetes mellitus. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%glumetza%" OR LOWER(tradeNames_string) LIKE "%glumetza%" OR LOWER(drugSynonyms_string) LIKE "%glumetza%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1887', 'tradeNames_string': 'Bolamyn sr, Diagemet xl, Fortamet, Glucamet 500, Glucamet 850, Glucient sr, Glucophage, Glucophage sr, Glucophage xr, Glumetza, Glyformin, Janumet, Ledermetin, Metabet sr, Metformin hydrochloride, Metsol, Milform, Orabet, Riomet, Riomet er, Sukkarto sr', 'drugName': 'Metformin Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Multiple Myeloma (EFO_0001378), Fanconi Anemia (MONDO_0019391), Obesity (EFO_0001073), Lung Carcinoma (EFO_0001071), Prostate Carcinoma (EFO_0001663), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Ascites (HP_0001541), Gliosarcoma (EFO_1001465), Polycystic Ovary Syndrome (EFO_0000660), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Diabetic Foot (EFO_1001459), Oral Squamous Cell Carcinoma (EFO_0000199), Pleural Effusion (EFO_0009637), Endometrial Carcinoma (EFO_1001512), Pancreatic Carcinoma (EFO_0002618), Lung Adenocarcinoma (EFO_0000571), Gestational Diabetes (EFO_0004593), Peritoneum Cancer (MONDO_0002087), Hyperinsulinemia (HP_0000842), Inflammation (MP_0001845), Stargardt Disease (MONDO_0019353), Breast Ductal Carcinoma In Situ (EFO_0000432), Endometrioid Carcinoma (EFO_0000466), Chronic Kidney Disease (EFO_0003884), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Diabetic Neuropathy (EFO_1000783), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Heart Failure (EFO_0003144), Non-Small Cell Lung Carcinoma (EFO_0003060), Metabolic Syndrome (EFO_0000195), Type 2 Diabetes Mellitus (MONDO_0005148)', 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1995, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1888', 'tradeNames_string': 'Bolamyn sr, Diagemet xl, Fortamet, Glucamet 500, Glucamet 850, Glucient sr, Glucophage, Glucophage sr, Glucophage xr, Glumetza, Glyformin, Janumet, Ledermetin, Metabet sr, Metformin hydrochloride, Metsol, Milform, Orabet, Riomet, Riomet er, Sukkarto sr', 'drugName': 'Metformin Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Mitochondrial complex I (NADH dehydrogenase) inhibitor', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Multiple Myeloma (EFO_0001378), Fanconi Anemia (MONDO_0019391), Obesity (EFO_0001073), Lung Carcinoma (EFO_0001071), Prostate Carcinoma (EFO_0001663), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Ascites (HP_0001541), Gliosarcoma (EFO_1001465), Polycystic Ovary Syndrome (EFO_0000660), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Diabetic Foot (EFO_1001459), Oral Squamous Cell Carcinoma (EFO_0000199), Pleural Effusion (EFO_0009637), Endometrial Carcinoma (EFO_1001512), Pancreatic Carcinoma (EFO_0002618), Lung Adenocarcinoma (EFO_0000571), Gestational Diabetes (EFO_0004593), Peritoneum Cancer (MONDO_0002087), Hyperinsulinemia (HP_0000842), Inflammation (MP_0001845), Stargardt Disease (MONDO_0019353), Breast Ductal Carcinoma In Situ (EFO_0000432), Endometrioid Carcinoma (EFO_0000466), Chronic Kidney Disease (EFO_0003884), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Diabetic Neuropathy (EFO_1000783), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Heart Failure (EFO_0003144), Non-Small Cell Lung Carcinoma (EFO_0003060), Metabolic Syndrome (EFO_0000195), Type 2 Diabetes Mellitus (MONDO_0005148)', 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1995, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.556 | Q22 | What is Perseris Kit? | Perseris Kit, also known generically as Risperidone, was approved by the FDA in 1993 to treat bipolar disorder, aggressive behavior, autism, psychosis, schizoaffective disorder, bipolar I disorder, and schizophrenia. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%perseris kit%" OR LOWER(tradeNames_string) LIKE "%perseris kit%" OR LOWER(drugSynonyms_string) LIKE "%perseris kit%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3865', 'tradeNames_string': 'Perseris kit, Risperdal, Risperdal Consta Long Acting, Risperdal M, Risperdal M-Tab, Risperdal consta, Risperdal quicklet, Risperidone', 'drugName': 'Risperidone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 2a (5-HT2a) receptor antagonist', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Alzheimer Disease (MONDO_0004975), Bipolar I Disorder (EFO_0009963), Tourette Syndrome (EFO_0004895), Schizotypal Personality Disorder (MONDO_0001087), Intellectual Disability (HP_0001249), Conduct Disorder (EFO_0004216), Drug-Induced Dyskinesia (EFO_1000904), Vascular Dementia (EFO_0004718), Post-Traumatic Stress Disorder (EFO_0001358), Huntington Disease (MONDO_0007739), Dementia (HP_0000726), Schizoaffective Disorder (EFO_0005411), Anxiety (EFO_0005230), Fish-Eye Disease (Orphanet_79292), Cocaine Dependence (EFO_0002610), Autism Spectrum Disorder (EFO_0003756), Aggressive Behavior (EFO_0003015), Methamphetamine Dependence (EFO_0004701), Drug Dependence (EFO_0003890), Oppositional Defiant Disorder (HP_0010865), Obsessive-Compulsive Disorder (EFO_0004242), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Rett Syndrome (MONDO_0010726), Opioid Dependence (EFO_0005611), Psychosis (EFO_0005407), Unipolar Depression (EFO_0003761), Asperger Syndrome (EFO_0003757), Developmental Disability (EFO_0003852), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090), Neurodevelopmental Disorder (EFO_0010642)', 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD2 (ENSG00000149295)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1993, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3866', 'tradeNames_string': 'Perseris kit, Risperdal, Risperdal Consta Long Acting, Risperdal M, Risperdal M-Tab, Risperdal consta, Risperdal quicklet, Risperidone', 'drugName': 'Risperidone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 2c (5-HT2c) receptor antagonist', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Alzheimer Disease (MONDO_0004975), Bipolar I Disorder (EFO_0009963), Tourette Syndrome (EFO_0004895), Schizotypal Personality Disorder (MONDO_0001087), Intellectual Disability (HP_0001249), Conduct Disorder (EFO_0004216), Drug-Induced Dyskinesia (EFO_1000904), Vascular Dementia (EFO_0004718), Post-Traumatic Stress Disorder (EFO_0001358), Huntington Disease (MONDO_0007739), Dementia (HP_0000726), Schizoaffective Disorder (EFO_0005411), Anxiety (EFO_0005230), Fish-Eye Disease (Orphanet_79292), Cocaine Dependence (EFO_0002610), Autism Spectrum Disorder (EFO_0003756), Aggressive Behavior (EFO_0003015), Methamphetamine Dependence (EFO_0004701), Drug Dependence (EFO_0003890), Oppositional Defiant Disorder (HP_0010865), Obsessive-Compulsive Disorder (EFO_0004242), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Rett Syndrome (MONDO_0010726), Opioid Dependence (EFO_0005611), Psychosis (EFO_0005407), Unipolar Depression (EFO_0003761), Asperger Syndrome (EFO_0003757), Developmental Disability (EFO_0003852), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090), Neurodevelopmental Disorder (EFO_0010642)', 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD2 (ENSG00000149295)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1993, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3867', 'tradeNames_string': 'Perseris kit, Risperdal, Risperdal Consta Long Acting, Risperdal M, Risperdal M-Tab, Risperdal consta, Risperdal quicklet, Risperidone', 'drugName': 'Risperidone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Dopamine D2 receptor antagonist', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Alzheimer Disease (MONDO_0004975), Bipolar I Disorder (EFO_0009963), Tourette Syndrome (EFO_0004895), Schizotypal Personality Disorder (MONDO_0001087), Intellectual Disability (HP_0001249), Conduct Disorder (EFO_0004216), Drug-Induced Dyskinesia (EFO_1000904), Vascular Dementia (EFO_0004718), Post-Traumatic Stress Disorder (EFO_0001358), Huntington Disease (MONDO_0007739), Dementia (HP_0000726), Schizoaffective Disorder (EFO_0005411), Anxiety (EFO_0005230), Fish-Eye Disease (Orphanet_79292), Cocaine Dependence (EFO_0002610), Autism Spectrum Disorder (EFO_0003756), Aggressive Behavior (EFO_0003015), Methamphetamine Dependence (EFO_0004701), Drug Dependence (EFO_0003890), Oppositional Defiant Disorder (HP_0010865), Obsessive-Compulsive Disorder (EFO_0004242), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Rett Syndrome (MONDO_0010726), Opioid Dependence (EFO_0005611), Psychosis (EFO_0005407), Unipolar Depression (EFO_0003761), Asperger Syndrome (EFO_0003757), Developmental Disability (EFO_0003852), Major Depressive Disorder (MONDO_0002009), Schizophrenia (MONDO_0005090), Neurodevelopmental Disorder (EFO_0010642)', 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD2 (ENSG00000149295)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1993, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.548 | Q22 | What is Exservan? | Exservan, also known generically as Riluzole, was approved by the FDA in 1995 to treat amyotrophic lateral sclerosis. It is a small molecule therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%exservan%" OR LOWER(tradeNames_string) LIKE "%exservan%" OR LOWER(drugSynonyms_string) LIKE "%exservan%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2334', 'tradeNames_string': 'Exservan, Rilutek, Riluzole, Teglutik, Tiglutik kit', 'drugName': 'Riluzole', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Sodium channel alpha subunit blocker', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Peripheral Neuropathy (EFO_0003100), Multiple Sclerosis (MONDO_0005301), Cerebellar Ataxia (MONDO_0000437), Spinal Cord Injury (EFO_1001919), Atrial Fibrillation (EFO_0000275), Post-Traumatic Stress Disorder (EFO_0001358), Breast Cancer (MONDO_0007254), Huntington Disease (MONDO_0007739), Spinal Muscular Atrophy (EFO_0008525), Multiple System Atrophy (EFO_1001050), Autism Spectrum Disorder (EFO_0003756), Secondary Progressive Multiple Sclerosis (EFO_0008522), Myelopathy (HP_0002196), Obsessive-Compulsive Disorder (EFO_0004242), Progressive Supranuclear Palsy (MONDO_0019037), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Cutaneous Melanoma (EFO_0000389), Spinocerebellar Ataxia Type 2 (MONDO_0008458), Amyotrophic Lateral Sclerosis (MONDO_0004976), Major Depressive Disorder (MONDO_0002009)', 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1995, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.223 | Q22 | What is Rozlytrek? | Rozlytrek, also known generically as Entrectinib, was approved by the FDA in 2019 to treat cancer, neoplasm, and non-small cell lung carcinoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rozlytrek%" OR LOWER(tradeNames_string) LIKE "%rozlytrek%" OR LOWER(drugSynonyms_string) LIKE "%rozlytrek%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1203', 'tradeNames_string': 'Rozlytrek', 'drugName': 'Entrectinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Proto-oncogene tyrosine-protein kinase ROS inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Myeloid Leukemia (EFO_0000222), Central Nervous System Cancer (EFO_0000326), Cutaneous Melanoma (EFO_0000389), Invasive Lobular Carcinoma (EFO_0000553)', 'newLinkedTargets_string': 'ROS1 (ENSG00000047936), ALK (ENSG00000171094), NTRK1 (ENSG00000198400), NTRK2 (ENSG00000148053), NTRK3 (ENSG00000140538)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1204', 'tradeNames_string': 'Rozlytrek', 'drugName': 'Entrectinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Neurotrophic tyrosine kinase receptor inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Myeloid Leukemia (EFO_0000222), Central Nervous System Cancer (EFO_0000326), Cutaneous Melanoma (EFO_0000389), Invasive Lobular Carcinoma (EFO_0000553)', 'newLinkedTargets_string': 'ROS1 (ENSG00000047936), ALK (ENSG00000171094), NTRK1 (ENSG00000198400), NTRK2 (ENSG00000148053), NTRK3 (ENSG00000140538)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1205', 'tradeNames_string': 'Rozlytrek', 'drugName': 'Entrectinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'ALK tyrosine kinase receptor inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Myeloid Leukemia (EFO_0000222), Central Nervous System Cancer (EFO_0000326), Cutaneous Melanoma (EFO_0000389), Invasive Lobular Carcinoma (EFO_0000553)', 'newLinkedTargets_string': 'ROS1 (ENSG00000047936), ALK (ENSG00000171094), NTRK1 (ENSG00000198400), NTRK2 (ENSG00000148053), NTRK3 (ENSG00000140538)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.641 | Q22 | What is Spiriva Respimat? | Spiriva Respimat, also known generically as Tiotropium Bromide, was approved by the FDA in 2004 to treat Airway obstruction, Bronchospasm, chronic obstructive pulmonary disease, emphysema, chronic bronchitis, and asthma. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%spiriva respimat%" OR LOWER(tradeNames_string) LIKE "%spiriva respimat%" OR LOWER(drugSynonyms_string) LIKE "%spiriva respimat%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4878', 'tradeNames_string': 'Spiriva, Spiriva respimat', 'drugName': 'Tiotropium Bromide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Muscarinic acetylcholine receptor M3 antagonist', 'linkedDiseasesDrug_string': 'Bronchospasm (HP_0025428), Asthma (MONDO_0004979), Chronic Bronchitis (EFO_0006505), Neoplasm (EFO_0000616), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Cystic Fibrosis (MONDO_0009061), Renal Insufficiency (HP_0000083), Emphysema (EFO_0000464), Spinal Cord Injury (EFO_1001919)', 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_547', 'tradeNames_string': 'Braltus, Spiriva, Spiriva respimat', 'drugName': 'Tiotropium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Muscarinic acetylcholine receptor M3 antagonist', 'linkedDiseasesDrug_string': 'Bronchospasm (HP_0025428), Asthma (MONDO_0004979), Chronic Bronchitis (EFO_0006505), Neoplasm (EFO_0000616), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Cystic Fibrosis (MONDO_0009061), Renal Insufficiency (HP_0000083), Emphysema (EFO_0000464), Spinal Cord Injury (EFO_1001919)', 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.536 | Q22 | What is Lyrica Cr? | Lyrica Cr, also known generically as Pregabalin, was approved by the FDA in 2004 to treat Seizure, Focal-onset seizure, epilepsy, fibromyalgia, neuropathic pain, neuralgia, and Spinal cord injury. It is a small molecule therapy that acts as a(n) modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lyrica cr%" OR LOWER(tradeNames_string) LIKE "%lyrica cr%" OR LOWER(drugSynonyms_string) LIKE "%lyrica cr%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2991', 'tradeNames_string': 'Alzain, Axalid, Lecaent, Lyrica, Lyrica cr, Pregabalin, Rewisca', 'drugName': 'Pregabalin', 'drugMolecularType': 'Small molecule', 'drugActionType': 'modulator', 'drugMechanismOfAction': 'Voltage-gated calcium channel modulator', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Complex Regional Pain Syndrome (EFO_1001998), Nausea (HP_0002018), Peripheral Neuropathy (EFO_0003100), Overactive Bladder (EFO_1000781), Migraine Disorder (MONDO_0005277), Cough (HP_0012735), Pain (EFO_0003843), Focal-Onset Seizure (HP_0007359), Irritable Bowel Syndrome (EFO_0000555), Cannabis Dependence (EFO_0007191), Dry Eye Syndrome (EFO_1000906), Mononeuropathy (EFO_0009558), Refractive Error (MONDO_0004892), Muscle Cramp (EFO_0009846), Pregnancy (EFO_0002950), Neuropathy (EFO_0004149), Spinal Cord Injury (EFO_1001919), Breast Cancer (MONDO_0007254), Nicotine Dependence (EFO_0003768), Intervertebral Disc Degeneration (HP_0008419), Dementia (HP_0000726), Neuropathic Pain (EFO_0005762), Anxiety (EFO_0005230), Fibromyalgia (EFO_0005687), Partial Epilepsy (EFO_0004263), Epilepsy (EFO_0000474), Chronic Pancreatitis (EFO_0000342), Seizure (HP_0001250), Herpes Zoster (EFO_0006510), Neurotic Disorder (EFO_0004257), Bone Fracture (EFO_0003931), Complex Partial Epilepsy (EFO_1000877), Pruritus (HP_0000989), Restless Legs Syndrome (EFO_0004270), Oropharynx Cancer (EFO_1001931), Generalized Anxiety Disorder (EFO_1001892), Depressive Disorder (MONDO_0002050), Insomnia (EFO_0004698), Alcohol Dependence (MONDO_0007079), Bilateral Tonic-Clonic Seizure (HP_0002069), Opioid Dependence (EFO_0005611), Osteoarthritis (MONDO_0005178), Diabetic Neuropathy (EFO_1000783), Essential Tremor (EFO_0003108), Squamous Cell Carcinoma (EFO_0000707), Postherpetic Neuralgia (MONDO_0041052), Chronic Pain (HP_0012532), Radiculopathy (MONDO_0002959), Prostatitis (EFO_0003830), Neuralgia (EFO_0009430), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'CACNA1H (ENSG00000196557), CACNA2D1 (ENSG00000153956), CACNA1C (ENSG00000151067), CACNA2D3 (ENSG00000157445), CACNA1S (ENSG00000081248), CACNA2D2 (ENSG00000007402), CACNA1D (ENSG00000157388), CACNA1A (ENSG00000141837), CACNA1B (ENSG00000148408), CACNA1G (ENSG00000006283), CACNA2D4 (ENSG00000151062), CACNA1I (ENSG00000100346), CACNA1F (ENSG00000102001), CACNA1E (ENSG00000198216), CACNB4 (ENSG00000182389), CACNB2 (ENSG00000165995), CACNB1 (ENSG00000067191), CACNB3 (ENSG00000167535), CACNG7 (ENSG00000105605), CACNG5 (ENSG00000075429), CACNG2 (ENSG00000166862), CACNG4 (ENSG00000075461), CACNG8 (ENSG00000142408), CACNG3 (ENSG00000006116), CACNG6 (ENSG00000130433), CACNG1 (ENSG00000108878)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2004, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.644 | Q22 | What is Mounjaro? | Mounjaro, also known generically as Tirzepatide, was approved by the FDA in 2022 to treat type 2 diabetes mellitus. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mounjaro%" OR LOWER(tradeNames_string) LIKE "%mounjaro%" OR LOWER(drugSynonyms_string) LIKE "%mounjaro%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5134', 'tradeNames_string': 'Mounjaro', 'drugName': 'Tirzepatide', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Gastric inhibitory polypeptide receptor agonist', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148), Obesity (EFO_0001073), Non-Alcoholic Steatohepatitis (EFO_1001249)', 'newLinkedTargets_string': 'GIPR (ENSG00000010310), GLP1R (ENSG00000112164)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2022, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5135', 'tradeNames_string': 'Mounjaro', 'drugName': 'Tirzepatide', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucagon-like peptide 1 receptor agonist', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148), Obesity (EFO_0001073), Non-Alcoholic Steatohepatitis (EFO_1001249)', 'newLinkedTargets_string': 'GIPR (ENSG00000010310), GLP1R (ENSG00000112164)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2022, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.543 | Q22 | What is Stivarga? | Stivarga, also known generically as Regorafenib, was approved by the FDA in 2012 to treat cancer, colorectal adenocarcinoma, neoplasm, colorectal neoplasm, colorectal cancer, and colorectal carcinoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%stivarga%" OR LOWER(tradeNames_string) LIKE "%stivarga%" OR LOWER(drugSynonyms_string) LIKE "%stivarga%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_800', 'tradeNames_string': 'Stivarga', 'drugName': 'Regorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase receptor RET inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_801', 'tradeNames_string': 'Stivarga', 'drugName': 'Regorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_802', 'tradeNames_string': 'Stivarga', 'drugName': 'Regorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Fibroblast growth factor receptor 2 inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_803', 'tradeNames_string': 'Stivarga', 'drugName': 'Regorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Ephrin type-A receptor 2', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_804', 'tradeNames_string': 'Stivarga', 'drugName': 'Regorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase TIE-2 inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_805', 'tradeNames_string': 'Stivarga', 'drugName': 'Regorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'MAP kinase p38 beta inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_806', 'tradeNames_string': 'Stivarga', 'drugName': 'Regorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serine/threonine-protein kinase RAF inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_807', 'tradeNames_string': 'Stivarga', 'drugName': 'Regorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase FRK inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_808', 'tradeNames_string': 'Stivarga', 'drugName': 'Regorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Platelet-derived growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_809', 'tradeNames_string': 'Stivarga', 'drugName': 'Regorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Stem cell growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_810', 'tradeNames_string': 'Stivarga', 'drugName': 'Regorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase ABL inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_811', 'tradeNames_string': 'Stivarga', 'drugName': 'Regorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Fibroblast growth factor receptor 1 inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_812', 'tradeNames_string': 'Stivarga', 'drugName': 'Regorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Discoidin domain-containing receptor 2 inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_813', 'tradeNames_string': 'Stivarga', 'drugName': 'Regorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Nerve growth factor receptor Trk-A', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_814', 'tradeNames_string': 'Stivarga', 'drugName': 'Regorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serine/threonine-protein kinase B-raf inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Macular Degeneration (EFO_0009606), Adenoid Cystic Carcinoma (EFO_0000231), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Angiosarcoma (EFO_0003968), Hepatocellular Carcinoma (EFO_0000182), Colorectal Neoplasm (EFO_0004142), Acute Myeloid Leukemia (EFO_0000222), Liposarcoma (EFO_0000569), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Colorectal Cancer (MONDO_0005575), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Ovarian Neoplasm (EFO_0003893), Rectum Cancer (EFO_1000657), Bile Duct Carcinoma (EFO_0005540), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Neoplasm (EFO_0000616), Colorectal Adenocarcinoma (EFO_0000365), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Esophageal Cancer (MONDO_0007576)', 'newLinkedTargets_string': 'EPHA2 (ENSG00000142627), TEK (ENSG00000120156), MAPK11 (ENSG00000185386), RAF1 (ENSG00000132155), FRK (ENSG00000111816), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), KIT (ENSG00000157404), FGFR1 (ENSG00000077782), DDR2 (ENSG00000162733), NTRK1 (ENSG00000198400), BRAF (ENSG00000157764), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), ABL1 (ENSG00000097007), RET (ENSG00000165731), FGFR2 (ENSG00000066468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.392 | Q22 | What is Latuda? | Latuda, also known generically as Lurasidone Hydrochloride, was approved by the FDA in 2010 to treat bipolar disorder, bipolar I disorder, and schizophrenia. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%latuda%" OR LOWER(tradeNames_string) LIKE "%latuda%" OR LOWER(drugSynonyms_string) LIKE "%latuda%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3924', 'tradeNames_string': 'Latuda', 'drugName': 'Lurasidone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Dopamine D2 receptor antagonist', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Bipolar Disorder (MONDO_0004985), Bipolar I Disorder (EFO_0009963)', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3925', 'tradeNames_string': 'Latuda', 'drugName': 'Lurasidone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 2a (5-HT2a) receptor antagonist', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Bipolar Disorder (MONDO_0004985), Bipolar I Disorder (EFO_0009963)', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5708', 'tradeNames_string': 'Latuda', 'drugName': 'Lurasidone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Dopamine D2 receptor antagonist', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Autism (EFO_0003758), Bipolar I Disorder (EFO_0009963), Schizoaffective Disorder (EFO_0005411), Major Depressive Disorder (MONDO_0002009), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5709', 'tradeNames_string': 'Latuda', 'drugName': 'Lurasidone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 2a (5-HT2a) receptor antagonist', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Autism (EFO_0003758), Bipolar I Disorder (EFO_0009963), Schizoaffective Disorder (EFO_0005411), Major Depressive Disorder (MONDO_0002009), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), HTR2A (ENSG00000102468)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.683 | Q22 | What is Vasostrict? | Vasostrict, also known generically as Vasopressin, was approved by the FDA in 2014 to treat Sepsis and diabetes insipidus. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vasostrict%" OR LOWER(tradeNames_string) LIKE "%vasostrict%" OR LOWER(drugSynonyms_string) LIKE "%vasostrict%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3226', 'tradeNames_string': 'Beta-Hypophamine, Leiormone, Pitressin, Vasophysin, Vasostrict', 'drugName': 'Vasopressin', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Vasopressin receptor agonist', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Cardiac Arrest (EFO_0009492), Diabetes Insipidus (MONDO_0004782), Heart Disease (EFO_0003777), Pulmonary Hypertension (MONDO_0005149), Acute Lung Injury (EFO_0004610), Leiomyoma (MONDO_0001572), Hypotension (EFO_0005251), Septic Shock (EFO_0006834), Sepsis (HP_0100806), Benign Muscle Neoplasm (MONDO_0003061), Pain (EFO_0003843), Shock (HP_0031273), Sudden Cardiac Arrest (EFO_0004278), Major Depressive Disorder (MONDO_0002009), Pleural Effusion (EFO_0009637), Autism Spectrum Disorder (EFO_0003756), Congenital Heart Disease (EFO_0005207)', 'newLinkedTargets_string': 'AVPR2 (ENSG00000126895), AVPR1A (ENSG00000166148), AVPR1B (ENSG00000198049)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.516 | Q22 | What is Pemazyre? | Pemazyre, also known generically as Pemigatinib, was approved by the FDA in 2020 to treat cancer, neoplasm, and cholangiocarcinoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pemazyre%" OR LOWER(tradeNames_string) LIKE "%pemazyre%" OR LOWER(drugSynonyms_string) LIKE "%pemazyre%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3709', 'tradeNames_string': 'Pemazyre', 'drugName': 'Pemigatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Fibroblast growth factor receptor 1 inhibitor', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cancer (MONDO_0004992), Urogenital Neoplasm (EFO_0003863), Neoplasm (EFO_0000616), Myeloproliferative Disorder (EFO_0004251), Urinary Bladder Cancer (MONDO_0001187), Endometrial Cancer (MONDO_0011962), Non-Small Cell Lung Carcinoma (EFO_0003060), Urothelial Carcinoma (EFO_0008528), Acute Myeloid Leukemia (EFO_0000222), Glioblastoma Multiforme (EFO_0000519), Colorectal Carcinoma (EFO_1001951), Cholangiocarcinoma (EFO_0005221)', 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR2 (ENSG00000066468), FGFR3 (ENSG00000068078)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3710', 'tradeNames_string': 'Pemazyre', 'drugName': 'Pemigatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Fibroblast growth factor receptor 3 inhibitor', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cancer (MONDO_0004992), Urogenital Neoplasm (EFO_0003863), Neoplasm (EFO_0000616), Myeloproliferative Disorder (EFO_0004251), Urinary Bladder Cancer (MONDO_0001187), Endometrial Cancer (MONDO_0011962), Non-Small Cell Lung Carcinoma (EFO_0003060), Urothelial Carcinoma (EFO_0008528), Acute Myeloid Leukemia (EFO_0000222), Glioblastoma Multiforme (EFO_0000519), Colorectal Carcinoma (EFO_1001951), Cholangiocarcinoma (EFO_0005221)', 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR2 (ENSG00000066468), FGFR3 (ENSG00000068078)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3711', 'tradeNames_string': 'Pemazyre', 'drugName': 'Pemigatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Fibroblast growth factor receptor 2 inhibitor', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cancer (MONDO_0004992), Urogenital Neoplasm (EFO_0003863), Neoplasm (EFO_0000616), Myeloproliferative Disorder (EFO_0004251), Urinary Bladder Cancer (MONDO_0001187), Endometrial Cancer (MONDO_0011962), Non-Small Cell Lung Carcinoma (EFO_0003060), Urothelial Carcinoma (EFO_0008528), Acute Myeloid Leukemia (EFO_0000222), Glioblastoma Multiforme (EFO_0000519), Colorectal Carcinoma (EFO_1001951), Cholangiocarcinoma (EFO_0005221)', 'newLinkedTargets_string': 'FGFR1 (ENSG00000077782), FGFR2 (ENSG00000066468), FGFR3 (ENSG00000068078)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.271 | Q22 | What is Vanos? | Vanos, also known generically as Fluocinonide, was approved by the FDA in 1971 to treat skin disease and hemorrhoid. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vanos%" OR LOWER(tradeNames_string) LIKE "%vanos%" OR LOWER(drugSynonyms_string) LIKE "%vanos%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4918', 'tradeNames_string': 'Fluocinonide, Fluocinonide emulsified base, Lidex, Lidex-e, Metosyn, Metosyn fapg, Vanos', 'drugName': 'Fluocinonide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Hemorrhoid (EFO_0009552), Atopic Eczema (EFO_0000274), Skin Disease (EFO_0000701), Breast Carcinoma (EFO_0000305)', 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1971, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.447 | Q22 | What is Narcan? | Narcan, also known generically as Naloxone Hydrochloride, was approved by the FDA in 1971 to treat unipolar depression, pain, and septic shock. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%narcan%" OR LOWER(tradeNames_string) LIKE "%narcan%" OR LOWER(drugSynonyms_string) LIKE "%narcan%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3927', 'tradeNames_string': 'Evzio, Evzio (autoinjector), Kloxxado, Nalone, Naloxone, Naloxone hydrochloride, Naloxone hydrochloride (autoinjector), Narcan, Narcan neonatal, Narconil, Prenoxad, Zimhi', 'drugName': 'Naloxone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Opioid receptors; mu/kappa/delta antagonist', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Intestinal Obstruction (MONDO_0004565), Septic Shock (EFO_0006834), Pain (EFO_0003843), Constipation (HP_0002019), Opioid Dependence (EFO_0005611), Gambling Behaviour (EFO_0004699)', 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1971, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5202', 'tradeNames_string': 'Nalone, Narcan, Narcanti', 'drugName': 'Naloxone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Opioid receptors; mu/kappa/delta antagonist', 'linkedDiseasesDrug_string': "Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Pain (EFO_0003843), Obesity (EFO_0001073), Irritable Bowel Syndrome (EFO_0000555), Hypogonadotropic Hypogonadism (MONDO_0018555), Eating Disorder (EFO_0005203), Hepatitis C Virus Infection (EFO_0003047), Morphine Dependence (EFO_0005612), Substance Withdrawal Syndrome (EFO_0005800), Septic Shock (EFO_0006834), Neuropathic Pain (EFO_0005762), Parkinson Disease (MONDO_0005180), Mycosis Fungoides (EFO_1001051), Epilepsy (EFO_0000474), Pruritus (HP_0000989), Heroin Dependence (EFO_0004240), Restless Legs Syndrome (EFO_0004270), Drug Dependence (EFO_0003890), Diabetic Polyneuropathy (MONDO_0001583), Intestinal Obstruction (MONDO_0004565), Constipation (HP_0002019), Opioid Dependence (EFO_0005611), Gambling Behaviour (EFO_0004699), Unipolar Depression (EFO_0003761), Opioid Use Disorder (EFO_0010702), Osteoarthritis (MONDO_0005178), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419), Type 1 Diabetes Mellitus (MONDO_0005147)", 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1971, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.503 | Q22 | What is Farydak? | Farydak, also known generically as Panobinostat Lactate, was approved by the FDA in 2015 to treat multiple myeloma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%farydak%" OR LOWER(tradeNames_string) LIKE "%farydak%" OR LOWER(drugSynonyms_string) LIKE "%farydak%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4906', 'tradeNames_string': 'Farydak', 'drugName': 'Panobinostat', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Histone deacetylase inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Primary Myelofibrosis (EFO_0002430), Non-Hodgkins Lymphoma (EFO_0005952), Skin Cancer (MONDO_0002898), Thyroid Carcinoma (EFO_0002892), Graft Versus Host Disease (MONDO_0013730), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Plasmacytoma (EFO_0006738), Metastatic Melanoma (EFO_0002617), Myelodysplastic Syndrome (EFO_0000198), Plasma Cell Leukemia (EFO_0006475), Colorectal Carcinoma (EFO_1001951), Polycythemia Vera (EFO_0002429), Gastric Cancer (MONDO_0001056), Chronic Myelogenous Leukemia (EFO_0000339), Prostate Adenocarcinoma (EFO_0000673), Malignant Colon Neoplasm (MONDO_0021063), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Mantle Cell Lymphoma (EFO_1001469), Myelofibrosis (MONDO_0044903), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Chronic Myelomonocytic Leukemia (EFO_1001779), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Malignant Glioma (MONDO_0100342), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Sickle Cell Anemia (MONDO_0011382), Clear Cell Renal Carcinoma (EFO_0000349), Renal Cell Carcinoma (EFO_0000681), Waldenstrom Macroglobulinemia (EFO_0009441), Glioma (EFO_0005543), Cutaneous T-Cell Lymphoma (EFO_0002913), Hodgkins Lymphoma (EFO_0000183), Liver Cancer (MONDO_0002691), Rectum Cancer (EFO_1000657), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Hiv Infection (EFO_0000764), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Lung Cancer (MONDO_0008903), Nasopharyngeal Neoplasm (EFO_0004252), Non-Small Cell Lung Carcinoma (EFO_0003060), Classic Hodgkin Lymphoma (MONDO_0009348), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519)', 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5237', 'tradeNames_string': 'Farydak', 'drugName': 'Panobinostat Lactate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Histone deacetylase inhibitor', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378)', 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.115 | Q22 | What is Cometriq? | Cometriq, also known generically as Cabozantinib S-Malate, was approved by the FDA in 2012 to treat clear cell renal carcinoma, papillary renal cell carcinoma, papillary thyroid carcinoma, renal cell carcinoma, thyroid carcinoma, and thyroid cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cometriq%" OR LOWER(tradeNames_string) LIKE "%cometriq%" OR LOWER(drugSynonyms_string) LIKE "%cometriq%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3579', 'tradeNames_string': 'Cabometyx, Cometriq', 'drugName': 'Cabozantinib S-Malate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Hepatocyte growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Papillary Thyroid Carcinoma (EFO_0000641), Thyroid Carcinoma (EFO_0002892), Small Cell Carcinoma (EFO_0008524), Central Nervous System Cancer (EFO_0000326), Angiosarcoma (EFO_0003968), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Astrocytoma (EFO_0000272), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Papillary Renal Cell Carcinoma (EFO_0000640), Fallopian Tube Carcinoma (EFO_1000251), Endometrial Carcinoma (EFO_1001512), Clear Cell Renal Carcinoma (EFO_0000349), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519), Adrenal Gland Pheochromocytoma (EFO_0000239)', 'newLinkedTargets_string': 'MET (ENSG00000105976), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3580', 'tradeNames_string': 'Cabometyx, Cometriq', 'drugName': 'Cabozantinib S-Malate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor 2 inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Papillary Thyroid Carcinoma (EFO_0000641), Thyroid Carcinoma (EFO_0002892), Small Cell Carcinoma (EFO_0008524), Central Nervous System Cancer (EFO_0000326), Angiosarcoma (EFO_0003968), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Astrocytoma (EFO_0000272), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Papillary Renal Cell Carcinoma (EFO_0000640), Fallopian Tube Carcinoma (EFO_1000251), Endometrial Carcinoma (EFO_1001512), Clear Cell Renal Carcinoma (EFO_0000349), Renal Cell Carcinoma (EFO_0000681), Thyroid Cancer (MONDO_0002108), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Non-Small Cell Lung Carcinoma (EFO_0003060), Glioblastoma Multiforme (EFO_0000519), Adrenal Gland Pheochromocytoma (EFO_0000239)', 'newLinkedTargets_string': 'MET (ENSG00000105976), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4806', 'tradeNames_string': 'Cabometyx, Cometriq', 'drugName': 'Cabozantinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Hepatocyte growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Liver Disease (EFO_0001421), Thyroid Carcinoma (EFO_0002892), Small Cell Carcinoma (EFO_0008524), Gastrointestinal Stromal Tumor (MONDO_0011719), Central Nervous System Cancer (EFO_0000326), Urothelial Carcinoma (EFO_0008528), Metastatic Melanoma (EFO_0002617), Collecting Duct Carcinoma (EFO_0003016), Intrahepatic Cholangiocarcinoma (EFO_1001961), Colorectal Carcinoma (EFO_1001951), Angiosarcoma (EFO_0003968), Prostate Adenocarcinoma (EFO_0000673), Neuroendocrine Carcinoma (MONDO_0002120), Breast Carcinoma (EFO_0000305), Astrocytoma (EFO_0000272), Papillary Renal Cell Carcinoma (EFO_0000640), Gliosarcoma (EFO_1001465), Fallopian Tube Carcinoma (EFO_1000251), Breast Cancer (MONDO_0007254), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Anaplastic Astrocytoma (EFO_0002499), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Endometrial Carcinoma (EFO_1001512), Pulmonary Neuroendocrine Tumor (EFO_0005220), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Carcinoid Tumor (EFO_0004243), Salivary Gland Cancer (MONDO_0004669), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Cervical Cancer (MONDO_0002974), Rectum Cancer (EFO_1000657), Urogenital Neoplasm (EFO_0003863), Osteosarcoma (EFO_0000637), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Urinary Bladder Cancer (MONDO_0001187), Meningioma (MONDO_0016642), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Adrenal Cortex Carcinoma (EFO_1000796), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Adrenal Gland Pheochromocytoma (EFO_0000239)', 'newLinkedTargets_string': 'MET (ENSG00000105976), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4807', 'tradeNames_string': 'Cabometyx, Cometriq', 'drugName': 'Cabozantinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor 2 inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Liver Disease (EFO_0001421), Thyroid Carcinoma (EFO_0002892), Small Cell Carcinoma (EFO_0008524), Gastrointestinal Stromal Tumor (MONDO_0011719), Central Nervous System Cancer (EFO_0000326), Urothelial Carcinoma (EFO_0008528), Metastatic Melanoma (EFO_0002617), Collecting Duct Carcinoma (EFO_0003016), Intrahepatic Cholangiocarcinoma (EFO_1001961), Colorectal Carcinoma (EFO_1001951), Angiosarcoma (EFO_0003968), Prostate Adenocarcinoma (EFO_0000673), Neuroendocrine Carcinoma (MONDO_0002120), Breast Carcinoma (EFO_0000305), Astrocytoma (EFO_0000272), Papillary Renal Cell Carcinoma (EFO_0000640), Gliosarcoma (EFO_1001465), Fallopian Tube Carcinoma (EFO_1000251), Breast Cancer (MONDO_0007254), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Anaplastic Astrocytoma (EFO_0002499), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Endometrial Carcinoma (EFO_1001512), Pulmonary Neuroendocrine Tumor (EFO_0005220), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Carcinoid Tumor (EFO_0004243), Salivary Gland Cancer (MONDO_0004669), Thyroid Cancer (MONDO_0002108), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Cervical Cancer (MONDO_0002974), Rectum Cancer (EFO_1000657), Urogenital Neoplasm (EFO_0003863), Osteosarcoma (EFO_0000637), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Follicular Thyroid Carcinoma (EFO_0000501), Urinary Bladder Cancer (MONDO_0001187), Meningioma (MONDO_0016642), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Adrenal Cortex Carcinoma (EFO_1000796), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Colon Adenocarcinoma (EFO_1001949), Glioblastoma Multiforme (EFO_0000519), Adrenal Gland Pheochromocytoma (EFO_0000239)', 'newLinkedTargets_string': 'MET (ENSG00000105976), KDR (ENSG00000128052)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.236 | Q22 | What is Elestrin? | Elestrin, also known generically as Estradiol, was approved by the FDA in 1975 to treat Premature ovarian insufficiency, Dyspareunia, and hypogonadism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%elestrin%" OR LOWER(tradeNames_string) LIKE "%elestrin%" OR LOWER(drugSynonyms_string) LIKE "%elestrin%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6277', 'tradeNames_string': 'Adgyn estro, Alora, Aquagen, Bedol, Climara, Climara Pro, Dermestril 100, Dermestril 25, Dermestril 50, Dermestril septem 25, Dermestril septem 50, Dermestril septem 75, Divigel, E-Cypionate, Elestrim, Elestrin, Elleste solo, Elleste solo mx 40, Elleste solo mx 80, Esclim, Estrace, Estraderm, Estraderm mx 100, Estraderm mx 25, Estraderm mx 50, Estraderm mx 75, Estraderm tts 100, Estraderm tts 25, Estraderm tts 50, Estradiol, Estrasorb, Estring, Estrogel, Evamist, Evorel 100, Evorel 25, Evorel 50, Evorel 75, Fematrix 40, Fematrix 80, Fempatch, Femseven 100, Femseven 50, Femseven 75, Gvnodiol, Gynodiol, Gynogen, Imvexxy, Innofem, Menorest 37.5, Menorest 50, Menorest 75, Menoring 50, Menostar, Minivelle, Oestradiol, Progynova ts, Sandrena, Vagifem, Vagifem 18, Vagifem 8, Vivelle, Vivelle-dot, Zumenon', 'drugName': 'Estradiol', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Estrogen receptor alpha agonist', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Multiple Sclerosis (MONDO_0005301), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Uterine Fibroid (EFO_0000731), Migraine Disorder (MONDO_0005277), Dysmenorrhea (HP_0100607), Obesity (EFO_0001073), Dry Eye Syndrome (EFO_1000906), Atherosclerosis (EFO_0003914), Aging (GO_0007568), Anorexia Nervosa (MONDO_0005351), Hot Flashes (HP_0031217), Prostate Carcinoma (EFO_0001663), Breast Carcinoma (EFO_0000305), Myocardial Ischemia (EFO_1001375), Post-Traumatic Stress Disorder (EFO_0001358), Osteoporosis (EFO_0003882), Breast Neoplasm (EFO_0003869), Prostate Cancer (MONDO_0008315), Cerebral Arterial Disease (EFO_1000859), Breast Cancer (MONDO_0007254), Polycystic Ovary Syndrome (EFO_0000660), Osteopenia (HP_0000938), Postpartum Depression (EFO_0007453), Premature Ovarian Insufficiency (HP_0008209), Schizoaffective Disorder (EFO_0005411), Non-Alcoholic Steatohepatitis (EFO_1001249), Endometriosis (EFO_0001065), Amenorrhea (EFO_0010269), Sexual Dysfunction (EFO_0004714), Postmenopausal Atrophic Vaginitis (MONDO_0001410), Hypogonadism (MONDO_0002146), Turner Syndrome (MONDO_0019499), Menopause (EFO_0003922), Infertility (EFO_0000545), Urinary Tract Infection (EFO_0003103), Carcinoid Tumor (EFO_0004243), Hiv-1 Infection (EFO_0000180), Depressive Disorder (MONDO_0002050), Hiv Infection (EFO_0000764), Type 2 Diabetes Mellitus (MONDO_0005148), Atrophic Vaginitis (EFO_1001271), Blood Coagulation Disease (EFO_0009314), Atrophy (EFO_1000096), Bulimia Nervosa (EFO_0005204), Type 1 Diabetes Mellitus (MONDO_0005147), Dyspareunia (HP_0030016), Schizophrenia (MONDO_0005090), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145)', 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1975, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.613 | Q22 | What is Vtama? | Vtama, also known generically as Tapinarof, was approved by the FDA in 2022 to treat psoriasis. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vtama%" OR LOWER(tradeNames_string) LIKE "%vtama%" OR LOWER(drugSynonyms_string) LIKE "%vtama%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_192', 'tradeNames_string': 'Vtama', 'drugName': 'Tapinarof', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Aryl hydrocarbon receptor agonist', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Atopic Eczema (EFO_0000274)', 'newLinkedTargets_string': 'AHR (ENSG00000106546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2022, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.379 | Q22 | What is Vyvanse? | Vyvanse, also known generically as Lisdexamfetamine Dimesylate, was approved by the FDA in 2007 to treat glaucoma, attention deficit hyperactivity disorder, drug dependence, binge eating, and arteriosclerosis disorder. It is a small molecule therapy that acts as a(n) inhibitor and releasing agent. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vyvanse%" OR LOWER(tradeNames_string) LIKE "%vyvanse%" OR LOWER(drugSynonyms_string) LIKE "%vyvanse%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2130', 'tradeNames_string': 'Elvanse, Elvanse adult, Vyvanse', 'drugName': 'Lisdexamfetamine Dimesylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Synaptic vesicular amine transporter inhibitor', 'linkedDiseasesDrug_string': 'Binge Eating (EFO_0005924), Drug Dependence (EFO_0003890), Obesity (EFO_0001073), Attention Deficit Hyperactivity Disorder (EFO_0003888), Arteriosclerosis Disorder (MONDO_0002277), Major Depressive Disorder (MONDO_0002009), Bulimia Nervosa (EFO_0005204), Insomnia (EFO_0004698), Eating Disorder (EFO_0005203), Schizophrenia (MONDO_0005090), Glaucoma (MONDO_0005041)', 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2007, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2131', 'tradeNames_string': 'Elvanse, Elvanse adult, Vyvanse', 'drugName': 'Lisdexamfetamine Dimesylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'releasing agent', 'drugMechanismOfAction': 'Norepinephrine transporter releasing agent', 'linkedDiseasesDrug_string': 'Binge Eating (EFO_0005924), Drug Dependence (EFO_0003890), Obesity (EFO_0001073), Attention Deficit Hyperactivity Disorder (EFO_0003888), Arteriosclerosis Disorder (MONDO_0002277), Major Depressive Disorder (MONDO_0002009), Bulimia Nervosa (EFO_0005204), Insomnia (EFO_0004698), Eating Disorder (EFO_0005203), Schizophrenia (MONDO_0005090), Glaucoma (MONDO_0005041)', 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2007, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2132', 'tradeNames_string': 'Elvanse, Elvanse adult, Vyvanse', 'drugName': 'Lisdexamfetamine Dimesylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'releasing agent', 'drugMechanismOfAction': 'Dopamine transporter releasing agent', 'linkedDiseasesDrug_string': 'Binge Eating (EFO_0005924), Drug Dependence (EFO_0003890), Obesity (EFO_0001073), Attention Deficit Hyperactivity Disorder (EFO_0003888), Arteriosclerosis Disorder (MONDO_0002277), Major Depressive Disorder (MONDO_0002009), Bulimia Nervosa (EFO_0005204), Insomnia (EFO_0004698), Eating Disorder (EFO_0005203), Schizophrenia (MONDO_0005090), Glaucoma (MONDO_0005041)', 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646), SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2007, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.237 | Q22 | What is Evamist? | Evamist, also known generically as Estradiol, was approved by the FDA in 1975 to treat Premature ovarian insufficiency, Dyspareunia, and hypogonadism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%evamist%" OR LOWER(tradeNames_string) LIKE "%evamist%" OR LOWER(drugSynonyms_string) LIKE "%evamist%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6277', 'tradeNames_string': 'Adgyn estro, Alora, Aquagen, Bedol, Climara, Climara Pro, Dermestril 100, Dermestril 25, Dermestril 50, Dermestril septem 25, Dermestril septem 50, Dermestril septem 75, Divigel, E-Cypionate, Elestrim, Elestrin, Elleste solo, Elleste solo mx 40, Elleste solo mx 80, Esclim, Estrace, Estraderm, Estraderm mx 100, Estraderm mx 25, Estraderm mx 50, Estraderm mx 75, Estraderm tts 100, Estraderm tts 25, Estraderm tts 50, Estradiol, Estrasorb, Estring, Estrogel, Evamist, Evorel 100, Evorel 25, Evorel 50, Evorel 75, Fematrix 40, Fematrix 80, Fempatch, Femseven 100, Femseven 50, Femseven 75, Gvnodiol, Gynodiol, Gynogen, Imvexxy, Innofem, Menorest 37.5, Menorest 50, Menorest 75, Menoring 50, Menostar, Minivelle, Oestradiol, Progynova ts, Sandrena, Vagifem, Vagifem 18, Vagifem 8, Vivelle, Vivelle-dot, Zumenon', 'drugName': 'Estradiol', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Estrogen receptor alpha agonist', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Multiple Sclerosis (MONDO_0005301), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Uterine Fibroid (EFO_0000731), Migraine Disorder (MONDO_0005277), Dysmenorrhea (HP_0100607), Obesity (EFO_0001073), Dry Eye Syndrome (EFO_1000906), Atherosclerosis (EFO_0003914), Aging (GO_0007568), Anorexia Nervosa (MONDO_0005351), Hot Flashes (HP_0031217), Prostate Carcinoma (EFO_0001663), Breast Carcinoma (EFO_0000305), Myocardial Ischemia (EFO_1001375), Post-Traumatic Stress Disorder (EFO_0001358), Osteoporosis (EFO_0003882), Breast Neoplasm (EFO_0003869), Prostate Cancer (MONDO_0008315), Cerebral Arterial Disease (EFO_1000859), Breast Cancer (MONDO_0007254), Polycystic Ovary Syndrome (EFO_0000660), Osteopenia (HP_0000938), Postpartum Depression (EFO_0007453), Premature Ovarian Insufficiency (HP_0008209), Schizoaffective Disorder (EFO_0005411), Non-Alcoholic Steatohepatitis (EFO_1001249), Endometriosis (EFO_0001065), Amenorrhea (EFO_0010269), Sexual Dysfunction (EFO_0004714), Postmenopausal Atrophic Vaginitis (MONDO_0001410), Hypogonadism (MONDO_0002146), Turner Syndrome (MONDO_0019499), Menopause (EFO_0003922), Infertility (EFO_0000545), Urinary Tract Infection (EFO_0003103), Carcinoid Tumor (EFO_0004243), Hiv-1 Infection (EFO_0000180), Depressive Disorder (MONDO_0002050), Hiv Infection (EFO_0000764), Type 2 Diabetes Mellitus (MONDO_0005148), Atrophic Vaginitis (EFO_1001271), Blood Coagulation Disease (EFO_0009314), Atrophy (EFO_1000096), Bulimia Nervosa (EFO_0005204), Type 1 Diabetes Mellitus (MONDO_0005147), Dyspareunia (HP_0030016), Schizophrenia (MONDO_0005090), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145)', 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1975, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.557 | Q22 | What is Xarelto? | Xarelto, also known generically as Rivaroxaban, was approved by the FDA in 2011 to treat Recurrent thrombophlebitis, Venous thrombosis, atrial fibrillation, pulmonary embolism, deep vein thrombosis, and thrombotic disease. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%xarelto%" OR LOWER(tradeNames_string) LIKE "%xarelto%" OR LOWER(drugSynonyms_string) LIKE "%xarelto%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_816', 'tradeNames_string': 'Xarelto', 'drugName': 'Rivaroxaban', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Coagulation factor X inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Coronary Artery Disease (EFO_0001645), Hemorrhage (MP_0001914), Peripheral Arterial Disease (EFO_0004265), Covid-19 (MONDO_0100096), Venous Thrombosis (HP_0004936), Pulmonary Embolism (EFO_0003827), Atrial Fibrillation (EFO_0000275), Recurrent Thrombophlebitis (HP_0004419), Ischemic Stroke (HP_0002140), Rheumatic Heart Disease (EFO_1001161), Thrombotic Disease (MONDO_0000831), Thromboembolism (HP_0001907), Aortic Valve Disease (EFO_0009531), Acute Coronary Syndrome (EFO_0005672), Renal Insufficiency (HP_0000083), Morbid Obesity (EFO_0001074), Antiphospholipid Syndrome (EFO_0002689), Thrombocytopenia (HP_0001873), Hematoma (EFO_0010680), Aortic Stenosis (EFO_0000266), Stroke (EFO_0000712), Sickle Cell Anemia (MONDO_0011382), Myocardial Infarction (EFO_0000612), Venous Thromboembolism (EFO_0004286), Chronic Kidney Disease (EFO_0003884), Heart Disease (EFO_0003777), Neoplasm (EFO_0000616), Deep Vein Thrombosis (EFO_0003907), Ischemia (EFO_0000556), Blood Coagulation Disease (EFO_0009314), Type 2 Diabetes Mellitus (MONDO_0005148), Severe Acute Respiratory Syndrome (EFO_0000694), Cirrhosis Of Liver (EFO_0001422)', 'newLinkedTargets_string': 'F10 (ENSG00000126218)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2011, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.322 | Q22 | What is Tegsedi? | Tegsedi, also known generically as Inotersen Sodium, was approved by the FDA in 2018 to treat familial amyloid neuropathy, polyneuropathy, and amyloidosis. It is a oligonucleotide therapy that acts as a(n) antisense inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tegsedi%" OR LOWER(tradeNames_string) LIKE "%tegsedi%" OR LOWER(drugSynonyms_string) LIKE "%tegsedi%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3256', 'tradeNames_string': 'Tegsedi', 'drugName': 'Inotersen Sodium', 'drugMolecularType': 'Oligonucleotide', 'drugActionType': 'antisense inhibitor', 'drugMechanismOfAction': 'Transthyretin mRNA antisense inhibitor', 'linkedDiseasesDrug_string': 'Amyloidosis (EFO_1001875), Familial Amyloid Neuropathy (EFO_0004129), Polyneuropathy (EFO_0009562)', 'newLinkedTargets_string': 'TTR (ENSG00000118271)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2018, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.416 | Q22 | What is Methylin? | Methylin, also known generically as Methylphenidate Hydrochloride, was approved by the FDA in 1955 to treat attention deficit hyperactivity disorder. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%methylin%" OR LOWER(tradeNames_string) LIKE "%methylin%" OR LOWER(drugSynonyms_string) LIKE "%methylin%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_845', 'tradeNames_string': 'Adhansia xr, Aptensio xr, Concerta, Delmosart, Equasym, Equasym xl, Jornay pm, Matoride xl, Medikinet, Medikinet xl, Metadate cd, Metadate er, Methylin, Methylin er, Methylphenidate hydrochloride, Quillichew er, Quillivant xr, Relexxii, Ritalin, Ritalin la, Ritalin sr, Ritalin-sr, Tranquilyn, Xenidate xl', 'drugName': 'Methylphenidate Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Sleep Disorder (EFO_0008568), Conduct Disorder (EFO_0004216), Nicotine Dependence (EFO_0003768), Chronic Progressive Multiple Sclerosis (EFO_0003840), Attention Deficit Hyperactivity Disorder (EFO_0003888), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Fatigue (HP_0012378), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090), Childhood Apraxia Of Speech (MONDO_0011184)', 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_846', 'tradeNames_string': 'Adhansia xr, Aptensio xr, Concerta, Delmosart, Equasym, Equasym xl, Jornay pm, Matoride xl, Medikinet, Medikinet xl, Metadate cd, Metadate er, Methylin, Methylin er, Methylphenidate hydrochloride, Quillichew er, Quillivant xr, Relexxii, Ritalin, Ritalin la, Ritalin sr, Ritalin-sr, Tranquilyn, Xenidate xl', 'drugName': 'Methylphenidate Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dopamine transporter inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Sleep Disorder (EFO_0008568), Conduct Disorder (EFO_0004216), Nicotine Dependence (EFO_0003768), Chronic Progressive Multiple Sclerosis (EFO_0003840), Attention Deficit Hyperactivity Disorder (EFO_0003888), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Fatigue (HP_0012378), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090), Childhood Apraxia Of Speech (MONDO_0011184)', 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2370', 'tradeNames_string': 'Concerta, Cotempla xr-odt, Daytrana', 'drugName': 'Methylphenidate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dopamine transporter inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Alzheimer Disease (MONDO_0004975), Orthostatic Hypotension (EFO_0005252), Multiple Sclerosis (MONDO_0005301), Eating Disorder (EFO_0005203), Conduct Disorder (EFO_0004216), Prostate Carcinoma (EFO_0001663), Lymphoid Neoplasm (EFO_0001642), Post-Traumatic Stress Disorder (EFO_0001358), Prostate Cancer (MONDO_0008315), Nicotine Dependence (EFO_0003768), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Attention Deficit Hyperactivity Disorder (EFO_0003888), Anxiety (EFO_0005230), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Cocaine Dependence (EFO_0002610), Asthenia (EFO_0007625), Childhood Apraxia Of Speech (MONDO_0011184), Sleep Disorder (EFO_0008568), Methamphetamine Dependence (EFO_0004701), Drug Dependence (EFO_0003890), Delirium (EFO_0009267), Chronic Progressive Multiple Sclerosis (EFO_0003840), Sickle Cell Anemia (MONDO_0011382), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Brain Neoplasm (EFO_0003833), Brain Injury (MONDO_0043510), Depressive Disorder (MONDO_0002050), Bipolar Disorder (MONDO_0004985), Alcohol Dependence (MONDO_0007079), Opioid Dependence (EFO_0005611), Post-Operative Sign Or Symptom (EFO_0005323), Chronic Pain (HP_0012532), Major Depressive Disorder (MONDO_0002009), Fatigue (HP_0012378), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2371', 'tradeNames_string': 'Concerta, Cotempla xr-odt, Daytrana', 'drugName': 'Methylphenidate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Alzheimer Disease (MONDO_0004975), Orthostatic Hypotension (EFO_0005252), Multiple Sclerosis (MONDO_0005301), Eating Disorder (EFO_0005203), Conduct Disorder (EFO_0004216), Prostate Carcinoma (EFO_0001663), Lymphoid Neoplasm (EFO_0001642), Post-Traumatic Stress Disorder (EFO_0001358), Prostate Cancer (MONDO_0008315), Nicotine Dependence (EFO_0003768), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Attention Deficit Hyperactivity Disorder (EFO_0003888), Anxiety (EFO_0005230), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Cocaine Dependence (EFO_0002610), Asthenia (EFO_0007625), Childhood Apraxia Of Speech (MONDO_0011184), Sleep Disorder (EFO_0008568), Methamphetamine Dependence (EFO_0004701), Drug Dependence (EFO_0003890), Delirium (EFO_0009267), Chronic Progressive Multiple Sclerosis (EFO_0003840), Sickle Cell Anemia (MONDO_0011382), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Brain Neoplasm (EFO_0003833), Brain Injury (MONDO_0043510), Depressive Disorder (MONDO_0002050), Bipolar Disorder (MONDO_0004985), Alcohol Dependence (MONDO_0007079), Opioid Dependence (EFO_0005611), Post-Operative Sign Or Symptom (EFO_0005323), Chronic Pain (HP_0012532), Major Depressive Disorder (MONDO_0002009), Fatigue (HP_0012378), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.630 | Q22 | What is Testim? | Testim, also known generically as Testosterone, was approved by the FDA in 1972 to treat Hypogonadotropic hypogonadism, Klinefelter's syndrome, orchitis, hypogonadism, and hypogonadotropic hypogonadism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%testim%" OR LOWER(tradeNames_string) LIKE "%testim%" OR LOWER(drugSynonyms_string) LIKE "%testim%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5308', 'tradeNames_string': 'Androderm, Androgel, Androgel 1%, Andropatch, Axiron, Fortesta, Intrinsa, Natesto, Striant, Striant sr, Testim, Testim 1%, Testoderm, Testoderm tts, Testogel, Testopatch, Testopel, Testoral, Testosterone, Tostran, Vogelxo', 'drugName': 'Testosterone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Androgen Receptor agonist', 'linkedDiseasesDrug_string': "Erectile Dysfunction (EFO_0004234), Cancer (MONDO_0004992), Hip Fracture (EFO_0003964), Coronary Artery Disease (EFO_0001645), Multiple Sclerosis (MONDO_0005301), Obesity (EFO_0001073), Aids (EFO_0000765), Hypogonadotropic Hypogonadism (MONDO_0018555), Klinefelter'S Syndrome (EFO_1001006), Aging (GO_0007568), Anorexia Nervosa (MONDO_0005351), Prostate Carcinoma (EFO_0001663), Spinal Cord Injury (EFO_1001919), Orchitis (EFO_1001078), Polycystic Ovary Syndrome (EFO_0000660), Prostate Cancer (MONDO_0008315), Cerebral Arterial Disease (EFO_1000859), Growth Delay (HP_0001510), Muscular Disease (EFO_0002970), Hypogonadotropic Hypogonadism (HP_0000044), Sexual Dysfunction (EFO_0004714), Hypogonadism (MONDO_0002146), Insulin Resistance (EFO_0002614), Abnormality Of Connective Tissue (HP_0003549), Sarcopenia (EFO_1000653), Menopause (EFO_0003922), Infertility (EFO_0000545), Chronic Kidney Disease (EFO_0003884), Kallmann Syndrome (MONDO_0018800), Testicular Carcinoma (EFO_0005088), Heart Failure (EFO_0003144), Metastatic Prostate Cancer (EFO_0000196), Metabolic Syndrome (EFO_0000195), Dyspareunia (HP_0030016), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145), Genetic Disorder Of Sex Development (Orphanet_325690)", 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1972, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.364 | Q22 | What is Skyla? | Skyla, also known generically as Levonorgestrel, was approved by the FDA in 1982 to treat Menorrhagia. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%skyla%" OR LOWER(tradeNames_string) LIKE "%skyla%" OR LOWER(drugSynonyms_string) LIKE "%skyla%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2857', 'tradeNames_string': 'Athentia next, Emerres, Emerres una, Ezinelle, Fallback solo, Her style, Isteranda, Jadelle, Jaydess, Kyleena, Levonelle, Levonelle one step, Levonelle-2, Levonorgestrel, Levosert, Liletta, Microval, Mirena, Norgeston, Norplant, Norplant Ii, Norplant System, Opcicon one-step, Ovrette, Plan B, Plan b one-step, Postinor-2, Skyla, Upostelle', 'drugName': 'Levonorgestrel', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Progesterone receptor agonist', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Adenomyosis (EFO_1001757), Menorrhagia (HP_0000132), Osteopenia (HP_0000938), Hiv Infection (EFO_0000764), Chronic Lymphocytic Leukemia (EFO_0000095), Chronic Hepatitis B Virus Infection (EFO_0004239), Hemorrhage (MP_0001914), Migraine Disorder (MONDO_0005277), Pain (EFO_0003843), Non-Alcoholic Steatohepatitis (EFO_1001249), Dysmenorrhea (HP_0100607), Hiv-1 Infection (EFO_0000180), Endometriosis (EFO_0001065), Chronic Hepatitis C Virus Infection (EFO_0004220), Type 2 Diabetes Mellitus (MONDO_0005148), Anorexia Nervosa (MONDO_0005351)', 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1982, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.262 | Q22 | What is Toviaz? | Toviaz, also known generically as Fesoterodine Fumarate, was approved by the FDA in 2008 to treat urgency urinary incontinence and overactive bladder. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%toviaz%" OR LOWER(tradeNames_string) LIKE "%toviaz%" OR LOWER(drugSynonyms_string) LIKE "%toviaz%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3362', 'tradeNames_string': 'Fesoterodine fumarate, Toviaz', 'drugName': 'Fesoterodine Fumarate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Muscarinic acetylcholine receptor M3 antagonist', 'linkedDiseasesDrug_string': 'Urgency Urinary Incontinence (EFO_0006865), Urinary Incontinence (HP_0000020), Overactive Bladder (EFO_1000781)', 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM2 (ENSG00000181072)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3363', 'tradeNames_string': 'Fesoterodine fumarate, Toviaz', 'drugName': 'Fesoterodine Fumarate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Muscarinic acetylcholine receptor M2 antagonist', 'linkedDiseasesDrug_string': 'Urgency Urinary Incontinence (EFO_0006865), Urinary Incontinence (HP_0000020), Overactive Bladder (EFO_1000781)', 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM2 (ENSG00000181072)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.286 | Q22 | What is Daurismo? | Daurismo, also known generically as Glasdegib Maleate, was approved by the FDA in 2018 to treat acute myeloid leukemia. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%daurismo%" OR LOWER(tradeNames_string) LIKE "%daurismo%" OR LOWER(drugSynonyms_string) LIKE "%daurismo%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2876', 'tradeNames_string': 'Daurismo', 'drugName': 'Glasdegib Maleate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Smoothened homolog antagonist', 'linkedDiseasesDrug_string': 'Acute Myeloid Leukemia (EFO_0000222)', 'newLinkedTargets_string': 'SMO (ENSG00000128602)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2018, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.382 | Q22 | What is Zokinvy? | Zokinvy, also known generically as Lonafarnib, was approved by the FDA in 2020 to treat Hutchinson-Gilford progeria syndrome and progeria. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zokinvy%" OR LOWER(tradeNames_string) LIKE "%zokinvy%" OR LOWER(drugSynonyms_string) LIKE "%zokinvy%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5762', 'tradeNames_string': 'Zokinvy', 'drugName': 'Lonafarnib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Protein farnesyltransferase inhibitor', 'linkedDiseasesDrug_string': 'Hutchinson-Gilford Progeria Syndrome (MONDO_0008310), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Chronic Myelogenous Leukemia (EFO_0000339), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Breast Cancer (MONDO_0007254), Hepatitis D Virus Infection (EFO_0007304), Chronic Myelomonocytic Leukemia (EFO_1001779), Lymphoma (EFO_0000574), Metastasis (EFO_0009708), Urethra Cancer (MONDO_0004192), Central Nervous System Neoplasm (EFO_1000158), Liver Cancer (MONDO_0002691), Progeria (MONDO_0020732), Head And Neck Malignant Neoplasia (EFO_0006859), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'newLinkedTargets_string': 'FNTA (ENSG00000168522), FNTB (ENSG00000257365)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.390 | Q22 | What is Oxlumo? | Oxlumo, also known generically as Lumasiran Sodium, was approved by the FDA in 2020 to treat primary hyperoxaluria type 1. It is a oligonucleotide therapy that acts as a(n) rnai inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oxlumo%" OR LOWER(tradeNames_string) LIKE "%oxlumo%" OR LOWER(drugSynonyms_string) LIKE "%oxlumo%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1071', 'tradeNames_string': 'Oxlumo', 'drugName': 'Lumasiran Sodium', 'drugMolecularType': 'Oligonucleotide', 'drugActionType': 'rnai inhibitor', 'drugMechanismOfAction': 'Hydroxyacid oxidase 1 mRNA RNAi inhibitor', 'linkedDiseasesDrug_string': 'Primary Hyperoxaluria Type 1 (MONDO_0009823)', 'newLinkedTargets_string': 'HAO1 (ENSG00000101323)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.228 | Q22 | What is Halaven? | Halaven, also known generically as Eribulin, was approved by the FDA in 2010 to treat cancer and neoplasm. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%halaven%" OR LOWER(tradeNames_string) LIKE "%halaven%" OR LOWER(drugSynonyms_string) LIKE "%halaven%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3175', 'tradeNames_string': 'Halaven', 'drugName': 'Eribulin Mesylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tubulin inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Urothelial Carcinoma (EFO_0008528), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Primary Brain Neoplasm (MONDO_0021632), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Urethra Cancer (MONDO_0004192), Triple-Negative Breast Cancer (EFO_0005537), Soft Tissue Sarcoma (EFO_1001968), Salivary Gland Cancer (MONDO_0004669), Cervical Cancer (MONDO_0002974), Head And Neck Malignant Neoplasia (EFO_0006859), Osteosarcoma (EFO_0000637), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5604', 'tradeNames_string': 'Halaven', 'drugName': 'Eribulin', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tubulin inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Urothelial Carcinoma (EFO_0008528), Metastatic Melanoma (EFO_0002617), Epithelioid Hemangioendothelioma (MONDO_0015523), Angiosarcoma (EFO_0003968), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Primary Brain Neoplasm (MONDO_0021632), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Male Breast Carcinoma (EFO_0006861), Urethra Cancer (MONDO_0004192), Inflammatory Breast Carcinoma (EFO_1000984), Solitary Fibrous Tumor (MONDO_0016238), Triple-Negative Breast Cancer (EFO_0005537), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Salivary Gland Cancer (MONDO_0004669), Cutaneous Melanoma (EFO_0000389), Cervical Cancer (MONDO_0002974), Head And Neck Malignant Neoplasia (EFO_0006859), Osteosarcoma (EFO_0000637), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Sarcoma (EFO_0000691), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145)', 'newLinkedTargets_string': 'TUBB4B (ENSG00000188229), TUBB1 (ENSG00000101162), TUBA3C (ENSG00000198033), TUBA4A (ENSG00000127824), TUBB3 (ENSG00000258947), TUBA1A (ENSG00000167552), TUBB4A (ENSG00000104833), TUBB8 (ENSG00000261456), TUBB (ENSG00000196230), TUBA1B (ENSG00000123416), TUBA1C (ENSG00000167553), TUBA3E (ENSG00000152086), TUBB2A (ENSG00000137267), TUBB2B (ENSG00000137285), TUBB6 (ENSG00000176014)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.690 | Q22 | What is Qelbree? | Qelbree, also known generically as Viloxazine Hydrochloride, was approved by the FDA in 2021 to treat attention deficit hyperactivity disorder. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%qelbree%" OR LOWER(tradeNames_string) LIKE "%qelbree%" OR LOWER(drugSynonyms_string) LIKE "%qelbree%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5502', 'tradeNames_string': 'Qelbree, Vivalan', 'drugName': 'Viloxazine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.575 | Q22 | What is Retevmo? | Retevmo, also known generically as Selpercatinib, was approved by the FDA in 2020 to treat cancer, neoplasm, non-small cell lung carcinoma, thyroid cancer, and medullary thyroid gland carcinoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%retevmo%" OR LOWER(tradeNames_string) LIKE "%retevmo%" OR LOWER(drugSynonyms_string) LIKE "%retevmo%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_896', 'tradeNames_string': 'Retevmo', 'drugName': 'Selpercatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neoplasm (EFO_0000616), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Thyroid Cancer (MONDO_0002108), Renal Insufficiency (HP_0000083)', 'newLinkedTargets_string': 'RET (ENSG00000165731), CCDC6 (ENSG00000108091), KIF5B (ENSG00000170759)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_897', 'tradeNames_string': 'Retevmo', 'drugName': 'Selpercatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neoplasm (EFO_0000616), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Thyroid Cancer (MONDO_0002108), Renal Insufficiency (HP_0000083)', 'newLinkedTargets_string': 'RET (ENSG00000165731), CCDC6 (ENSG00000108091), KIF5B (ENSG00000170759)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_898', 'tradeNames_string': 'Retevmo', 'drugName': 'Selpercatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase receptor RET inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neoplasm (EFO_0000616), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Liver Disease (EFO_0001421), Non-Small Cell Lung Carcinoma (EFO_0003060), Thyroid Cancer (MONDO_0002108), Renal Insufficiency (HP_0000083)', 'newLinkedTargets_string': 'RET (ENSG00000165731), CCDC6 (ENSG00000108091), KIF5B (ENSG00000170759)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.478 | Q22 | What is Zuplenz? | Zuplenz, also known generically as Ondansetron, was approved by the FDA in 1991 to treat Nausea and vomiting, Nausea, cancer, post operative nausea and vomiting, Chemotherapy-induced nausea and vomiting, and Radiation-induced nausea and vomiting. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zuplenz%" OR LOWER(tradeNames_string) LIKE "%zuplenz%" OR LOWER(drugSynonyms_string) LIKE "%zuplenz%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4695', 'tradeNames_string': 'Ondansetron, Zofran, Zofran odt, Zuplenz', 'drugName': 'Ondansetron', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 3a (5-HT3a) receptor antagonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Nausea (HP_0002018), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Pain (EFO_0003843), Irritable Bowel Syndrome (EFO_0000555), Post Operative Nausea And Vomiting (EFO_0004888), Hypotension (EFO_0005251), Gastroparesis (EFO_1000948), Breast Neoplasm (EFO_0003869), Alcohol Abuse (MONDO_0002046), Breast Cancer (MONDO_0007254), Nicotine Dependence (EFO_0003768), Brain Disease (EFO_0005774), Dementia (HP_0000726), Neuropathic Pain (EFO_0005762), Fish-Eye Disease (Orphanet_79292), Female Reproductive System Neoplasm (MONDO_0021148), Cervical Carcinoma (EFO_0001061), Cocaine Dependence (EFO_0002610), Hallucinations (HP_0000738), Concussion (EFO_0011023), Malignant Glioma (MONDO_0100342), Gastroenteritis (EFO_1001463), Pancreatic Carcinoma (EFO_0002618), Methamphetamine Dependence (EFO_0004701), Radiation-Induced Nausea And Vomiting (EFO_0006912), Obsessive-Compulsive Disorder (EFO_0004242), Neoplasm Of Mature B-Cells (EFO_0000096), Brain Injury (MONDO_0043510), Recurrent Tonsillitis (HP_0011110), Alcohol Dependence (MONDO_0007079), Opioid Dependence (EFO_0005611), Dyspnea (HP_0002094), Mycobacterium Avium Complex Disease (EFO_0007386), Hiv Infection (EFO_0000764), Nausea And Vomiting (HP_0002017), Sarcoma (EFO_0000691), Vomiting (HP_0002013), Schizophrenia (MONDO_0005090), Cholecystitis (HP_0001082)', 'newLinkedTargets_string': 'HTR3A (ENSG00000166736)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1991, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.353 | Q22 | What is Keppra? | Keppra, also known generically as Levetiracetam, was approved by the FDA in 1999 to treat Seizure, Bilateral tonic-clonic seizure, Focal-onset seizure, epilepsy, and epilepsy with generalized tonic-clonic seizures. It is a small molecule therapy that acts as a(n) modulator and blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%keppra%" OR LOWER(tradeNames_string) LIKE "%keppra%" OR LOWER(drugSynonyms_string) LIKE "%keppra%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_283', 'tradeNames_string': 'Desitrend, Elepsia xr, Keppra, Keppra xr, Levetiracetam, Levetiracetam in sodium chloride, Matever, Spritam', 'drugName': 'Levetiracetam', 'drugMolecularType': 'Small molecule', 'drugActionType': 'modulator', 'drugMechanismOfAction': 'Synaptic vesicle glycoprotein 2A modulator', 'linkedDiseasesDrug_string': 'Canavan Disease (MONDO_0010079), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), Movement Disorder (EFO_0004280), Focal-Onset Seizure (HP_0007359), Central Nervous System Cancer (EFO_0000326), Panic Disorder (EFO_0004262), Status Epilepticus (EFO_0008526), Drug-Induced Dyskinesia (EFO_1000904), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Aphasia (HP_0002381), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Partial Epilepsy (EFO_0004263), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Photosensitive Epilepsy (MONDO_0015643), Seizure (HP_0001250), Acute Myeloid Leukemia (EFO_0000222), Alcohol Withdrawal (EFO_0004777), Restless Legs Syndrome (EFO_0004270), Obsessive-Compulsive Disorder (EFO_0004242), Stroke (EFO_0000712), Sickle Cell Anemia (MONDO_0011382), Subarachnoid Hemorrhage (EFO_0000713), Brain Neoplasm (EFO_0003833), Glioma (EFO_0005543), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Bilateral Tonic-Clonic Seizure (HP_0002069), Opioid Dependence (EFO_0005611), Psychosis (EFO_0005407), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Postherpetic Neuralgia (MONDO_0041052), Torticollis (HP_0000473), Polyneuropathy (EFO_0009562), Generalized Non-Motor (Absence) Seizure (HP_0002121), Glioblastoma Multiforme (EFO_0000519), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'CACNA1B (ENSG00000148408), SV2A (ENSG00000159164)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1999, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_284', 'tradeNames_string': 'Desitrend, Elepsia xr, Keppra, Keppra xr, Levetiracetam, Levetiracetam in sodium chloride, Matever, Spritam', 'drugName': 'Levetiracetam', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Voltage-gated N-type calcium channel alpha-1B subunit blocker', 'linkedDiseasesDrug_string': 'Canavan Disease (MONDO_0010079), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), Movement Disorder (EFO_0004280), Focal-Onset Seizure (HP_0007359), Central Nervous System Cancer (EFO_0000326), Panic Disorder (EFO_0004262), Status Epilepticus (EFO_0008526), Drug-Induced Dyskinesia (EFO_1000904), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Aphasia (HP_0002381), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Partial Epilepsy (EFO_0004263), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Photosensitive Epilepsy (MONDO_0015643), Seizure (HP_0001250), Acute Myeloid Leukemia (EFO_0000222), Alcohol Withdrawal (EFO_0004777), Restless Legs Syndrome (EFO_0004270), Obsessive-Compulsive Disorder (EFO_0004242), Stroke (EFO_0000712), Sickle Cell Anemia (MONDO_0011382), Subarachnoid Hemorrhage (EFO_0000713), Brain Neoplasm (EFO_0003833), Glioma (EFO_0005543), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Bilateral Tonic-Clonic Seizure (HP_0002069), Opioid Dependence (EFO_0005611), Psychosis (EFO_0005407), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Postherpetic Neuralgia (MONDO_0041052), Torticollis (HP_0000473), Polyneuropathy (EFO_0009562), Generalized Non-Motor (Absence) Seizure (HP_0002121), Glioblastoma Multiforme (EFO_0000519), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'CACNA1B (ENSG00000148408), SV2A (ENSG00000159164)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1999, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.512 | Q22 | What is Omontys Preservative Free? | Omontys Preservative Free, also known generically as Peginesatide Acetate, was approved by the FDA in 2012 to treat anemia (phenotype). It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%omontys preservative free%" OR LOWER(tradeNames_string) LIKE "%omontys preservative free%" OR LOWER(drugSynonyms_string) LIKE "%omontys preservative free%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5606', 'tradeNames_string': 'Omontys, Omontys preservative free', 'drugName': 'Peginesatide Acetate', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Erythropoietin receptor agonist', 'linkedDiseasesDrug_string': 'Anemia (Phenotype) (EFO_0004272)', 'newLinkedTargets_string': 'EPOR (ENSG00000187266)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.695 | Q22 | What is Zolinza? | Zolinza, also known generically as Vorinostat, was approved by the FDA in 2006 to treat cancer, neoplasm, Cutaneous T-cell lymphoma, and T-cell non-Hodgkin lymphoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zolinza%" OR LOWER(tradeNames_string) LIKE "%zolinza%" OR LOWER(drugSynonyms_string) LIKE "%zolinza%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2372', 'tradeNames_string': 'Zolinza', 'drugName': 'Vorinostat', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Histone deacetylase 1 inhibitor', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Verrucous Carcinoma (EFO_0007535), Essential Thrombocythemia (EFO_0000479), Malignant Colon Neoplasm (MONDO_0021063), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Acute Leukemia Of Ambiguous Lineage (MONDO_0019460), Urinary Bladder Carcinoma (MONDO_0004986), Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (EFO_1001830), Sickle Cell Anemia (MONDO_0011382), Clear Cell Renal Carcinoma (EFO_0000349), Hiv-1 Infection (EFO_0000180), Brain Neoplasm (EFO_0003833), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Malt Lymphoma (EFO_0000191), Liver Cancer (MONDO_0002691), Follicular Lymphoma (MONDO_0018906), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Anus Cancer (MONDO_0001879), Colorectal Adenocarcinoma (EFO_0000365), Malignant Pleural Mesothelioma (EFO_0000770), Glioblastoma Multiforme (EFO_0000519), Schizophrenia (MONDO_0005090), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Mantle Cell Lymphoma (EFO_1001469), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Cutaneous T-Cell Lymphoma (EFO_0002913), Hodgkins Lymphoma (EFO_0000183), Rectum Cancer (EFO_1000657), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Mycosis Fungoides (EFO_1001051), Pancreatic Carcinoma (EFO_0002618), Neoplasm Of Mature B-Cells (EFO_0000096), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Oropharyngeal Carcinoma (MONDO_0044926), Niemann-Pick Disease (EFO_1001380), Pituitary-Dependent Cushing'S Disease (EFO_1001110), Neoplasm (EFO_0000616), Sarcoma (EFO_0000691), Medulloblastoma (EFO_0002939), Mixed Glioma (MONDO_0003268), Burkitts Lymphoma (EFO_0000309), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Juvenile Myelomonocytic Leukemia (EFO_1000309), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Brain Disease (EFO_0005774), Male Breast Carcinoma (EFO_0006861), Spinal Cord Neoplasm (EFO_0003828), Lymphoblastic Lymphoma (MONDO_0000873), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Skin Neoplasm (EFO_0004198), Ovarian Neoplasm (EFO_0003893), Brain Cancer (MONDO_0001657), Fallopian Tube Cancer (MONDO_0002158), Melanoma (EFO_0000756), Esophageal Cancer (MONDO_0007576)", 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC2 (ENSG00000196591), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2373', 'tradeNames_string': 'Zolinza', 'drugName': 'Vorinostat', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Histone deacetylase 3 inhibitor', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Verrucous Carcinoma (EFO_0007535), Essential Thrombocythemia (EFO_0000479), Malignant Colon Neoplasm (MONDO_0021063), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Acute Leukemia Of Ambiguous Lineage (MONDO_0019460), Urinary Bladder Carcinoma (MONDO_0004986), Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (EFO_1001830), Sickle Cell Anemia (MONDO_0011382), Clear Cell Renal Carcinoma (EFO_0000349), Hiv-1 Infection (EFO_0000180), Brain Neoplasm (EFO_0003833), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Malt Lymphoma (EFO_0000191), Liver Cancer (MONDO_0002691), Follicular Lymphoma (MONDO_0018906), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Anus Cancer (MONDO_0001879), Colorectal Adenocarcinoma (EFO_0000365), Malignant Pleural Mesothelioma (EFO_0000770), Glioblastoma Multiforme (EFO_0000519), Schizophrenia (MONDO_0005090), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Mantle Cell Lymphoma (EFO_1001469), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Cutaneous T-Cell Lymphoma (EFO_0002913), Hodgkins Lymphoma (EFO_0000183), Rectum Cancer (EFO_1000657), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Mycosis Fungoides (EFO_1001051), Pancreatic Carcinoma (EFO_0002618), Neoplasm Of Mature B-Cells (EFO_0000096), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Oropharyngeal Carcinoma (MONDO_0044926), Niemann-Pick Disease (EFO_1001380), Pituitary-Dependent Cushing'S Disease (EFO_1001110), Neoplasm (EFO_0000616), Sarcoma (EFO_0000691), Medulloblastoma (EFO_0002939), Mixed Glioma (MONDO_0003268), Burkitts Lymphoma (EFO_0000309), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Juvenile Myelomonocytic Leukemia (EFO_1000309), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Brain Disease (EFO_0005774), Male Breast Carcinoma (EFO_0006861), Spinal Cord Neoplasm (EFO_0003828), Lymphoblastic Lymphoma (MONDO_0000873), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Skin Neoplasm (EFO_0004198), Ovarian Neoplasm (EFO_0003893), Brain Cancer (MONDO_0001657), Fallopian Tube Cancer (MONDO_0002158), Melanoma (EFO_0000756), Esophageal Cancer (MONDO_0007576)", 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC2 (ENSG00000196591), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2374', 'tradeNames_string': 'Zolinza', 'drugName': 'Vorinostat', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Histone deacetylase 2 inhibitor', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Verrucous Carcinoma (EFO_0007535), Essential Thrombocythemia (EFO_0000479), Malignant Colon Neoplasm (MONDO_0021063), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Acute Leukemia Of Ambiguous Lineage (MONDO_0019460), Urinary Bladder Carcinoma (MONDO_0004986), Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (EFO_1001830), Sickle Cell Anemia (MONDO_0011382), Clear Cell Renal Carcinoma (EFO_0000349), Hiv-1 Infection (EFO_0000180), Brain Neoplasm (EFO_0003833), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Malt Lymphoma (EFO_0000191), Liver Cancer (MONDO_0002691), Follicular Lymphoma (MONDO_0018906), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Anus Cancer (MONDO_0001879), Colorectal Adenocarcinoma (EFO_0000365), Malignant Pleural Mesothelioma (EFO_0000770), Glioblastoma Multiforme (EFO_0000519), Schizophrenia (MONDO_0005090), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Mantle Cell Lymphoma (EFO_1001469), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Cutaneous T-Cell Lymphoma (EFO_0002913), Hodgkins Lymphoma (EFO_0000183), Rectum Cancer (EFO_1000657), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Mycosis Fungoides (EFO_1001051), Pancreatic Carcinoma (EFO_0002618), Neoplasm Of Mature B-Cells (EFO_0000096), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Oropharyngeal Carcinoma (MONDO_0044926), Niemann-Pick Disease (EFO_1001380), Pituitary-Dependent Cushing'S Disease (EFO_1001110), Neoplasm (EFO_0000616), Sarcoma (EFO_0000691), Medulloblastoma (EFO_0002939), Mixed Glioma (MONDO_0003268), Burkitts Lymphoma (EFO_0000309), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Juvenile Myelomonocytic Leukemia (EFO_1000309), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Brain Disease (EFO_0005774), Male Breast Carcinoma (EFO_0006861), Spinal Cord Neoplasm (EFO_0003828), Lymphoblastic Lymphoma (MONDO_0000873), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Skin Neoplasm (EFO_0004198), Ovarian Neoplasm (EFO_0003893), Brain Cancer (MONDO_0001657), Fallopian Tube Cancer (MONDO_0002158), Melanoma (EFO_0000756), Esophageal Cancer (MONDO_0007576)", 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC2 (ENSG00000196591), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2375', 'tradeNames_string': 'Zolinza', 'drugName': 'Vorinostat', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Histone deacetylase 6 inhibitor', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Verrucous Carcinoma (EFO_0007535), Essential Thrombocythemia (EFO_0000479), Malignant Colon Neoplasm (MONDO_0021063), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Acute Leukemia Of Ambiguous Lineage (MONDO_0019460), Urinary Bladder Carcinoma (MONDO_0004986), Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (EFO_1001830), Sickle Cell Anemia (MONDO_0011382), Clear Cell Renal Carcinoma (EFO_0000349), Hiv-1 Infection (EFO_0000180), Brain Neoplasm (EFO_0003833), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Malt Lymphoma (EFO_0000191), Liver Cancer (MONDO_0002691), Follicular Lymphoma (MONDO_0018906), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Anus Cancer (MONDO_0001879), Colorectal Adenocarcinoma (EFO_0000365), Malignant Pleural Mesothelioma (EFO_0000770), Glioblastoma Multiforme (EFO_0000519), Schizophrenia (MONDO_0005090), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Mantle Cell Lymphoma (EFO_1001469), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Cutaneous T-Cell Lymphoma (EFO_0002913), Hodgkins Lymphoma (EFO_0000183), Rectum Cancer (EFO_1000657), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Mycosis Fungoides (EFO_1001051), Pancreatic Carcinoma (EFO_0002618), Neoplasm Of Mature B-Cells (EFO_0000096), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Oropharyngeal Carcinoma (MONDO_0044926), Niemann-Pick Disease (EFO_1001380), Pituitary-Dependent Cushing'S Disease (EFO_1001110), Neoplasm (EFO_0000616), Sarcoma (EFO_0000691), Medulloblastoma (EFO_0002939), Mixed Glioma (MONDO_0003268), Burkitts Lymphoma (EFO_0000309), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Juvenile Myelomonocytic Leukemia (EFO_1000309), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Brain Disease (EFO_0005774), Male Breast Carcinoma (EFO_0006861), Spinal Cord Neoplasm (EFO_0003828), Lymphoblastic Lymphoma (MONDO_0000873), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Skin Neoplasm (EFO_0004198), Ovarian Neoplasm (EFO_0003893), Brain Cancer (MONDO_0001657), Fallopian Tube Cancer (MONDO_0002158), Melanoma (EFO_0000756), Esophageal Cancer (MONDO_0007576)", 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC2 (ENSG00000196591), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.652 | Q22 | What is Trokendi Xr? | Trokendi Xr, also known generically as Topiramate, was approved by the FDA in 1996 to treat Seizure, epilepsy, migraine disorder, and Lennox-Gastaut syndrome. It is a small molecule therapy that acts as a(n) inhibitor, positive modulator, blocker, and antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%trokendi xr%" OR LOWER(tradeNames_string) LIKE "%trokendi xr%" OR LOWER(drugSynonyms_string) LIKE "%trokendi xr%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1592', 'tradeNames_string': 'Epitomax, Eprontia, Qudexy xr, Topamax, Topamax sprinkle, Topiramate, Trokendi xr', 'drugName': 'Topiramate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Sodium channel alpha subunit blocker', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Hypertriglyceridemia (EFO_0004211), Multiple Sclerosis (MONDO_0005301), Liver Disease (EFO_0001421), Migraine Disorder (MONDO_0005277), Tourette Syndrome (EFO_0004895), Obesity (EFO_0001073), Pain (EFO_0003843), Lennox-Gastaut Syndrome (MONDO_0016532), Cannabis Dependence (EFO_0007191), Prader-Willi Syndrome (MONDO_0008300), Eating Disorder (EFO_0005203), Deafness (EFO_0001063), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Sciatica (HP_0011868), Headache (HP_0002315), Nicotine Dependence (EFO_0003768), Hypertension (EFO_0000537), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Brain Ischemia (MONDO_0005299), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Partial Epilepsy (EFO_0004263), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Seizure (HP_0001250), Alcohol Drinking (EFO_0004329), Methamphetamine Dependence (EFO_0004701), Binge Eating (EFO_0005924), Obsessive-Compulsive Disorder (EFO_0004242), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Congenital Heart Disease (EFO_0005207), Gambling Behaviour (EFO_0004699), Smoking Cessation (EFO_0004319), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Metabolic Syndrome (EFO_0000195), Bulimia Nervosa (EFO_0005204), Type 2 Diabetes Mellitus (MONDO_0005148), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1593', 'tradeNames_string': 'Epitomax, Eprontia, Qudexy xr, Topamax, Topamax sprinkle, Topiramate, Trokendi xr', 'drugName': 'Topiramate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'positive modulator', 'drugMechanismOfAction': 'GABA-A receptor; anion channel positive modulator', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Hypertriglyceridemia (EFO_0004211), Multiple Sclerosis (MONDO_0005301), Liver Disease (EFO_0001421), Migraine Disorder (MONDO_0005277), Tourette Syndrome (EFO_0004895), Obesity (EFO_0001073), Pain (EFO_0003843), Lennox-Gastaut Syndrome (MONDO_0016532), Cannabis Dependence (EFO_0007191), Prader-Willi Syndrome (MONDO_0008300), Eating Disorder (EFO_0005203), Deafness (EFO_0001063), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Sciatica (HP_0011868), Headache (HP_0002315), Nicotine Dependence (EFO_0003768), Hypertension (EFO_0000537), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Brain Ischemia (MONDO_0005299), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Partial Epilepsy (EFO_0004263), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Seizure (HP_0001250), Alcohol Drinking (EFO_0004329), Methamphetamine Dependence (EFO_0004701), Binge Eating (EFO_0005924), Obsessive-Compulsive Disorder (EFO_0004242), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Congenital Heart Disease (EFO_0005207), Gambling Behaviour (EFO_0004699), Smoking Cessation (EFO_0004319), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Metabolic Syndrome (EFO_0000195), Bulimia Nervosa (EFO_0005204), Type 2 Diabetes Mellitus (MONDO_0005148), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1594', 'tradeNames_string': 'Epitomax, Eprontia, Qudexy xr, Topamax, Topamax sprinkle, Topiramate, Trokendi xr', 'drugName': 'Topiramate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Glutamate receptor ionotropic kainate antagonist', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Hypertriglyceridemia (EFO_0004211), Multiple Sclerosis (MONDO_0005301), Liver Disease (EFO_0001421), Migraine Disorder (MONDO_0005277), Tourette Syndrome (EFO_0004895), Obesity (EFO_0001073), Pain (EFO_0003843), Lennox-Gastaut Syndrome (MONDO_0016532), Cannabis Dependence (EFO_0007191), Prader-Willi Syndrome (MONDO_0008300), Eating Disorder (EFO_0005203), Deafness (EFO_0001063), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Sciatica (HP_0011868), Headache (HP_0002315), Nicotine Dependence (EFO_0003768), Hypertension (EFO_0000537), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Brain Ischemia (MONDO_0005299), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Partial Epilepsy (EFO_0004263), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Seizure (HP_0001250), Alcohol Drinking (EFO_0004329), Methamphetamine Dependence (EFO_0004701), Binge Eating (EFO_0005924), Obsessive-Compulsive Disorder (EFO_0004242), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Congenital Heart Disease (EFO_0005207), Gambling Behaviour (EFO_0004699), Smoking Cessation (EFO_0004319), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Metabolic Syndrome (EFO_0000195), Bulimia Nervosa (EFO_0005204), Type 2 Diabetes Mellitus (MONDO_0005148), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1595', 'tradeNames_string': 'Epitomax, Eprontia, Qudexy xr, Topamax, Topamax sprinkle, Topiramate, Trokendi xr', 'drugName': 'Topiramate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Carbonic anhydrase IV inhibitor', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Hypertriglyceridemia (EFO_0004211), Multiple Sclerosis (MONDO_0005301), Liver Disease (EFO_0001421), Migraine Disorder (MONDO_0005277), Tourette Syndrome (EFO_0004895), Obesity (EFO_0001073), Pain (EFO_0003843), Lennox-Gastaut Syndrome (MONDO_0016532), Cannabis Dependence (EFO_0007191), Prader-Willi Syndrome (MONDO_0008300), Eating Disorder (EFO_0005203), Deafness (EFO_0001063), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Sciatica (HP_0011868), Headache (HP_0002315), Nicotine Dependence (EFO_0003768), Hypertension (EFO_0000537), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Brain Ischemia (MONDO_0005299), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Partial Epilepsy (EFO_0004263), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Seizure (HP_0001250), Alcohol Drinking (EFO_0004329), Methamphetamine Dependence (EFO_0004701), Binge Eating (EFO_0005924), Obsessive-Compulsive Disorder (EFO_0004242), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Congenital Heart Disease (EFO_0005207), Gambling Behaviour (EFO_0004699), Smoking Cessation (EFO_0004319), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Metabolic Syndrome (EFO_0000195), Bulimia Nervosa (EFO_0005204), Type 2 Diabetes Mellitus (MONDO_0005148), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1596', 'tradeNames_string': 'Epitomax, Eprontia, Qudexy xr, Topamax, Topamax sprinkle, Topiramate, Trokendi xr', 'drugName': 'Topiramate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Carbonic anhydrase II inhibitor', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Hypertriglyceridemia (EFO_0004211), Multiple Sclerosis (MONDO_0005301), Liver Disease (EFO_0001421), Migraine Disorder (MONDO_0005277), Tourette Syndrome (EFO_0004895), Obesity (EFO_0001073), Pain (EFO_0003843), Lennox-Gastaut Syndrome (MONDO_0016532), Cannabis Dependence (EFO_0007191), Prader-Willi Syndrome (MONDO_0008300), Eating Disorder (EFO_0005203), Deafness (EFO_0001063), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Sciatica (HP_0011868), Headache (HP_0002315), Nicotine Dependence (EFO_0003768), Hypertension (EFO_0000537), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Brain Ischemia (MONDO_0005299), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Partial Epilepsy (EFO_0004263), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Seizure (HP_0001250), Alcohol Drinking (EFO_0004329), Methamphetamine Dependence (EFO_0004701), Binge Eating (EFO_0005924), Obsessive-Compulsive Disorder (EFO_0004242), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Congenital Heart Disease (EFO_0005207), Gambling Behaviour (EFO_0004699), Smoking Cessation (EFO_0004319), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Metabolic Syndrome (EFO_0000195), Bulimia Nervosa (EFO_0005204), Type 2 Diabetes Mellitus (MONDO_0005148), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1597', 'tradeNames_string': 'Epitomax, Eprontia, Qudexy xr, Topamax, Topamax sprinkle, Topiramate, Trokendi xr', 'drugName': 'Topiramate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Glutamate receptor ionotropic AMPA antagonist', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Hypertriglyceridemia (EFO_0004211), Multiple Sclerosis (MONDO_0005301), Liver Disease (EFO_0001421), Migraine Disorder (MONDO_0005277), Tourette Syndrome (EFO_0004895), Obesity (EFO_0001073), Pain (EFO_0003843), Lennox-Gastaut Syndrome (MONDO_0016532), Cannabis Dependence (EFO_0007191), Prader-Willi Syndrome (MONDO_0008300), Eating Disorder (EFO_0005203), Deafness (EFO_0001063), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Sciatica (HP_0011868), Headache (HP_0002315), Nicotine Dependence (EFO_0003768), Hypertension (EFO_0000537), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Brain Ischemia (MONDO_0005299), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Partial Epilepsy (EFO_0004263), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Seizure (HP_0001250), Alcohol Drinking (EFO_0004329), Methamphetamine Dependence (EFO_0004701), Binge Eating (EFO_0005924), Obsessive-Compulsive Disorder (EFO_0004242), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Congenital Heart Disease (EFO_0005207), Gambling Behaviour (EFO_0004699), Smoking Cessation (EFO_0004319), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Metabolic Syndrome (EFO_0000195), Bulimia Nervosa (EFO_0005204), Type 2 Diabetes Mellitus (MONDO_0005148), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.635 | Q22 | What is Jatenzo? | Jatenzo, also known generically as Testosterone Undecanoate, was approved by the FDA in 2014 to treat neoplasm, Klinefelter's syndrome, orchitis, hypogonadism, and hypogonadotropic hypogonadism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%jatenzo%" OR LOWER(tradeNames_string) LIKE "%jatenzo%" OR LOWER(drugSynonyms_string) LIKE "%jatenzo%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_939', 'tradeNames_string': 'Andriol, Aveed, Jatenzo, Kyzatrex, Nebido, Restandol, Restandol testocap, Tlando, Undestor', 'drugName': 'Testosterone Undecanoate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Androgen Receptor agonist', 'linkedDiseasesDrug_string': "Hypogonadism (MONDO_0002146), Coronary Artery Disease (EFO_0001645), Prostate Cancer (MONDO_0008315), Neoplasm (EFO_0000616), Respiratory Failure (EFO_0009686), Renal Cell Carcinoma (EFO_0000681), Klinefelter'S Syndrome (EFO_1001006), Hypogonadotropic Hypogonadism (MONDO_0018555), Aging (GO_0007568), Malnutrition (EFO_0008572), Sexual Dysfunction (EFO_0004714), Spinal Cord Injury (EFO_1001919), Orchitis (EFO_1001078)", 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q23.589 | Q23 | Is there a black box warning for the drug Doxepin? | Yes, the drug Doxepin has a black box warning from the FDA. | SELECT DISTINCT UUID, drugName, blackBoxWarning
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%doxepin%" OR LOWER(tradeNames_string) LIKE "%doxepin%" OR LOWER(drugSynonyms_string) LIKE "%doxepin%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2495', 'drugName': 'Doxepin Hydrochloride', 'blackBoxWarning': True}, {'UUID': 'DrugGeneTargets_v2_1761', 'drugName': 'Doxepin', 'blackBoxWarning': True}] | general | Distinct, Similarity Search | Metadata |
Q23.1868 | Q23 | Is there a black box warning for the drug Ruxolitinib Phosphate? | Yes, the drug Ruxolitinib Phosphate has a black box warning from the FDA. | SELECT DISTINCT UUID, drugName, blackBoxWarning
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ruxolitinib phosphate%" OR LOWER(tradeNames_string) LIKE "%ruxolitinib phosphate%" OR LOWER(drugSynonyms_string) LIKE "%ruxolitinib phosphate%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1727', 'drugName': 'Ruxolitinib Phosphate', 'blackBoxWarning': True}, {'UUID': 'DrugGeneTargets_v2_1728', 'drugName': 'Ruxolitinib Phosphate', 'blackBoxWarning': True}] | general | Distinct, Similarity Search | Metadata |
Q23.1061 | Q23 | Is there a black box warning for the drug Xanomeline? | No, the drug Xanomeline does not have a black box warning from the FDA. | SELECT DISTINCT UUID, drugName, blackBoxWarning
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%xanomeline%" OR LOWER(tradeNames_string) LIKE "%xanomeline%" OR LOWER(drugSynonyms_string) LIKE "%xanomeline%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3335', 'drugName': 'Xanomeline', 'blackBoxWarning': False}, {'UUID': 'DrugGeneTargets_v2_3336', 'drugName': 'Xanomeline', 'blackBoxWarning': False}] | general | Distinct, Similarity Search | Metadata |
Q23.1084 | Q23 | Is there a black box warning for the drug Lapatinib Ditosylate? | Yes, the drug Lapatinib Ditosylate has a black box warning from the FDA. | SELECT DISTINCT UUID, drugName, blackBoxWarning
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lapatinib ditosylate%" OR LOWER(tradeNames_string) LIKE "%lapatinib ditosylate%" OR LOWER(drugSynonyms_string) LIKE "%lapatinib ditosylate%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2160', 'drugName': 'Lapatinib Ditosylate', 'blackBoxWarning': True}, {'UUID': 'DrugGeneTargets_v2_2161', 'drugName': 'Lapatinib Ditosylate', 'blackBoxWarning': True}] | general | Distinct, Similarity Search | Metadata |
Q23.925 | Q23 | Is there a black box warning for the drug Mipomersen Sodium? | Yes, the drug Mipomersen Sodium has a black box warning from the FDA. | SELECT DISTINCT UUID, drugName, blackBoxWarning
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mipomersen sodium%" OR LOWER(tradeNames_string) LIKE "%mipomersen sodium%" OR LOWER(drugSynonyms_string) LIKE "%mipomersen sodium%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3718', 'drugName': 'Mipomersen Sodium', 'blackBoxWarning': True}] | general | Distinct, Similarity Search | Metadata |
Q23.73 | Q23 | Is there a black box warning for the drug Talmapimod? | No, the drug Talmapimod does not have a black box warning from the FDA. | SELECT DISTINCT UUID, drugName, blackBoxWarning
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%talmapimod%" OR LOWER(tradeNames_string) LIKE "%talmapimod%" OR LOWER(drugSynonyms_string) LIKE "%talmapimod%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_376', 'drugName': 'Talmapimod', 'blackBoxWarning': False}] | general | Distinct, Similarity Search | Metadata |
Q23.435 | Q23 | Is there a black box warning for the drug Imarikiren? | No, the drug Imarikiren does not have a black box warning from the FDA. | SELECT DISTINCT UUID, drugName, blackBoxWarning
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%imarikiren%" OR LOWER(tradeNames_string) LIKE "%imarikiren%" OR LOWER(drugSynonyms_string) LIKE "%imarikiren%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3903', 'drugName': 'Imarikiren Hydrochloride', 'blackBoxWarning': False}, {'UUID': 'DrugGeneTargets_v2_5101', 'drugName': 'Imarikiren', 'blackBoxWarning': False}] | general | Distinct, Similarity Search | Metadata |
Q23.911 | Q23 | Is there a black box warning for the drug Ono-2952? | No, the drug Ono-2952 does not have a black box warning from the FDA. | SELECT DISTINCT UUID, drugName, blackBoxWarning
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ono-2952%" OR LOWER(tradeNames_string) LIKE "%ono-2952%" OR LOWER(drugSynonyms_string) LIKE "%ono-2952%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5520', 'drugName': 'Ono-2952', 'blackBoxWarning': False}] | general | Distinct, Similarity Search | Metadata |
Q23.922 | Q23 | Is there a black box warning for the drug Emb-01? | No, the drug Emb-01 does not have a black box warning from the FDA. | SELECT DISTINCT UUID, drugName, blackBoxWarning
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%emb-01%" OR LOWER(tradeNames_string) LIKE "%emb-01%" OR LOWER(drugSynonyms_string) LIKE "%emb-01%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3669', 'drugName': 'Emb-01', 'blackBoxWarning': False}, {'UUID': 'DrugGeneTargets_v2_3670', 'drugName': 'Emb-01', 'blackBoxWarning': False}] | general | Distinct, Similarity Search | Metadata |
Q23.1679 | Q23 | Is there a black box warning for the drug Remimazolam? | Yes, the drug Remimazolam has a black box warning from the FDA. | SELECT DISTINCT UUID, drugName, blackBoxWarning
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%remimazolam%" OR LOWER(tradeNames_string) LIKE "%remimazolam%" OR LOWER(drugSynonyms_string) LIKE "%remimazolam%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3380', 'drugName': 'Remimazolam', 'blackBoxWarning': True}, {'UUID': 'DrugGeneTargets_v2_1800', 'drugName': 'Remimazolam Besylate', 'blackBoxWarning': True}] | general | Distinct, Similarity Search | Metadata |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.